Multimodality ImAging of Cardiovascular Dysfunction : risk factors, diagnostics and treatment options by Thiel, B.S. (Bibi) van
MAJOR ABDOMINAL SURGICAL COMPLICATIONS
INNOVATIVE APPROACHES
Simone ter Hoeve - Boersema
Cover
Format: 352x240 mm
Spine:  12 mm
Bookmark
Format: 60x230 mm
optima Grafische Communicatie
https://ogc.nl
Order: Bibi van Thiel Cover boekenlegger druk
Date: 24/05/2017
 
Multimodality ImAging of 
Cardiovascular Dysfunction
Risk factors, diagnostics and treatment options
Multimodality ImAging of 
Cardiovascular Dysfunction
Risk factors, diagnostics and treatment options
Bibi van Thiel
M
ultim
odality Im
Aging of Cardiovascular D
ysfunction
Risk factors, diagnostics and treatm
ent options 
 
 
Bibi van Thiel
Cardiovascular diseases are a major cause of mortality worldwide, and includes all diseases of the heart and circulation. Despite improvements in knowledge and 
treatment options over the last decades, it remains one of the 
leading causes of disability and death. The underlying mecha-
nisms vary depending on the disease in question. Some of 
these risk factors can be avoided, controlled, treated or modi-
 ed such as high cholesterol, high blood pressure and obesity. 
While others, such as family history and gender, cannot be 
avoided and their emphasis lies on monitoring and treatment. 
In this thesis, the role of DNA damage, atherosclerosis and the 
renin angiotensin system, factors that modulate cardiovascu-
lar damage and disease, are investigated and discussed. Addi-
tionally, the e­ ect of nutritional and therapeutic interventions 
is explored. 
UITNODIGING
Voor het bijwonen van de 
openbare verdediging van 
het proefschrift
Multimodality 
ImAging
of Cardiovascular 
Dysfunction
Risk factors, diagnostics 
and treatment options
door 
Bibi van Thiel
Op dinsdag 4 Juli 2017 
om 15.30 uur
Professor Andries Queridozaal
Onderwijscentrum Erasmus MC
Wytemaweg 80, Rotterdam
Na a oop van de promotie 
ben u van harte welkom voor 
de receptie in de foyer van het 
onderwijscentrum
Paranimfen
Yanto Ridwan
r.ridwan@erasmusmc.nl
Stephanie Lankhorst
Stephanie_lankhorst@hotmail.com
 Bibi van Thiel
Bernardus Gewinstraat 35A 
3031 SC Rotterdam
bibivanthiel@gmail.com

Multimodality ImAging of 
Cardiovascular Dysfunction
Risk factors, diagnostics and treatment options
Bibi van Thiel
To access the ePub, scan the following QR-code:
https://reader.ogc.nl/52705f8b-00bf-48d5-b22f-cc266ebd03ee.epub
wachtwoord = ImAgingCVD
Multimodality ImAging of cardiovascular dysfunction
Risk factors, diagnostics and treatment options
ISBN: 978-94-92683-56-4
Cover design: Heart watercolor art painting by Genefy Art ©
Layout and printed by: Optima Grafische Communicatie, Rotterdam, The Netherlands
Copyright © B. van Thiel 2017, Rotterdam, the Netherlands
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system of 
any nature, or transmitted in any form or means, without written permission of the author, 
or when appropriate, of the publishers of the publications.
Multimodality ImAging of 
Cardiovascular Dysfunction
Risk factors, diagnostics and treatment options
Multimodality ImAging 
van Hart- en Vaat Dysfunctie
Risicofactoren, diagnostiek en behandelingsmogelijkheden
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
 Prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
Dinsdag 4 Juli 2017 om 15.30 uur
door
Bibi Sherise van Thiel
geboren te Rotterdam
PROMOTIECOMISSIE
Promotoren:  Prof.dr. R. Kanaar 
   Prof.dr. A.H.J. Danser
   
Overige leden:   Prof.dr. H.J.M. Verhagen 
   Prof.dr. D.J.G.M. Duncker 
   Prof.dr. C.G. Schalkwijk
Copromot0ren:  Dr. J. Essers
   Dr. I. van der Pluijm
Financial support by the Dutch Heart Foundation and the Dutch Kidney Foundation for 
the publication of this thesis is gratefully acknowledged. 
Additional financial support for publication of this thesis was generously provided by the 
Erasmus MC

TABLE OF CONTENTS
Part I Introduction 9
Chapter 1 General introduction and scope of this thesis. 11
Chapter 2  Structure and cell biology of the vascular wall. 21
van Thiel et al. (2017) ESC Textbook of Vascular Biology. Oxford, 
Oxford University Press.
Chapter 3 The renin–angiotensin system and its involvement in vascular 
disease.
43
van Thiel et al. Eur J Pharmacol. 2015 Sep 15;763(Pt A):3-14.
Part II Aortic aneurysms 75
Chapter 4 Fibulin-4 deficiency induces thoracic and abdominal aortic wall 
dilation and altered plaque morphology in apolipoprotein E 
deficient mice.
77
Manuscript in preparation (shared 1th author)
Chapter 5 AT1 receptor blockade, but not renin inhibition, reduces aneurysm 
growth and cardiac failure in Fibulin-4 mice. 
101
te Riet et al. J Hypertens. 2016 Apr;34(4):654-65. (3th author)
Part III Cardiovascular aging 123
Chapter 6 Dietary restriction but not angiotensin II type 1 receptor blockade 
improves DNA damage-related vasodilator dysfunction. 
125
Manuscript submitted (shared 1th author)
Chapter 7 Hybrid Optical and CT Imaging reveals increased matrix metal-
loprotease activity and apoptosis preceding cardiac failure in 
progeroid Ercc1 mice.
145
Manuscript in preparation (1th author)
Part IV The renin-angiotensin system 165
Chapter 8 In vivo renin activity imaging in the kidney of progeroid Ercc1 
mutant mice. 
167
Manuscript in preparation (1th author)
Chapter 9 Brain renin-angiotensin system: does it exist? 185
van Thiel et al. Hypertension 2017 Jun;69:1136-1144 
Chapter 10 Maximum renal responses to renin inhibition in healthy subjects: 
VTP-27999 versus aliskiren.
211
Barkoudah et al. J Hypertens. 2016 May;34(5):935-41. (2nd author)
Part V Summary and future perspectives 227
Appendices Nederlandse Samenvatting 239
Curriculum Vitae 245
List of Publications 247
PhD Portfolio 249
Acknowledgement (Dankwoord) 253

Part   I
IntroductIon

ChaPter 1
General IntroductIon and 
scope of thIs thesIs

General introduction 13
1
GENERAL INTROduCTION ANd SCOPE OF ThIS ThESIS
Cardiovascular diseases are a major cause of mortality worldwide.1 Cardiovascular disease 
includes all diseases of the heart and circulation, including coronary diseases, such as an-
gina and myocardial infarction and other diseases like stroke, heart failure, hypertension 
(high blood pressure), and aortic aneurysm formation. The underlying mechanisms vary 
depending on the disease in question. In this thesis, the role of DNA damage, atheroscle-
rosis and the renin angiotensin system, factors that modulate cardiovascular damage and 
disease, are investigated and discussed.
dNA damage and aging
Aging is an inevitable part of life and unfortunately also a major risk factor for health 
complications and disease. As such, the prevalence of cardiovascular disease increases 
tremendously with age.2 During aging, diverse detrimental changes in cells and tissues 
occur and manifest differently in each cell type. These series of structural, architectural 
and compositional modifications also take place in the heart and the vasculature with age, 
which will eventually affect cardiovascular performance and sets the stage for the onset of 
cardiovascular disease including heart failure, myocardial infarction, hypertension, stroke 
and aneurysm formation. 
One of the principal causes of aging is the accumulation of DNA damages over time. 
Both endogenous (internal) and exogenous (external) agents can affect our DNA, resulting 
in irreversible DNA damage. Normally, these damages are recognized and can be repaired 
by different DNA repair systems. However, if DNA repair is hampered this can have se-
rious consequences for cells such as cell cycle arrest, cellular senescence and apoptosis, 
processes which are known to be involved in the development of cardiovascular disease. 
One of these DNA repair systems is the Nucleotide Excision Repair (NER) pathway.3 Four 
important steps in this system are damage recognition, helix unwinding, dual incision, 
and repair ligation. Key proteins that are involved in the dual incision step are the DNA 
endonucleases ERCC1/XPF and XPG. 
Ercc1 mouse model of accelerated aging
The ERCC1 (Excision Repair Cross Complementation group 1) protein, along with its 
binding partner XPF (Xeroderma Pigmentosum group F), forms an endonuclease that is 
involved in different DNA pathways; NER, interstand crosslink repair and homologous 
recombination repair. The ERCC1-XPF protein complex is responsible for excision of 
various types of DNA lesions at the 5’end of the damage. The XPF protein contains the 
endonuclease catalytic activity, and ERCC1 is necessary for DNA binding. Human patients 
and mouse mutants with mutations in the ERCC1-XPF complex can exhibit xeroderma 
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pigmentosum, severe Cockayne syndrome, XFE progeroid syndrome, Cerebro-oculo-
facio-skeletal syndrome and/or Fanconi anaemia features.4 
The Ercc1d/- mutant mouse is one of the most widely studied mouse models of ac-
celerated aging, containing one knockout allele and one protein truncating mutation, via 
which the last seven amino acids at the C-terminus of the Ercc1 protein are deleted. These 
mice have a severely compromised, but not completely inactive, DNA repair capacity and 
exhibit premature death (with a lifespan of ~24 weeks).5 During their life they experience 
a remarkably wide range of pathological, physiological and behavioral features related 
to accelerated aging such as progressive neurodegeneration (e.g. dementia, ataxia, pria-
pism, hearing and vision loss), osteoporosis, kyphosis, sarcopenia and retarded growth. 
Moreover, Ercc1d/- mutant display accelerated age-dependent vasodilator dysfunction, 
increased vascular stiffness, increased blood pressure and vascular cell senescence.6 Thus, 
the Ercc1d/- mouse model can be used to study the aging process due to endogenous DNA 
damage and its effects on the heart and vessels. 
Fat deposition (e.g. atherosclerosis)
A fatty streak is the first, by eye, visible lesion in the development of atherosclerotic disease. 
These fatty streaks, also called plaques, are caused by accumulation of fat, cholesterol and 
other substances. The build-up of these plaques in and around the vasculature is called 
atherosclerosis. These plaques can cause thickening and stiffening of the vessel wall. Over 
time, these plaques can become so thick that they can block the inside of the artery and 
interfere with normal blood flow. Some of the diseases that could develop as a result of 
this plaque build-up include coronary heart disease, carotid artery disease, peripheral 
artery disease and chronic kidney disease. Moreover, it is thought that atherosclerosis and 
aneurysms are highly associated, as atherosclerosis is frequently observed in the aortic 
wall of patients with abdominal aortic aneurysms. It should be noted that many of the risk 
factors for aortic aneurysms are similar to those for atherosclerosis, including smoking, 
hypertension, inflammation and family history. However, in some patients atherosclerosis 
leads to aortic narrowing, while in others it leads to aortic dilatation; consequently, there 
is much debate as to whether atherosclerosis is a causative factor in aneurysm formation. 
Aneurysmal Fibulin-4 mouse model
One of the mouse models that can be used to study the relation between atherosclerosis 
and aneurysms formation is the Fibulin-4 mouse model. Fibulin-4 is one of the seven 
members of extracellular matrix proteins that play an important role in elastic fiber and 
collagen assembly and function. Mice with a reduced expression of Fibulin-4 (indicated 
as ‘Fibulin-4R’, where R stands for reduced expression) display defects in the aortic wall, 
which could lead to aneurysm formation. Hence, mice with only 25% expression of Fibu-
line-4 (homozygous Fibulin-4R/R mice) develop aortic aneurysms, while mice with a 50% 
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expression of Fibulin-4 (heterozygous Fibulin-4+/R mice) develop minor aortic abnormali-
ties.7 These heterozygous Fibulin-4+/R mice do not yet develop aneurysms spontaneously 
but are susceptible to develop aneurysms upon exposure to different stressors such as age 
and high fat diet, and thus are a good model to test the effect of risk factors on aneurysm 
formation. 
The renin-angiotensin system 
The renin angiotensin system (RAS) has emerged as one of the most important links in the 
pathophysiology of many types of cardiovascular diseases.8 Besides its classical regulatory 
effects on blood pressure and sodium homeostasis, the RAS is involved in the regulation 
of vascular tone and remodeling of the vessel wall. Dysregulation and overproduction of 
the RAS hormone angiotensin II (Ang II), the main peptide of the RAS, is believed to con-
tribute to the initiation and progression of several cardiovascular diseases. Historically, 
Ang II in circulating blood was seen as a regulatory hormone involved in the regulation of 
blood pressure, aldosterone release and sodium reabsorption. Yet, now there is also ample 
evidence that locally produced Ang II promotes cell proliferation, apoptosis, fibrosis, 
oxidative stress and inflammation, processes known to contribute to remodeling of the 
vasculature.9 It is generally believed that the local production of Ang II is involved in the 
pathogenesis and progression of atherosclerosis and aneurysm disease, and that inhibi-
tion of the RAS has beneficial therapeutic effects on the vasculature, possibly even on 
aortic aneurysms. Moreover, since Ang II signaling affects the aging process, while many 
vascular diseases are age-related, it is important to understand how the RAS is regulated 
during normal aging. Although we know that the systemic RAS is suppressed during ag-
ing, the activity of tissue RAS in the elderly is not fully understood yet and needs to be 
further explored. 
Scope of this thesis
Cardiovascular diseases are life-threatening and their occurrence increases with age. Most 
often there is not one cause for disease, but instead several risk factors are involved that in-
crease the risk of development and progression of disease. In this thesis, important factors 
are explored that play a role in cardiovascular damage and disease, such as DNA damage, 
atherosclerosis and the RAS. Chapter 2, part I, starts with describing the general structure 
and cell biology of the vessel wall. In Chapter 3 the focus lies on the components that are 
under the influence of the RAS and that contribute to the development and progression of 
vascular disease; e.g. extracellular matrix defects, atherosclerosis and aging.
In part II, we studied the effect of two risk factors, atherosclerosis and increased RAS sig-
naling, on the development and progression of aortic aneurysms. In the clinic it is known 
that in some patients atherosclerosis leads to aortic narrowing, while in others it leads to 
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aortic dilatation. Hence, a better understanding on the differences in pathogenesis leading 
to both atherosclerosis and aneurysm formation is required. Therefore, in Chapter 4 the 
relation between atherosclerosis and aortic aneurysms formation was investigated, with 
the intention to find molecular pathways and markers that differentiate these two diseases. 
Furthermore, it has been well established that activation of the RAS plays an important 
role in the physiology and pathophysiology of the cardiovascular system and it has been 
suggested that over activation of the RAS promotes the development of aortic aneurysms. 
In Chapter 5 the therapeutic potential of the RAS blocker losartan, an angiotensin II type 
1 (AT1) receptor, on aneurysm progression was examined. 
In part III, the effect of defective DNA repair and the consequential aging process on the 
development of cardiovascular damage is investigated. Chapter 6 discusses the effect of 
accelerated aging on vascular function and morphology, as well as the effect of dietary 
restriction, known to induce an anti-aging response, on the vasculature. In Chapter 7, 
the effect of aging on the heart was characterized and the use of fluorescent molecular 
markers for the early detection of cardiovascular disease was tested.  
In part IV, the role of the RAS was investigate under various conditions. Though it is 
suggested that changes in the reactivity and/or responsiveness of the systemic RAS oc-
cur with aging, little is known about the regulation and activity of the RAS within local 
tissues during aging. Yet, this knowledge is required to successively treat and/or prevent 
renal disease in the elderly. In Chapter 8 the use of the renin activatable near-infrared 
fluorescent probe ReninSense680™ was tested to facilitate non-invasive imaging of renin 
activity in vivo. In addition, the intrarenal renin activity was determined in accelerated 
aging Ercc1d/- mice with age-related kidney pathology. Besides the traditional role of the 
RAS in blood pressure regulation, it is hypothesized that certain RAS components are 
synthesized in the brain and that this so-called brain RAS is relevant in the regulation of 
the cardiovascular system. However, the concept of a brain RAS has been controversial 
and this controversy continues to this day. Therefore, in Chapter 9 the occurrence of (pro)
renin in the brain was re-evaluated. Inhibition of the RAS with aliskiren, a potent renin 
inhibitor, is hampered by diarrhea at high doses and thus no maximum effect of renin 
inhibition in humans has been established. Accordingly, in Chapter 10 the use of VTP-
27999, a novel renin inhibitor -without major side-effects at high doses- was examined in 
order to establish the maximum effect of renin inhibition, focusing on the kidney. 
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Figure 1. Schematic overview of topics and relationship discussed in this thesis. 
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INTROduCTION
A healthy heart pumps about 6000-8000 liters of blood around the body each day. Blood 
is carried through the body via blood vessels. The blood vessels form a closed system that 
begins and ends at the heart. In mammals blood circulates through two separate circuits: 
the pulmonary circuit and the systemic circuit (Fig. 1.1). 
•	 Pulmonary circuit: the right ventricle of the heart pumps blood into the lungs, where 
waste gases are exchanged for oxygen, after which the blood is transported back to the 
left atrium of the heart. 
•	 Systemic circuit: the left ventricle pumps oxygenated blood to all tissues and organs of 
the body via the aorta after which deoxygenated blood is transported back to the right 
atrium of the heart. 
Figure 1.1: Schematic overview of the cardiovascular circulatory system. Note that arteries and oxygen-
ated blood are depicted in red and veins and deoxygenated blood are depicted in blue.
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Figure 1.1 gives a simplified overview of the blood flow through the body, where de-
oxygenated blood is depicted in blue and oxygenated blood is depicted in red. Note that 
somewhat counterintuitively, deoxygenated blood does not refer to blood without oxygen. 
Rather, it refers to a lower oxygenation grade than that of oxygenated blood because a 
certain amount of oxygen has been delivered to tissues. As a result, deoxygenated blood 
still contains about 75% of oxygen compared to oxygenated blood. 
A well-functioning cardiovascular system is essential for all vertebrates. The blood vessels 
are a conduit for a variety of molecules, such as nutrients, oxygen and waste products, to 
and from all parts of the body. Blood vessels have several main functions:
1. Distribution of blood containing nutrients (e.g. glucose and amino acids), oxygen 
(O2), water and hormones to all the tissues and organs of the body.
2. Removal of metabolic waste products and carbon dioxide (CO2) from the tissues to the 
excretory organs and the lungs, respectively.
3. Regulation of blood pressure. 
4. Maintenance of constant body temperature (thermoregulation).
Distribution of nutrients, gases and removal of waste products
The primary function of blood vessels is to transport blood around the body, thereby sup-
plying organs with the necessary O2 and nutrients. At the same time, the vessels remove 
waste products and CO2 to be processed or removed from the body. 
Regulation of blood pressure
Blood vessels control blood pressure by changing the diameter of the vessel through either 
constriction (vasoconstriction) or dilation (vasodilation). Variations in blood pressure oc-
cur in various parts of the circulation depending on the diameter of the vessel. 
Maintenance of constant body temperature (thermoregulation)
Blood vessels help maintain a stable body temperature by controlling the blood flow to 
the surface area of the skin. To prevent overheating, blood vessels near the surface of the 
skin can dilate, allowing excessive heat of the blood to be released to the surroundings. In 
contrast, blood vessels near the skin’s surface can constrict, reducing heat loss through the 
skin when needed under cold circumstances. 
STRuCTuRE OF ThE vESSEL wALL
Blood vessels need to be well-constructed, as they have to withstand the pressure of circu-
lating blood through the body every day. The vessel wall is arranged in three distinct layers, 
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termed tunica: an inner layer (tunica intima), a middle layer (tunica media) and an outer 
layer (tunica adventitia) (Fig. 1.2). These layers mainly contain endothelial cells, vascular 
smooth muscle cells and extracellular matrix, including collagen and elastic fi bers. 
Figure 1.2: General structure of the vessel wall, showing the tunica intima, tunica media and tunica 
adventitia and a close-up depicting the diff erent structures within these layers.
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Tunica intima
The tunica intima (‘inner coat’) is the innermost layer of a blood vessel. In healthy ves-
sels, it consists of a thin single layer of endothelial cells, which are in direct contact with 
the blood in the lumen, as well as a subendothelial layer made-up mostly by connective 
tissue. The single layer of endothelial cells, called endothelium, has a smooth surface that 
minimizes the friction of the blood as it moves through the lumen. The endothelium plays 
a role in vascular permeability, inflammation, coagulation and vascular tone, which refers to 
the maximal degree of contraction by vascular smooth muscle cell relative to its maximally 
dilated state. The subendothelial layer, also called basal lamina, provides a physical support 
base for the endothelial cells and flexibility of the vessel for stretching and recoil. Moreover, 
it guides cell and molecular movement during tissue repair of the vessel wall. The tunica 
intima is the thinnest layer of the blood vessel and minimally contributes to the thickness of 
the vessel wall. In arteries and arterioles, the outer margin of the tunica intima is separated 
from the surrounding tunica media by the internal elastic membrane, a thick layer of elastic 
fibers. The internal elastic membrane provides structure and elasticity to the vessel and al-
lows diffusion of materials through the tunica intima to the tunica media. Microscopically, 
the lumen and the tunica intima of an artery appear wavy because of the partial constriction 
of the vascular smooth muscle cells in the tunica media, the middle layer of the blood vessel, 
whereas the tunica intima of a vein appears smooth. 
Tunica media 
The middle layer, tunica media, is considered to be the muscular layer of the blood vessel 
as it primarily contains circularly arranged smooth muscle fibers together with extracellular 
matrix, mostly elastin sheets. It is often the thickest layer of the arterial wall and much thicker 
in arteries than in veins. The tunica media provides structural support as well as vasoreactiv-
ity (the ability of blood vessels to contract or to relax in response to stimuli) and elasticity 
to the blood vessel. The primary role of the vascular smooth muscle cells is to regulate the 
diameter of the vessel lumen. Concerning blood pressure regulation, the vascular smooth 
muscle cells in the tunica media can either contract causing vasoconstriction, or relax causing 
vasodilation. During vasoconstriction, the lumen of the vessel narrows, leading to an increase 
in blood pressure, whereas vasodilation widens the lumen allowing blood pressure to drop. 
Both vasoconstriction and vasodilation are partially regulated by nerves (nervi vasorum). 
The tunica media is separated from the tunica adventitia by a dense elastic lamina called the 
external elastic membrane. Under the microscope, these laminae appear as wavy lines. This 
structure is usually not apparent in small arteries and veins. 
Tunica adventitia
The tunica adventitia (also known as tunica externa) is the outermost layer of the vessel 
wall, surrounding the tunica media. The adventitia is predominantly made-up by extracel-
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lular matrix (collagen and elastic fi bers), nutrient vessels (vasa vasorum) and autonomic 
nerves (nervi vasorum). Fibroblasts and numerous macrophages are also present in this 
layer. The tunica adventitia is often the thickest layer in veins, sometimes even thicker 
than the tunica media in larger arteries. The tunica adventitia helps to anchor the vessel 
to the surrounding tissue and provides strength to the vessels as it protects the vessel from 
overexpansion.
Vasa vasorum
Characteristic of the adventitial layer is the presence of small blood vessels, called the vasa 
vasorum. The vasa vasorum supplies blood and nourishment to the tunica adventitia and 
outer parts of the tunica media, as these layers are too thick to be nourished merely by 
diff usion from blood in the lumen, and removes ‘waste’ products. Because of the thick and 
muscular walls of the arteries, the vasa vasorum are more frequent in the wall of arteries 
than in the wall of veins. 
COMPONENTS OF ThE vASCuLAR wALL
The vascular wall is composed of many cell types and constituents that infl uence the dia-
meter and functional control of the vessel wall. Several main cell types include endothelial 
cells, vascular smooth muscle cells and immune cells (Fig. 1.3). Interaction between these 
Figure 1.3. Summary of the major components of the vessel wall.
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cell types allows the vessel to adapt to alterations in pressure and various physical stimuli 
by either dilation or contraction. 
Endothelium
Vascular endothelial cells lining the entire circulatory system, from the heart and arteries 
to the small capillary beds, are in direct contact with blood. They form a single-cell layer 
(monolayer) called the endothelium, which has been estimated to cover a surface area of 
more than 1000 m2 in humans. The morphological shape of endothelial cells varies across 
the circulatory system (Flaherty et al. 2012). In large arteries, endothelial cells are aligned 
and elongated in the direction of the blood flow, whereas in region of disturbed flow, e.g. 
near bifurcations, endothelial cells are more round and do not align in a specific direction. 
Varying among the vascular tree, endothelial cells are between 0.2 to 2.0 μm thick and 1 to 
20 μm long. They are joined together by tight junctions, which restrict the transportation 
of large molecules across the endothelium. Endothelial cells are active contributors to a 
variety of vessel-related activities, including permeability, vascular tone and hemostasis. 
Vascular endothelial cells have several important functions (Box 1.1). 
Box 1.1 Vascular endothelial cell function
1. Providing a semi-permeable barrier between the vessel lumen, containing the blood, and the 
surrounding tissues. Selective material, electrolytes, macromolecules, fluid and cells can pass the 
barrier entering or leaving the bloodstream. 
2. Regulating vascular tone, by secreting vasoactive substances that stimulate the smooth muscle cells of 
the tunica media to relax or contract, thus widening or narrowing the vessel.
3. Modulating cellular adhesion and inflammation of the vasculature, as endothelial cells regulate 
lymphocyte and leucocyte adhesion and transendothelial migration, from the bloodstream across the 
barrier into the vessel wall, by expression of surface adhesion molecules.
4. Modulating haemostasis and coagulation. Under normal conditions, endothelial cells express a wide 
variety of non-thrombogenic factors that maintain blood fluidity and help prevent inappropriate blood 
clotting. 
5. Involved in the formation of new blood vessels (angiogenesis). Angiogenesis is in part regulated by the 
endothelial cell, which is important in wound healing.
The endothelium has a strategic position in the vessel wall, right between the circulating 
blood and the vascular smooth muscle cell. From this position, the endothelium plays 
a vital role in controlling vascular function, as it is able to respond to mechanical and 
hormonal signals and receive information from cellular constituents of the vessel wall. 
Endothelial cells are highly dynamic as they need to interpret changes in blood composi-
tion and mechanical changes, and respond properly to several stimuli, either physical or 
chemical, by producing a variety of factors that contribute to the control of vascular tone, 
vascular inflammation, cellular adhesion, hemostasis and coagulation. For instance, the 
endothelium serves as a semi-permeable barrier, restricting and controlling the move-
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ment of fluids, molecules and cells across the blood vessel wall. This movement across the 
endothelial lining can occur via different mechanisms, either through the endothelial cells 
(transcellular) or by passing the junction between two adjacent endothelial cells (paracel-
lular). The permeability of the barrier can be altered in response to specific stimuli that 
act on endothelial cells. Also, endothelial cells themselves can secrete different vasoactive 
substances that influence the activity of the underlying vascular smooth muscle cell, and 
thereby the contractile state of the vessel. For instance, endothelial cells can secrete nitric 
oxide which causes the vascular smooth muscle cells to relax, consequently leading to 
vasodilation. Moreover, endothelial cells tightly regulate the expression of adhesion mol-
ecules on their surface. These adhesion molecules not only modulate cell migration but 
are also important in response to local injury, as platelets and other inflammatory cells are 
recruited to the site of damage in need of defense or repair. Furthermore, endothelial cells 
are required to maintain blood fluidity and prevent thrombus formation. They bind and 
display tissue factors that have anti-coagulant properties thereby preventing the initiation 
of coagulation. 
Injury and dysfunction of the endothelium directly or indirectly plays a vital role 
in the initiation and development of most of human vascular diseases. Endothelial dys-
function not only leads to an imbalance between vasoconstriction and vasodilation but 
also causes coagulation disorders and can be involved in the malignant growth of tumors. 
It is also involved in numerous other physiological and pathological conditions such as 
hypertension, septic shock, diabetes and hypercholesterolemia. Moreover, endothelial 
dysfunction is seen as the initial step in the atherosclerotic process. 
Vascular smooth muscle cells
Vascular smooth muscle cells are the most prominent cell type of an artery and, depend-
ing on the size of the artery, may comprise several layers. Vascular smooth muscle cells 
are typically 2 to 5 μm in diameter, and vary from 100 to 500 μm in length. Yet, as the 
vascular smooth muscle cells can either relax or contract, their actual length depends on 
the physiological conditions and functioning of the cell. The vascular smooth muscle cells 
exert different functions, which translates into two different phenotypes of the vascular 
smooth muscle: contractile or synthetic. The contractile smooth muscle cells are long 
spindle-shaped cells that contain a single centrally positioned elongated nucleus, whereas 
the synthetic vascular smooth muscle cell are less elongated and have a more cobblestone 
morphology. Each smooth muscle cell is enclosed by a variable amount of extracellular 
matrix, containing collagen, elastin and various proteoglycans. Smooth muscle cells are 
arranged in different orientations, either circumferentially or helically, along the longi-
tudinal axis of the vessel. Smooth muscle cells are connected to each other by tight- and 
gap-junctions. These junctions permit the transfer of signaling molecules between cells 
and increase the tensile strength of the medial layer, respectively, allowing the control 
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of the diameter of the vessel. Smooth muscle cell are normally quiescent cells that do 
not divide. However, damage to the vessel wall can drive the smooth muscle cells into a 
proliferative state in which they will divide and migrate. 
In the artery, almost all smooth muscle cells are present in the tunica media. The pri-
mary function of smooth muscle cells is to regulate the diameter of the vessel lumen, 
as it directly controls vessel tone and regulates blood pressure by either contraction or 
relaxation. In the small arteries (less than 300 μm in diameter) and veins, contraction of 
the vascular smooth muscle cell is responsible for the regional distribution of the blood 
flow as it gives a reduction in lumen diameter and thereby increases vascular resistance, 
leading to a higher blood pressure. Vasoconstriction in the larger arteries has a different 
hemodynamic effect and mostly affects the stiffness (compliance) of the blood vessel, 
increasing the impedance to move blood through the artery. 
Regulation of the vascular diameter by activation/deactivation of vascular smooth 
muscle cells is primarily under control by the autonomic nerves in the adventitial layer 
that act on specific receptors present on the outside of vascular smooth muscle cell. Yet, 
other locally produced and blood-borne factors can also act directly on the vascular 
smooth muscle cell and thus play an important role in its function. Smooth muscle cell 
contraction can be initiated by electrical, chemical or mechanical stimuli. Contractility 
of smooth muscle cells is controlled by actin and myosin filaments of the cytoskeleton, 
which make up a substantial portion of the cytoplasm of smooth muscle cells. Besides 
contractility, vascular smooth muscle cells also perform other functions such as migration, 
proliferation, proinflammatory and secretory, responses that become progressively impor-
tant during vessel remodeling, injury and disease. For example, the smooth muscle cells 
produce a variety of extracellular matrix components, including collagen and elastin. Acti-
vated vascular smooth muscle cells also secrete matrix metalloproteinases (MMPs), which 
facilitate extracellular matrix remodeling. The ratio between vascular smooth muscle cells 
and the amount of extracellular matrix determines the overall mechanical properties and 
structural integrity of the vessel. The phenotype of the vascular smooth muscle cell can 
range from contractile to synthetic. These two phenotypes of smooth muscle cells not only 
differ in morphology but also in expression levels of different genes and their prolifera-
tive and migratory properties. Contractile smooth muscle cells are most often quiescent 
whereas synthetic smooth muscle cells have a high proliferation and migratory rate. The 
vascular smooth muscle cells can switch between these two phenotypes in response to 
changes in environmental cues, therefore these cells are not only important in short-term 
regulation of the lumen diameter but also in long-term adaptation of the vessel through 
structural remodeling. 
There is clear evidence that vascular smooth muscle cells are involved in the patho-
genesis of several vascular diseases, including atherosclerosis, restenosis, hypertension, 
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asthma and vascular aneurysms. Upon vascular injury, the smooth muscle cells undergo 
a phenotypic switch from contractile to synthetic, which most often includes increased 
proliferation, migration to the site of damage and increased excretion of extracellular 
matrix proteins. These characteristics play an important role in vascular repair, however, 
when occurring in high degrees, it predisposes the cell to acquire characteristics that con-
tribute to the development of vascular diseases. The most acknowledged disease, in which 
smooth muscle cells play a key role, is atherosclerosis. However, the precise role of smooth 
muscle cells in atherosclerotic disease progression most likely depends on disease stage, as 
smooth muscle cells play a disadvantageous role in lesion development and progression, 
whereas they have a beneficial role in stabilizing the fibrous cap and consequently prevent 
plaque rupture. 
Pericytes
Pericytes are the contractile cells of the capillaries and venules, whereas vascular smooth 
muscle cells are the contractile cells of other blood vessels (arteries, arterioles and veins). 
The size and morphology of pericytes greatly depends on location and type of vessel, 
and may be irregular in a single vessel. Generally, they have an elongated shape with a 
prominent round nucleus, and are surrounded by basal lamina material that is continuous 
with the basement membrane of the tunica intima. These pericytes are wrapped around 
the endothelial cells on the luminal side of the basement membrane. Pericytes have been 
associated with regulating capillary blood flow and stabilization of microvessels.
Cytoskeleton proteins
Cytoskeletal proteins are structural elements surrounding the cell membrane and are 
important to maintain cellular shape and integrity. These proteins play an active role in the 
interaction between blood vessels and the surrounding environment. Key cytoskeleton 
proteins include actin filaments, microtubules and intermediate filaments. Actin fila-
ments are important in cell-cell control and cell-matrix interactions as they can bind to 
plasma membrane proteins. Actin filaments surrounding the endothelial cell are therefore 
involved in fluid and molecule exchange between the tissue and the circulating blood, 
by tightly regulating the vascular barrier. Furthermore, actin filaments are involved in 
cell motility, particular in the contraction of the vessel wall through association with the 
motor protein myosin. As such, when vascular smooth muscle cells become activated, the 
cytoskeleton proteins actin and myosin rapidly reorganize, creating membrane bound, 
parallel-organized units termed ‘stress fibers’. In this complex, myosin slides along the 
actin filaments, which produces an increased intracellular tension leading to contraction 
of the cell. The microtubules not only support the cellular structure, but also are involved 
in cell division, as they facilitate the formation of spindles during mitosis. Intermediate 
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filaments appear to have a structural role in maintaining cellular integrity but might also 
provide an anchoring for contractile proteins. 
Vascular extracellular matrix 
The extracellular matrix is a highly-organized network of proteins containing collagen 
and elastin fibers and a loose network of proteoglycans. Foremost, the extracellular matrix 
provides structural support and elasticity to the vessel wall, keeping cells in place and 
allowing adaptation of the vessel wall to high blood pressure. Endothelial cells of the 
tunica intima, vascular smooth muscle cells of the tunica media and fibroblasts of the 
tunica adventitia all produce extracellular matrix proteins that have a different function 
in each tunica. The extracellular matrix proteins of the tunica intima make up the sub-
endothelial basement membrane, which provides flexibility of vessels for stretching and 
recoil, whereas the extracellular matrix of the tunica media is responsible for strength and 
stretch of the vessel wall, as well as for transmission of muscle contraction. The tunica 
adventitia is made up principally by extracellular matrix, and contains a limited number 
of cells. This layer adds further strength to the vessels wall. Additionally, the extracellular 
matrix provides specific informational cues to vascular cells, thereby regulating cellular 
adhesion, proliferation, differentiation and migration. 
Collagen
Physical properties of the blood vessel wall largely depend on collagen fibers. These collagen 
fibers provide a supporting framework that anchors smooth muscle cells in place. When in-
ternal pressures are high, the collagen network becomes rigid, limiting elasticity of the vessel 
wall. Collagen types I, III, and IV are present in the adventitia, tunica media and basement 
membranes, respectively. Veins tend to have a higher collagen content than arteries. Once 
blood vessels start to lose their collagen, tiny ruptures can occur in the vessel wall.
Elastin
Elastin provides vessels with the ability to stretch and recoil in response to hemodynamic 
forces resulting from alterations in blood pressure. Many elastin molecules are cross-linked 
and connected to each other and other molecules, including microfibrils, fibulins and col-
lagen, to form an elastic fiber. These elastic fibers allow the vessels to expand during the 
contractile phase of the heart and then recoil during the filling phase of the heart, keeping 
the blood flowing forward. These elastic fibers are mainly found in the tunica media of arter-
ies, where smooth muscle cells and collagen fibers are present between these elastic layers. 
Depletion of elastin is often due to destruction rather than reduced production. 
Integrity of the extracellular matrix is essential to maintain both physical and 
biological properties of the vessel, as changes in the extracellular matrix affect the local 
environment that vascular cells are embedded in. As a result, cellular adhesion, prolif-
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eration, migration, differentiation, and gene expression of several vascular cells will be 
affected. Moreover, disruption and/or deletion of these extracellular matrix proteins has 
deleterious effects on the structure and function of vessels, as it contributes to weakening 
of the vessel wall. Maintaining a proper balance between the different matrix components 
depends on new synthesis of matrix proteins and on matrix degradation by enzymes, such 
as MMPs. An imbalance of extracellular matrix proteins in favor of matrix degradation is 
for instance seen in vascular diseases like aneurysms, where it leads to vessel wall rupture, 
and atherosclerosis, where it is involved in plaque destabilization. 
Infiltrating immune cells 
Endothelial cells and vascular smooth muscle cells are able to produce a variety of immune 
and inflammatory mediators, such as tumor necrosis factor-a (TNF-a), interleukins (IL), 
platelet-derived growth factors (PDGF). These factors stimulate migration of immune cells 
and inflammatory cells from the blood into the tissue. As a result, different immune cells can 
be found in the vessel wall, including macrophages and lymphocytes. For instance, activated 
endothelial cells can express adhesion molecules that allow mononuclear leucocytes, such 
as monocytes and T-cells, to attach to the endothelium and penetrate into the tunica intima. 
Penetration of these cells into the tunica media by endothelial cells is seen as one of the early 
steps in the development of atherosclerotic lesions.
TyPES OF BLOOd vESSELS
Blood vessels are found throughout the body and can be categorized by function and by 
composition of the wall. There are five general types of blood vessels: arteries, arterioles, 
capillaries, venules and veins (Fig. 1.4). As these types of blood vessels have to withstand 
different degrees of blood pressure, the composition of the wall varies among these types 
(see Table 1.1). 
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Figure 1.4: Schematic drawing showing major structural characteristics of the diff erent types of blood 
vessels. 
Arteries
Arteries carry highly pressurized oxygen rich blood away from the heart to other organs 
of the body. Because arteries experience high blood pressure and pulsatile fl ow as blood 
is ejected from the heart, they must be strong, elastic and fl exible and therefore have a 
much thicker wall than veins. Arteries consist of three layers, tunica intima, media and 
adventitia. The tunica media of an artery is very thick and contains more smooth muscle 
cells and elastic fi bers than that of veins, allowing the arteries to be more contractile and 
elastic, respectively. The large arteries of the body contain a lot of elastic laminae that 
allows the artery to stretch and accommodate to high blood pressure. The arteries branch 
repeatedly into smaller and smaller vessels, eventually becoming arterioles. According to 
size and function, arteries can be divided into two groups. 
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Table 1: Summary of the characteristics of different blood vessels.
Type of 
vessel
Actions Structure vessel wall Structure fits function
Artery Carries blood away from the 
heart to the arterioles at high 
pressure
Three-layer thick wall 
(endothelial lining, middle 
smooth muscle and elastic 
tissue layer, outer connective 
tissue layer; strong, elastic and 
flexible; narrow lumen
Strong, elastic walls and narrow 
lumen help to maintain high 
blood pressure
Arteriole Helps control blood flow from 
arteries to capillaries
Similar three layers as arteries 
but thinner; very narrow lumen
Vessel wall helps control blood 
flow by constricting or dilating
Capillary Supply tissue with nutrients 
and gases and removal of waste 
products
Single thin layer of endothelium Thin wall brings blood into 
close contact with tissue; 
allowing diffusion
Venule Connects capillaries to veins Thinner wall than arterioles, 
less smooth muscle and elastic 
tissue; extremely porous wall
Porous wall makes it easy for 
fluids and blood cells to pass 
through
Vein Carries relatively low-pressure 
blood from venules to the heart
Similar layers as arteries but 
thinner; thin middle layer but 
thicker outer layer; contains 
valves; wide lumen
Thin wall and wide lumen allow 
housing of a large volume of 
blood and offers less resistance 
to blood flow
1.	 Elastic	arteries
Elastic arteries are found close to the heart and receive blood directly from the heart. 
These arteries are called elastic because the tunica media is dominated by elastic laminae 
that give the vessel wall great elasticity, helping the artery to stretch in response to high 
pulsatile blood pressures during each heartbeat. The aorta, pulmonary trunk and the 
larger arteries that originate from them, are types of elastic arteries. Their tunica intima 
is thicker than that of muscular arteries and is surrounded by an internal elastic lamina, 
which is less well defined because of the abundance of elastic laminae. The tunica media 
of elastic arteries is much thicker compared to other arteries. It is primarily made up of 
multiple elastic laminae alternating with thin layers of smooth muscle cells and collagen 
fibers, which together form a lamellar unit. The external elastic lamina is difficult to distin-
guish from other elastic lamellar units in the tunica media. The tunica adventitia appears 
thinner than the tunica media and contains vasa vasorum, as the walls of these arteries 
are too thick to receive enough oxygen and nutrients from blood flow in the vessel lumen. 
The vasa vasorum supplies both the tunica media and the tunica adventitia with oxygen.
2. Muscular arteries
Muscular arteries are medium-sized arteries, which distribute the blood to various tissues 
and organs. These types of arteries include the femoral, brachial and coronary arteries. 
The diameter of the muscular artery lumen is on average 0.1 mm to 10 mm. The tunica 
intima of muscular arteries is thinner than those of elastic arteries. The tunica media 
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consists mostly of multiple layers of smooth muscle cells and less of elastic laminae. The 
elastic laminae are confined to two circumscribed rings: the internal elastic laminae and 
the external elastic laminae. The thickness and appearance of the tunica adventitia is 
variable. The greater amount of smooth muscle cells combined with less elastic laminae 
results in less elasticity but a better ability to constrict and dilate. 
Arterioles
Arterioles are the smallest arteries of the body and have the same three layers as the larger 
arteries. The critical endothelial lining of the tunica intima is intact, and it still rests on 
the internal elastic laminae, which is not always well defined in histological sections. The 
tunica media generally consists of less than six layers of smooth muscle cells and there 
is no external elastic lamina. The tunica adventitia is about the same size as the tunica 
media. The arteriole lumen is around 10-100 μm in diameter. As arterioles have a small 
diameter, they generate a great resistance to blood flow and are critically involved in slow-
ing down blood flow. Smooth muscle cells of the tunica media form concentric rings that 
control distribution of blood flow by either contracting or dilating lumen size. Normally, 
smooth muscle cells are slightly contracted, causing the arterioles to maintain a consistent 
vascular tone. 
Capillaries
Blood moves from the arterioles into the capillaries, which are tiny, narrow, thin-walled 
vessels that connect arteries with veins. Capillaries are the smallest of all blood vessels, 
about 5-8 μm in diameter, and blood pressure further drops as it encounters extra resis-
tance flowing through the capillaries. Their walls consist of a single layer of endothelial 
cells and an underlying basement membrane, often accompanied by pericytes. The base-
ment membrane keeps cells in place and is largely made up of proteins. Capillaries have 
no tunica media or tunica adventitia. The diameter of a capillary is just wide enough to 
allow single red blood cells (erythrocytes) to pass through. The thin wall of the capillar-
ies facilitates its primary function: exchange of oxygen, nutrients and other substances, 
between blood and the underlying tissue. Most capillaries are organized into a network 
called capillary bed. Based on the morphology of their endothelial layer, capillaries can be 
classified into three different types. 
1. Continuous capillaries consist of an uninterrupted, continuous lining of endothelial 
cells, which are joined by tight non-permeable junctions, and a complete basement 
membrane. The continuous capillaries have a low permeability to molecules; it only 
allows small molecules, like water and ions, to diffuse through the tight junctions, 
which have gaps of unjointed membrane called intercellular clefts. They are commonly 
found in skin, muscles, lung and central nervous tissue.
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2. Fenestrated capillaries have leakier intracellular junctions and perforations in the 
endothelial cell body, called fenestrae or pores. The fenestrae are present at both the 
luminal and basal surface of the cell, and the endothelial cells are surrounded by a 
continuous basement membrane. Fenestrated capillaries are much more permeable 
compared to continuous capillaries, and allow larger molecules and a limited amount 
of proteins to bypass the endothelial cells. The extent of fenestra may depend on the 
physiological state of the surrounding tissue, as their numbers may depend on the 
need to absorb or secrete. They are found in tissues that participate in fluid exchange 
including endocrine glands, intestinal villi and kidney glomeruli.
3. Discontinuous capillaries, also called sinusoids, are the largest of all capillaries and 
have larger, open spaces in the endothelium, containing a lot more intracellular clefts. 
They are very permeable (leaky) and allow large molecules, including red and white 
blood cells and various serum proteins, to pass through the intracellular spaces of the 
endothelium. Discontinuous capillaries contain a basement membrane that is often 
incomplete. These discontinuous capillaries are found in areas where the exchange of 
substances is advantageous, i.e. in the liver, hematopoietic organs (spleen and bone 
marrow) and some endocrine organs. 
Venules
Blood flows from the capillary beds into very small veins called venules (10-200 μm in di-
ameter). Venules allow deoxygenated blood to return from the capillary beds to the larger 
blood vessels called veins. Venules consist of a tunica intima, a thin tunica media and a 
tunica adventitia. The vessel wall of venules is thinner than arterioles and is extremely 
porous, making it easy for fluids and blood cells to pass through their walls.  Venules 
can be further subclassified into muscular (50-200 μm) and post-capillary venules (10-50 
μm). The post-capillary venule starts where two capillaries from the capillary bed come 
together. It is a non-muscular vessel, as the tunica media consists of an incomplete layer 
of pericytes and scattered smooth muscle cells. Instead, the post-capillary venule has 
a thin very permeable endothelial layer, making them the preferred site of white blood 
cell (leucocyte) adhesion and transmigration. Hence, the response of the vasculature to 
inflammation is generally localized in the post-capillary venules. During inflammatory 
responses, vasoactive substances act on the endothelium which results in extravasation of 
fluid and the migration of leucocytes into the tissue. Post-capillary venules join together, 
forming larger muscular venules. In the muscular venules, the pericytes are replaced by 
one or two layers of smooth muscle cells. 
veins
Multiple venules unite to form veins. Veins carry deoxygenated blood back from tissues 
and organs towards the heart. One difference between veins and arteries is the direction of 
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blood fl ow. As in arteries, veins have three layers. However, veins have much thinner walls 
than arteries as they are distant from the heart and subsequently experience less pressure 
from the blood fl ow. The tunica intima and tunica adventitia are similar in structure to 
arteries though the tunica media is much thinner. The tunica intima consists of the en-
dothelial lining with its basement membrane, and surrounding internal elastic laminae. 
The tunica media of veins is thin and only contains a few smooth muscle cells and elastic 
laminae, whereas the tunica adventitia is much thicker, containing collagen and occasion-
ally some smooth muscle cells and elastic fi bers. In general, veins are larger in diameter 
(varying from 1 mm to 15 mm), containing a wide lumen, which together with the thin 
walls allows the accommodation of a large blood volume. Most of the blood volume of the 
body, around 60%, is contained within veins at any time. Because of these thin walls and 
a small medial layer, veins do not have the same elasticity and vasoconstriction capacities 
as arteries. Blood is displaced through veins by contraction of the surrounding muscles 
and pressure gradients that are created during inhalation and exhalation. Compared to 
arteries, veins are frequently irregular of shape and softer. Some veins also contain valves, 
particularly veins in the legs, which prevent backfl ow of blood as it travels back to the 
heart. Veins can be classifi ed into four main types as shown in Box 1.2. 
Figure 1.5. Schematic view of the structural changes of the vessel wall during aging.
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Box 1.2 Classification of veins
1. Pulmonary veins carry oxygenated blood from the lungs to the left atrium of the heart
2. Systemic veins return deoxygenated blood from the rest of the body to the right atrium of the heart.
3. Superficial	veins are located close to the surface of the skin and are not located near a corresponding 
artery.
4. Deep veins are located within muscle tissue and typically near a corresponding artery.
Lymphatic vessels: secondary drainage system
The general structure of lymphatic vessels is based on the three tunica described above. 
Lymphatic vessels are lined by endothelial cells and have a thin layer of smooth muscle 
cells followed by the adventitia. They are part of the lymphatic system that transports fluid 
away from tissues and plays an important role in the body’s defense system. The fluid that 
lymphatic vessels carry is not blood, but is clear fluid, called lymph, that comes from blood 
plasma that exits blood vessels at the site of the capillaries. 
AGING ANd ThE vASCuLAR wALL
The prevalence of cardiovascular disease increases progressively with age. To understand 
why aging is closely linked to cardiovascular disease, it is essential to know what happens 
to our vessels during normal aging. Aging is a natural biological process that begins as 
soon as adulthood is reached and it causes diverse detrimental changes in cells and tis-
sues. A series of structural, architectural and compositional modification take place in 
the vasculature during aging (Fig. 1.5). As such, with increasing age, blood vessels lose 
their flexibility and structural integrity, which diminishes the ability of blood vessels to 
expand and contract efficiently. In addition, age-related vascular alterations lead to loss of 
adequate tissue perfusion (ischemia), insufficient vascular growth or excessive remodel-
ing. Eventually these changes affect cardiovascular performance and set the stage for the 
onset of several cardiovascular diseases including hypertension (high blood pressure), 
atherosclerosis, stroke and aneurysm formation. 
Age-related structural changes
At a microscopic level, principal age-related structural changes of the vasculature include 
an increase in vessel lumen size and thickening and stiffening of the intimal and medial 
layer. Important structural changes causally related to vessel wall thickening and stiffen-
ing include vascular smooth muscle enlargement and relocation to the subendothelial 
space, increased extracellular matrix accumulation (particularly rich in glycosaminogly-
cans), and increased deposition of lipids and calcium salts. While the content of collagen 
increases, elastin fibers become disorganized, thinner and fragmented.
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As an individual grows older, the endothelial barrier of the tunica intima becomes 
damaged and some of its specialized functions are blunted. The endothelial barrier 
becomes porous (leaky), the self-renewal process weakens and endothelial signaling is 
modified. For example, with increasing age endothelial cells produce substances that sig-
nal blood cells to adhere to the endothelial layer of the tunica media instead of smoothly 
flowing through the blood vessel lumen. Additionally, endothelial cells transmit signals 
to the underlying vascular smooth muscle cells in the tunica media that prompt these 
cells to change. These changes result in vascular smooth muscle cells to translocate and 
move towards the site of injury, where they reposition in the tunica intima just beneath 
the endothelial layer. At this site, the vascular smooth muscle cells multiply and produce 
matrix proteins, which eventually results in thickening of the tunica intima. Moreover, 
with age, some of the vascular smooth muscles of the tunica media die, increasing the 
workload of the remaining vascular smooth muscle cells and causing them to grow larger. 
Some changes cause vascular smooth muscle cells to switch from a contractile state to 
a state in which they produce excessive amounts of collagen proteins and other matrix 
substances, thereby creating imbalance between the elastin and collagen content of the 
tunica media. The ratio of collagen to elastin increases in favor of collagen, which is a 100 
to 1000 times stiffer than elastin, resulting in a stiffer wall and a less compliant blood ves-
sel. Moreover, vessel wall stiffening has been associated with the formation of cross-links 
between glucose and collagen. Growing levels of cross-links reduce elasticity of the vessel 
wall, as these cross-links glue together important proteins of the extracellular matrix 
thereby degrading its primary structure, preventing it from functioning correctly. Aging 
also affects elastin, as it becomes overloaded with calcium, stretches out, and eventually 
becomes fragmentized and disorganized. 
Related diseases
Due to structural changes in the vessel wall with age, many of the arteries are less able to 
withstand the forces of pulsating blood. High systolic blood pressure, which is commonly 
observed in the elderly, may exacerbate this problem. As a result, the vessel wall becomes 
weakened and more prone to develop several vascular diseases, including aneurysms. 
Moreover, aging increases incidence and severity of atherosclerosis, as the age-related 
changes of the vessel wall make it easier for fatty substances to accumulate inside of the 
blood vessel. Several studies suggest that exercise, good nutrition and therapeutic inter-
ventions can slow down the aging process occurring within blood vessels. For example, it 
in elderly who regularly exercise arterial stiffening is less pronounced. 
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SuMMARy
The vessel wall consists of three different layers termed tunica intima, tunica media and 
tunica adventitia. The main components of these layers include endothelial cells, vascular 
smooth muscle cells, cytoskeleton proteins and extracellular matrix proteins. Interaction 
between these components of the different layers determines the biological and physical 
properties of the blood vessel. Changes and damage to these components and cellular 
constituents contribute to the pathogenesis and progression of several vascular diseases, 
as well as to aging of the vasculature. The subsequent chapters in this book will cover, in 
greater detail, related diseases of the vasculature.
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ABSTRACT
The renin-angiotensin system (RAS) plays a critical role in the pathogenesis of many types 
of cardiovascular diseases including cardiomyopathy, valvular heart disease, aneurysms, 
stroke, coronary artery disease and vascular injury. Besides the classical regulatory effects 
on blood pressure and sodium homeostasis, the RAS is involved in the regulation of 
contractility and remodeling of the vessel wall. Numerous studies have shown beneficial 
effect of inhibition of this system in the pathogenesis of cardiovascular diseases. However, 
dysregulation and overexpression of the RAS, through different molecular mechanisms, 
also induces, the initiation of vascular damage. The key effector peptide of the RAS, an-
giotensin II (Ang II) promotes cell proliferation, apoptosis, fibrosis, oxidative stress and 
inflammation, processes known to contribute to remodeling of the vasculature. In this 
review, we focus on the components that are under the influence of the RAS and contrib-
ute to the development and progression of vascular disease; extracellular matrix defects, 
atherosclerosis and aging. Furthermore, the beneficial therapeutic effects of inhibition of 
the RAS on the vasculature are discussed, as well as the need for additive effects on top of 
RAS inhibition. 
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1. gEnERAL FunCTIon oF ThE REnIn-AngIoTEnSIn SYSTEM 
The renin-angiotensin system (RAS) is a peptide cascade well known for its critical role in 
the regulation of arterial blood pressure and sodium homeostasis, as well as cardiovascular 
regulation and remodeling. It regulates fl uid and electrolyte balance through coordinated 
eff ects on the heart, blood vessels and kidneys. Angiotensin II (Ang II) is the primary 
eff ector hormone of this system that can act either as a systemic hormone or as a locally 
produced factor. Ang II is generated in two sequential steps: renin, secreted from the 
juxtaglomerular apparatus of the kidney, cleaves angiotensin I (Ang I) from liver-derived 
angiotensinogen, and Ang I is subsequently hydrolyzed by endothelial angiotensin-
converting enzyme (ACE) to form Ang II. Ang II stimulates the adrenals to produce 
aldosterone and acts on cardiovascular and other tissues to regulate blood pressure and 
remodeling (Fig. 1). The recent identifi cation of angiotensin-converting enzyme 2 (ACE2), 
which is responsible for the conversion of Ang II to angiotensin (1-7), suggest that this en-
zyme is a negative regulator of Ang II production, and thus the balance between ACE and 
ACE2 is important in the regulation of Ang II levels, as depicted in Figure 1. In addition to 
Figure 1. Schematic overview of the renin-angiotensin system (RAS) and its intervening compounds. 
Liver-derived angiotensinogen is cleaved into angiotensin I (Ang I) by renin that is secreted from the 
kidney. Ang I is subsequently hydrolyzed by endothelial angiotensin-converting enzyme (ACE) to form 
angiotensin II (Ang II). Ang II stimulates the adrenals, via the angiotensin type 1 receptor (AT1R), to 
produce aldosterone and acts on cardiovascular and other tissues to regulate blood pressure and re-
modeling via the AT1R and angiotensin type 2 receptor (AT2R). Parts indicated in grey are only briefl y 
discussed in the review.
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the circulating RAS, there is increasing evidence for the existence of local or tissue RAS, 
which generate the Ang II that is involved in paracrine and/or autocrine signaling within 
organs and tissues. Tissue RAS is thought to be present in all major organs, including 
brain, heart, blood vessels, adrenals and the kidney.1 The exact function of vascular tissue 
RAS remains elusive, but it most likely contributes to the fine-tuning of Ang II actions on 
vascular tone and remodeling. A schematic representation of the RAS, based on what is 
currently known, is depicted in Figure 1. 
Ang II mediates its physiological actions mainly via two distinct receptors: angio-
tensin II  type 1 (AT1) and type 2 (AT2) receptors. The majority of the functions of Ang II 
are mediated through AT1 receptor binding, while the role and biological function of the 
AT2 receptor is less well-defined. Binding of Ang II to the AT1 receptor activates a series of 
signaling cascades leading to tissue remodeling and acute vasoconstriction, whereas bind-
ing to the AT2 receptor is believed to have counteractive effects, as it has been reported to 
inhibit and antagonize the AT1 receptor-mediated functions.2, 3 
1.1 Role of the RAS in the pathogenesis of vascular disease 
Cardiovascular diseases are a major cause of mortality worldwide. It is well established 
that RAS dysregulation and/or overexpression leads to a variety of harmful vascular ef-
fects, thereby contributing to the pathophysiology of cardiovascular diseases including 
hypertension, aneurysms, congestive heart failure, stroke, coronary artery disease and 
vascular injury.4 Besides the classical regulatory effects on blood pressure and sodium 
homeostasis, the RAS is involved in the regulation of vascular tone and remodeling of 
the vessel wall. Activation of the AT1 receptor by Ang II induces its well-known actions 
such as vasoconstriction, aldosterone and vasopressin release, renal tubular sodium re-
absorption, renal blood flow reduction, and production of reactive oxygen species. The 
signal transduction pathway for vasoconstriction is established by stimulation of the 
AT1 receptor which in turn activates phospholipase C, which cleaves the phospholipid 
phosphatidylinositol 4,5-bisphosphate into inositol-1,4,5-trisphosphate and diacylglyc-
erol. Inositol-1,4,5-trisphosphate induces Ca2+ release into the cytosol, thereby activating 
myosin light chain kinase which phosphorylates myosin. Diacylglycerol activates protein 
kinase C, which phosphorylates C-kinase potentiated protein phosphatase-1 which di-
rectly inhibits the activity of myosin light chain phosphatase.5 Both processes result in 
phosphorylation of myosin and thereby induce smooth muscle contraction. Moreover, 
AT1 receptor stimulation has been implicated to mediate tissue remodeling as it promotes 
vascular smooth muscle cell migration and senescence, vascular hypertrophy, endothelial 
dysfunction, oxidative stress and the synthesis and release of extracellular matrix protein.6 
Multiple signal transduction cascades with complex interactions are activated by the AT1 
receptor (Fig. 2), including the mitogen activated protein kinase (MAPK) and the janus 
kinase/signal transducers and activators of transcription pathway7, which together induce 
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cell growth, migration, proliferation and other processes linked to vascular remodeling. 
In addition, it is reported that Ang II acts pro-infl ammatory and pro-atherogenic, both 
contributing to vascular remodeling and damage. Accordingly, overstimulation of the 
AT1 receptor has been linked to various cardiovascular and renal pathologies such as left 
ventricular hypertrophy, vascular media hypertrophy, cardiac arrhythmias, atherosclerosis 
and glomerusclerosis.6 
Figure 2. Eff ect of angiotensin II (Ang II) signaling on vascular tone and remodeling of the vessel wall, 
via the angiotensin type 1 and 2 receptors (AT1R and AT2R). AT1 receptor activation induces vasoconstric-
tion, mediated by the inositol trisphosphate (IP3)-Ca2+ and diacylglycerol (DAG)-protein kinase C (PKC) 
pathways. This eff ect is counteracted by AT2 receptor-induced activation of nitric oxide synthase (NOS) 
leading to vasorelaxation. AT1 receptor stimulation also activates several signal transduction pathways 
which regulate the expression of target genes promoting cell proliferation, migration and senescence, 
vascular hypertrophy, infl ammation, apoptosis, oxidative stress and the synthesis and release of extra-
cellular matrix (ECM) proteins. Stimulation of the AT2 receptor inhibits these processes by blocking the 
mitogen-activated protein kinase (MAPK) signaling pathway. Abbreviations: janus kinase (JAK), nitric 
oxide (NO), phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2), phospholipase C (PLC), signal 
transducers and activators of transcription (STAT)
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As mentioned above, besides the AT1 receptor, Ang II can also mediate its effect via 
the AT2 receptor. Generally, the counteractive effects of the AT2 receptors, opposing those 
of AT1 receptors, lead to vasodilatation8, and suppression of growth, fibrosis and inflam-
mation (Fig. 2). However, the latter is not a uniform finding, because it has been shown 
that under certain conditions, e.g. in the spontaneously hypertensive rat, AT2 receptors 
may become AT1 receptor-like.9, 10 The mechanism behind this phenotypic change is un-
clear, but most likely involves a difference in location of endothelial cell versus vascular 
smooth muscle cell and/or heterodimerization with AT1 receptor.3 Therefore, whether 
upregulation of AT2 receptors under pathological conditions is always beneficial, should 
be questioned.11 Similar opposing findings are found in the heart; upregulation of AT2 re-
ceptors in the post-myocardial infarction area has beneficial effects, but a massive increase 
of 9-fold overexpression of AT2 receptors did not yield a positive effect anymore.12 Thus, 
the balance between the AT1/AT2 receptors in traumatized tissue will probably determine 
whether the net effect is adaptive or maladaptive. 
2. CoMPonEnTS ConTRIbuTIng To ThE DEVELoPMEnT AnD 
PROGRESSION OF vASCuLAR dISEASE
Several components which are under the influence of the RAS contribute to the develop-
ment and progression of vascular disease (Fig. 3). The key components oxidative stress, 
extracellular matrix defects, atherosclerosis and aging and their effect on the vasculature 
will be discussed in this review.
2.1 oxidative stress leading to vascular damage
It is well established that reactive oxygen species play a fundamental role in vascular dam-
age and the development of cardiovascular disease.13, 14 Reactive oxygen species include 
free radicals, mainly superoxide anions and hydroxyl radicals, and other molecules such 
as hydrogen peroxide and ozone. They are generated during cellular metabolism, in the 
vessel wall by all vascular cells, including endothelial cells, smooth muscle cells and ad-
ventitial fibroblasts. Several cellular sources are known to produce reactive oxygen species, 
with mitochondria as a major site of production. In general, reactive oxygen species are es-
sential in the functioning of cells as they modulate many downstream signaling molecules 
regulating cell growth and vascular contraction and relaxation. However, an imbalance 
between reactive oxygen species generation and antioxidant protection, resulting in 
increased bioavailability of reactive oxygen species, leads to a state of oxidative stress. 
Oxidative stress contributes to vascular remodeling and dysfunction as it activates a series 
of signaling pathways involving MAPK, tyrosine kinases, protein tyrosine phosphatases, 
calcium channels and redox-sensitive transcription factors. Activation of all these factors 
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results in increased cell migration and proliferation, expression of pro-infl ammatory 
genes, extracellular matrix production and apoptosis in the vessel wall, which all play an 
important role in vascular injury.15, 16 In addition, oxidative stress induces enhanced oxida-
tion of low-density lipoproteins and inactivation of endothelial derived nitric oxide, pro-
cesses known to be involved in atherosclerotic disease. Moreover, oxidative stress is known 
to induce DNA damage. As such, reactive oxygen species are the most likely trigger of DNA 
damage in atherosclerosis17, where DNA damage is present in both plaques of patients 
with atherosclerosis as well as in the circulating blood cells of these patients.18 Multiple 
lines of evidence indicate that the RAS contributes to reactive oxygen species generation 
and its deleterious eff ects. One of the eff ects of AT1 receptor activation in cardiovascular 
tissue is the generation of reactive oxygen species19, as Ang II stimulates the expression and 
activation of nicotinamide adenine dinucleotide phosphate-oxidase (NAD(P)H) in various 
cells (Fig. 4).20, 21  In several Ang II-associated vascular diseases the occurrence of oxidative 
stress has been shown to be the result of activation of NAD(P)H oxidase, mitochondrial 
dysfunction, infl ammation and the reduction of endogenous antioxidant enzymes.22 In 
various pathological conditions it was found that elevated Ang II levels lead to upregula-
tion of the NAD(P)H oxidase subunits in endothelial, adventitial and vascular smooth 
muscle cells, resulting in increased levels of reactive oxygen species in the vessel wall.15 
Figure 3. Interplay between the renin angiotensin system (RAS) and reactive oxygen species on three 
important components; extracellular matrix (ECM) defects, plaque build-up and aging, together con-
tributing to the development and progression of age-related vascular disease. Abbreviations: reactive 
oxygen species (ROS).
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Of note, reactive oxygen species in turn have been shown to cause increased expression of 
the AT1 receptor, thereby modulating the generation of reactive oxygen species, creating 
a vicious circle.23, 24 Moreover, in recent years it has become evident that Ang II not only 
activates NAD(P)H but also stimulates mitochondrial reactive oxygen species production 
and induces mitochondrial dysfunction, presented as increased mitochondrial hydrogen 
peroxide production, and decreased mitochondrial glutathione, state 3 respiration and 
membrane potential.25, 26 Molecular mechanisms that are involved in Ang II-induced 
mitochondrial dysfunction include protein kinase C activation, which in turn activates 
NAD(P)H and stimulates peroxinitrite formation.25 Moreover, Ang II-derived reactive 
oxygen species production triggers mitochondrial ATP-dependent potassium (mitoKATP) 
channel opening, which further promotes mitochondrial reactive oxygen species gen-
eration.27 Research has shown that mitochondria-derived reactive oxygen species play an 
important role in the development of cardiovascular disease, and therapeutic targeting 
of mitochondrial reactive oxygen species by using a mitochondria-targeted antioxidant, 
significantly decreased blood pressure in Ang II-induced hypertension, and improved 
endothelial dysfunction.28, 29 Moreover, it is suggested that mitochondrial dysfunction 
initiated by reactive oxygen species is one of the causes of aging, implying an important 
role of Ang II in aging and age-related diseases (Fig. 4). 
2.2 Extracellular matrix defects and vascular disease
The extracellular matrix is composed of numerous macromolecules, including collagens, 
elastin and proteoglycans. These extracellular matrix molecules not only provide structural 
support to cells and tissues, but also exhibit important functional roles that control the 
behavior of cells such as adhesion, migration, proliferation and differentiation. Moreover, 
the extracellular matrix provides mechanical properties required for the functioning of 
the vasculature.30 Minor alterations in extracellular matrix composition of the vasculature 
can lead to changes in cellular phenotype and function, which can ultimately lead to 
development of vascular disease. Diseases that are associated with an extracellular matrix 
defect include cutis laxa, osteogenesis imperfecta, Ehlers-Danlos and Marfan syndrome.31 
Moreover, it is suggested that alterations towards the breakdown of the extracellular ma-
trix contributes to the progression of atherosclerosis and plaque instability32, and to the 
formation of aortic aneurysms.33, 34 It is suggested that the RAS plays a role in the alteration 
of extracellular matrix components as numerous studies have shown that blockade of the 
RAS reduces the incidence and progression of aortic aneurysms (which is discussed in 
section 3 of this review), although the precise role of the RAS in the onset of extracellular 
matrix defects is not well-understood yet. 
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2.2.1	The	involvement	of	RAS	in	alterati	ons	of	the	extracellular	matrix
Accumulating evidence indicates that increased Ang II signaling in the vessel wall results 
in the release of infl ammatory and pro-fi brotic factors, and regulate the genetic expres-
Figure 4. Eff ects of angiotensin type 1 receptor (AT1R) activation -via angiotensin II (Ang II) receptor 
binding- on reactive oxygen species generation, leading to age-related vascular diseases. AT1R stimula-
tion upregulates nicotinamide adenine dinucleotide phosphate-oxidase (NAD(P)H), thereby increas-
ing the formation of reactive oxygen species. Reactive oxygen species in turn activates several signal-
ing pathways and induces damage to macromolecules, eventually contributing to the pathogenesis of 
age-related vascular disease. Abbreviations: extracellular matrix (ECM), low density lipoprotein (LDL), 
mitogen-activated protein kinase (MAPK), nitric oxide (NO), renin angiotensin system (RAS), reactive 
oxygen species (ROS).
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sion of extracellular matrix proteins, which might lead to defects in the build-up of the 
extracellular matrix. As such, Ang II has been shown to promote vascular smooth muscle 
cells to synthesize extracellular matrix components.35 For instance, Ang II-induced cul-
tured rat vascular smooth muscle cells display increased levels of collagen, fibronectin, 
laminin and tenascin mRNA and protein.36-38 Additionally, in vivo Ang II infusion results in 
increased fibronectin mRNA and protein.39 Furthermore, Ang II stimulates the induction 
of various growth factors, inflammatory and pro-fibrotic factors including transforming 
growth factor beta (TGF-β)40, platelet-derived growth factor41, basic fibroblast growth fac-
tor40, vascular endothelial growth factor42 and insulin-like growth factor.43 Ang II-induced 
TGF-β mRNA expression in vascular smooth muscle cells is mediated by activation of 
extracellular-signal-regulated kinase (ERK) and activator protein-1.44 Ang II stimulates 
mRNA expression and activity of plasminogen activator inhibitor-1 and -2 in rat aortic 
smooth muscle cell.45 It is intriguing that all these factors could play an important role in 
Ang II-mediated vascular disease. 
2.2.2	Effect	of	Ang	II	induced	TGF-β	activation	in	extracellular	matrix	disruption	and	
vascular disease
TGF-β production by Ang II has a pivotal role in vascular disease and fibrosis. TGF-b is a 
pleiotropic cytokine that regulates diverse functions such as proliferation, differentiation 
and apoptosis. Increased TGF-b-signaling results in increased pSmad2/3 signaling, the 
canonical pathway, and recent work has also shown an increase in pERK1/2 signaling, the 
so-called non-canonical pathway.46-48 Activation of these pathways leads to changes in 
adhesion, proliferation, migration and differentiation. Moreover, TGF-b signaling plays a 
crucial role in the regulation of the extracellular matrix, mainly by stimulating the expres-
sion of collagens, fibronectin and proteoglycans. Furthermore, it induces the production 
of metalloproteinases that affect extracellular matrix breakdown. Thus, persistent activa-
tion of TGF-β receptors leads to an abnormal deposition of connective tissue, which is 
associated with fibrotic disease and vascular disease.49, 50 
2.2.3	Involvement	of	Ang	II-mediated	extracellular	matrix	defects	in	aortic	aneurysms
The strength and elasticity of our blood vessels is mainly established by the extracellular 
matrix components elastin and collagen, which originate in the medial layer of the vessel 
wall. Degeneration of the medial layer of the aorta allows the development of an aneurysm, 
which is characterized by elastic fiber fragmentation, loss of smooth muscle cells, and ac-
cumulation of amorphous extracellular matrix.51 Two main types of aortic aneurysms can 
be distinguished; abdominal aortic aneurysm and thoracic aortic aneurysm. Abdominal 
aortic aneurysms are usually caused by multiple environmental factors, such as smoking, 
high blood pressure and inflammation, while the development of thoracic aortic aneu-
rysms often has a genetic origin. Different experimental mouse models for abdominal 
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aortic aneurysms exist, for instance the well-recognized mouse models with infusion of 
Ang II in atherosclerotic apolipoprotein E - or low density lipoproteins (LDL) receptor 
knock out mice resulting in abdominal aneurysm formation. In contrast, most mouse 
models for thoracic aortic aneurysms are genetically engineered, containing mutations 
in for example extracellular matrix proteins and TGF-b receptors. A well-known genetic 
disease characterized by thoracic aortic aneurysms is Marfan syndrome, which is caused 
by a mutation in the extracellular matrix protein fibrillin-1.52 Accumulating evidence 
in different thoracic aortic aneurysms mouse models has shown that increased TGF-b-
signaling in the vasculature is responsible for the development of aneurysms, which will 
be discussed in more detail below. It is suggested that this increase in TGF-b-signaling 
leading to aortic aneurysm development is initiated by Ang II.48, 53, 54 Moreover, recently it 
has been shown that blockade of the RAS downregulates pSmad2/3 and pERK1/2 signaling 
in aortic aneurysm, which gave rise to a new proposed signaling mechanism in which the 
AT1/AT2 receptors are directly involved in Smad2/3 and ERK1/2 activation.46, 47
2.3 Involvement of the RAS in atherosclerosis 
Atherosclerosis refers to the build-up of fat, cholesterol and other substances in and 
around the vasculature. Over time this build-up, so-called plaques, causes thickening 
and stiffening of the vessel wall. Moreover, as these plaques grow larger and larger, they 
eventually partially or totally block the blood flow through an artery. Numerous cardio-
vascular diseases are a direct consequence of the atherosclerotic process. Diseases that 
could develop as a result of this plaque build-up include coronary heart disease, carotid 
artery disease, peripheral artery disease and chronic kidney disease. Two types of plaques 
are described in literature; stable and unstable/vulnerable plaques, the latter having a 
high risk of rupture.55 Plaque rupture and subsequent thrombus formation are among  the 
main causes of acute cardiovascular events like unstable angina, acute myocardial infarc-
tion and sudden cardiac death.56 It is suggested that loss of vascular function together 
with oxidation and accumulation of low-density lipoprotein and endothelial damage 
promotes an inflammatory vascular response, which plays an essential role in the devel-
opment of atherosclerotic plaques. Several risk factors are strongly associated with the 
onset of plaque build-up such as aging, smoking, lack of physical activity, unhealthy diet, 
hypercholesterolemia, hypertension and genetic background. In addition, it is proposed 
that the RAS, and particularly Ang II, is involved in the initiation and progression of 
atherosclerotic plaques, since various atherogenic stimuli are mediated by RAS activity.57 
Ang II stimulates the atherogenic process not only through its hemodynamic effects but 
also through various effects on the vessel wall itself.58 In particular, Ang II promotes the 
generation of oxidative stress in the vasculature, which plays a pivotal role in endothelial 
dysfunction and lipoprotein oxidation. Furthermore, Ang II induces the expression of cel-
lular adhesion molecules and pro-inflammatory cytokines, which contribute to the induc-
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tion of the inflammatory process in the vessel wall. Ang II also triggers vascular smooth 
muscle cells to proliferate and migrate, subsequently leading them to produce growth 
factors and extracellular matrix components. It was also reported that overexpression of 
ACE2, which converts Ang II to Ang-(1-7), improves endothelial function and decreases 
plaque formation in atherosclerotic mice.59, 60 Moreover, several studies suggest that Ang II 
may be involved in the acute complications of atherosclerosis by promoting plaque vulner-
ability, eventually resulting in plaque rupture.61-64
2.3.1	Evidence	for	the	contribution	of	the	RAS	in	atherosclerotic	plaque	build-up
The initial steps of the atherogenic process include endothelial damage and dysfunction, 
which allows the migration of inflammatory cells and lipid particles into the damaged part 
of the vessel wall, where they accumulate and form a ‘fatty streak’. These lipid particles 
are taken up by macrophages and smooth muscle cells, which become fat-laden foam 
cells and release substances which trigger a greater inflammatory response. Next, smooth 
muscle cells migrate to the inner layer of the vessel wall, where they proliferate, produce 
extracellular matrix components and contribute to the formation of the fibrous cap cover-
ing the plaque. These processes together result in growth of the plaque.65 Over time the 
plaque may become destabilized, resulting in plaque rupture which manifests as acute 
cardiovascular events. 
It has become apparent that one of the most important mechanisms whereby Ang II 
exerts vascular damage, is the production and release of reactive oxygen species via stimu-
lation of NAD(P)H.19 Oxidative stress, which is caused by an imbalance between reactive 
oxygen species and antioxidants, induces nitric oxide inactivation, lipid oxidation, modi-
fications in DNA and proteins, and activation of adhesion molecules, pro-inflammatory 
cytokines and matrix metalloproteinases. As discussed, Ang II induces reactive oxygen 
species generation in various vascular cells including smooth muscle cells, endothelial 
cells and adventitial fibroblasts by binding to the AT1 receptor, expressed by these cells.66 
Enhanced levels of reactive oxygen species are an important feature of atherosclerosis. 
Reactive oxygen species are detected in all layers of the atherosclerotic vessel wall, par-
ticularly at pathophysiological relevant locations of the atherogenic process, such as the 
shoulder region of coronary atherosclerotic plaques where they co-localize with Ang II.67-69 
An additional mechanism by which Ang II promotes atherosclerosis is endothelial 
dysfunction, which is considered one of the earliest steps in the atherosclerotic process. 
Several animal studies show that Ang II causes endothelial dysfunction, measured by 
impaired vasorelaxation in response to acetylcholine, which is a endothelium-dependent 
vasodilator.20, 70, 71 Endothelial cells are the major regulators of vascular homeostasis and 
anticoagulant properties of the vessel. Endothelial dysfunction and/or apoptosis is consid-
ered to be an initial step in the development and progression of atherosclerotic plaques as 
it promotes abnormal vasomotion, a procoagulant state, and infiltration of inflammatory 
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cells into the vessel wall.72 Oxidative stress is recognized as one of the main factors that 
promotes vascular endothelial dysfunction, as elevated levels of reactive oxygen species 
caused by Ang II induce impaired endothelial relaxation and vascular function. Nitric ox-
ide, which is a potent vasodilator produced by endothelial cells, is inactivated in response 
to reactive oxygen species. Additionally, it is suggested that a more direct effect of Ang II 
on endothelial cells exist, as Ang II stimulates them to express various adhesion molecules 
and atherogenic genes. For instance, Ang II stimulates the mRNA and protein expression 
of vascular cell adhesion molecule-1, which leads to the recruitment of inflammatory cells 
to the site of plaque formation.73, 74 Furthermore, Ang II was shown to regulate the expres-
sion of plasminogen activator inhibitor-175, 76 and stimulate endothelial cell apoptosis77, 
resulting in an alteration in fibrinolytic balance which could lead to a highly thrombogenic 
state. 
Another phase in the atherosclerotic process is fatty streak formation, character-
ized by oxidation of LDL, which Ang II facilitates by promoting reactive oxygen species 
formation. Oxidized LDL particles have important atherogenic properties as they can 
penetrate the endothelial layer after which they are taken up by macrophages and vascu-
lar smooth muscle cells, contributing to the creation of so-called foam cells. Moreover, 
Ang II increases the uptake of oxidized LDL by endothelial cells and macrophages, as 
it upregulates the expression of receptors that take up oxidized LDL, in the end leading 
to endothelial dysfunction.78 Furthermore, oxidized LDL also triggers an inflammatory 
process that accelerates the formation of atherosclerotic plaques.  
In atherosclerosis, vascular smooth muscle cells are involved in the stability of the 
plaque as they contribute to the formation of the fibrous cap. It is reported that Ang II 
triggers vascular smooth muscle cells to proliferate and migrate to the outer layer of the 
atherosclerotic plaques, where they produce growth factors and extracellular matrix pro-
teins.21, 79 With the secretion of extracellular matrix components by smooth muscle cells, 
the plaques increase in size and eventually become occlusive resulting in the occurrence of 
acute complications. Thus, inhibition of smooth muscle cell migration and proliferation 
may be beneficial to prevent early lesion formation, though, it might influence the stabil-
ity of the plaque at the same time. 
The progression of atherosclerosis is considered to be inflammation-driven, as 
advanced lesions of atherosclerosis are predominantly constituted of macrophages and 
lymphocytes. As mentioned, activation of the RAS increases the expression of adhesion 
molecules and pro-inflammatory chemokines and cytokines, leading to the recruitment 
and activation of various inflammatory cells into the vessel wall.80 For example, Ang II 
activates nuclear factor κB (NFκB) which promotes the expression of adhesion molecules 
such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, 
and chemoattractant proteins such as monocyte chemoattractant protein-1.81 Moreover, 
a study by Daugherty et al. shows that Ang II infusion in mice promoted rapid formation 
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of atherosclerotic plaques, and that these lesions were mainly dominated by lipid-laden 
macrophages and lymphocytes.82 In addition, transiently heightened levels of Ang II in 
apolipoprotein E-deficient mice already caused a profound increase in atherosclerosis, 
attributable to stimulated expression of various immunological markers, including mono-
cyte chemoattractant protein-1.83 Ang II was also found to induce interleukin-6 expression 
in cultured vascular smooth muscle cells84 and in advanced atherosclerotic lesions Ang II 
stimulates the expression of matrix metalloproteinase and plasminogen activator inhibi-
tor-1, which leads to the destabilization of these plaques.76, 85 Thus, Ang II stimulates the 
interaction between vascular cells and leukocytes contributing to the pathophysiology of 
atherosclerosis. 
2.4 Aging: a key player in vascular damage
Aging is a natural biological process that is associated with diverse detrimental changes 
in cells and tissues resulting in an increased risk of health complications and disease with 
increasing age. As such, with age, various cardiovascular diseases including heart failure, 
myocardial infarction, atherosclerosis and hypertension increase tremendously.86 During 
aging, a general decline in organ function occurs, and alterations in structure and func-
tion of the heart and the vasculature will eventually affect cardiovascular performance. 
For instance, elderly people are more affected by cardiac rhythm disturbances such as 
atrial fibrillation and most often have a reduced cardiac output. Additionally, age-related 
changes in the vasculature often relate to arterial stiffening, atherosclerosis, as well as 
an increased blood pressure. Whether the prevalence of cardiovascular disorders in the 
elderly is due to the aging process or whether these disorders occur more frequently be-
cause of longer exposure to risk factors is not well-defined yet. Research has shown that 
age-associated changes in structure and function of the vasculature share similarities with 
vascular changes seen in early stages of cardiovascular disease.87, 88 With aging, the vessel 
wall gradually thickens and becomes stiffer, accompanied by impairment of vascular tone 
due to endothelial dysfunction. Moreover, age-related vascular damage is associated with 
increased extracellular matrix deposition, apoptosis, cell senescence and fibrosis.89-91 The 
mechanisms underlying age-related vascular disease involve multiple factors and path-
ways, including oxidative stress, mechanical fatigue and environmental factors (e.g. food 
intake and diet). Further, it is reported that the systemic RAS is suppressed during normal 
aging. However, the activity of tissue RAS is not well defined yet. Research has shown 
that during aging, ACE is increased in vascular smooth muscle cells as well as vascular 
endothelial cells.92-94 Additionally, upregulation of chymase is observed in the vessel wall 
during aging.93 Although chymase is capable of converting Ang I to Ang II in vitro, its role 
in vivo is still controversial.95, 96 Microarray analysis confirmed the upregulation of several 
genes within the RAS pathway in the vessel wall of aged mice.97 Consequently, Ang II 
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is increased in the vasculature during advanced aging and was found to induce arterial 
remodeling in young animals, which mimicked features of vascular aging.98
2.4.1	The	involvement	of	RAS	components	in	aging	and	the	effect	on	vascular	damage
During aging, dysfunction of both endothelial cells as well as vascular smooth muscle 
cells occurs. Advanced aging leads to impaired endothelial nitric oxide synthesis resulting 
in a decline in endothelium-dependent vascular dilatation and eventually vascular stiff-
ness.99, 100 Additionally, the endothelial barrier becomes porous allowing the migration 
of vascular smooth muscle cells into the intima layer of the vessel wall where they pro-
liferate and deposit extracellular matrix proteins resulting in vessel wall thickening. It is 
demonstrated that Ang II induces expression and activation of matrix metalloproteinase 
2 and calpain-1 in the arterial wall, which has been linked to an age-related increase in 
migration capacity of vascular smooth muscle cells.98, 101 The migration of these vascular 
smooth muscle cells is accompanied by Ang II-mediated increase in TGF-β-1 activity and 
collagen deposition, leading to thickening of the vessel wall mimicking features of the 
aging vasculature.98 Furthermore, Kunieda and co-workers showed that Ang II signaling 
promotes a vascular aging phenotype by inducing vascular cell senescence.102 
It has been proposed that a prominent cause of aging is the accumulation of unre-
paired DNA damage103-105, and considerable evidence supports a crucial role of DNA damage 
in the development of vascular disease, especially atherosclerosis.106 DNA damage can be 
induced by exogenous and endogenous sources, including reactive oxygen species. It has 
been widely postulated that oxidative stress is a major determinant of lifespan, as it trig-
gers mitochondrial dysfunction and cellular injury by targeting DNA, protein, lipids and 
other components of the cell, and thus is causatively involved in the aging process.25, 107, 108 
Oxidative stress not only leads to accumulation of reactive oxygen species but can also 
modify or damage DNA, processes known to be involved in aging. Research has linked 
enhanced reactive oxygen species to many age-related degenerative diseases including 
atherosclerosis, stroke and heart disease. Locally, an unbalance in reactive oxygen spe-
cies can have deleterious effects as it can disturb cell signaling and can trigger apoptosis, 
cellular senescence and inflammation. It has been demonstrated that the RAS plays a role 
in age-related upregulation of reactive oxygen species, as increased Ang II/AT1 receptor 
signaling activates NAD(P)H, leading to increased reactive oxygen species production in 
both vascular endothelial cells and vascular smooth muscle cells.109 Benigni et al. reported 
that disruption of the AT1 receptor in mice promotes longevity, probably through reduced 
oxidative stress and overexpression of pro-survival genes.110 During aging, these mice also 
develop less atherosclerotic plaques and cardiac injury. As mentioned, oxidative stress 
also modifies and/or damages DNA, leading to altered gene expression which contributes 
to the aging process. As such, it was shown that Ang II induces DNA damage in epithelial 
human and porcine kidney cell lines, as well as in isolated mouse kidneys.111, 112 In addition, 
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Ang II-induced reactive oxygen species results in DNA damage, leading to senescence 
and an accelerated aging phenotype of vascular smooth muscle cells.102, 113 Thus, Ang II 
increases oxidative stress in the vasculature which leads to cell and organ deterioration, 
thereby accelerating the aging process resulting in an increased risk for vascular disease.  
Moreover, mitochondrial dysfunction represents a common feature of the aging 
process. Mitochondria itself are a major source of reactive oxygen species during aging, and 
age-related mitochondrial dysfunction closely correlates with enhanced mitochondrial 
reactive oxygen species production reviewed by.114, 115 reactive oxygen species production 
by mitochondria contributes to Ang II-induced vascular alterations and dysfunction116 and 
Ang II blockade can protect against age-related mitochondrial dysfunction.117 A schematic 
representation of this interaction is given in Figure 4. Furthermore, transgenic mice over-
expressing mitochondrial superoxide dismutase 2, the critical scavenger of mitochondrial 
reactive oxygen species, demonstrated attenuated Ang II-induced hypertension and vas-
cular oxidative stress.28 
2.4.2 The role of RAS and aging in atherosclerosis
Especially atherosclerosis is an age-related disease as the prevalence and severity of 
atherosclerosis strikingly increase with age. There is evidence of accelerated cellular ag-
ing in atherosclerosis which includes impaired proliferation, cell senescence and DNA 
damage.118 It was also found by Wang et al. that age-associated arterial remodeling and 
the development and progression of experimental atherosclerosis in young animals share 
common mechanisms, such as increased matrix metalloproteinase activity and Ang II sig-
naling.93 Moreover, it is suggested that aging prolongs the exposure to risk factors, which 
can cause increased production of reactive oxygen species within the vessel wall and the 
atherosclerotic plaque.  
2.5 The role of RAS in age-associated gender differences in vascular disease
Growing evidence suggests that the development of vascular disease in women is different 
from that in men. Sex hormones play a key role in the gender-associated difference in 
pathophysiology of cardiovascular diseases.119 Young, premenopausal women have a lower 
cardiovascular risk compared to men, which points to estrogen as a protective factor. For 
instance, blood pressure is found to be higher in men compared to age-matched women, 
while after menopause blood pressure rises sharply in women, again suggestive for a role 
of estrogen.120 Furthermore, in menopausal and aged female rats, age-related vascular 
dysfunction is increased due to lack of estrogen.121, 122 Moreover, studies have shown that 
estrogen is involved in regulation of the RAS: estrogens increase angiotensinogen and AT2 
receptor density, while they decrease renin, ACE and AT1 receptor density.123 In animal mod-
els of menopause, chronic replacement of estrogen reduces ACE activity in the aorta.124, 125 
Hence, as estrogen inhibits ACE expression in the vasculature124, it subsequently reduces 
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the production of Ang II. Additionally, estrogen weakens the response and expression of 
the AT1 receptor in the heart and the aorta.126, 127 Thus, loss of estrogen production with 
menopause is associated with increased RAS signaling, leading to an increased risk for 
developing vascular disease. 
Research has shown that the systemic RAS is suppressed during normal aging, which 
could be related to an increase in systolic blood pressure as described in the elderly.128, 129 
An increase in blood pressure during aging may suppress renin release from the kidney 
due to a higher perfusion pressure at the juxtaglomerular cells, contributing to the decline 
in circulating RAS. However, the activity of tissue RAS during aging is not yet well-defined. 
In humans, increased levels of Ang II, AT1 receptor, ACE and adventitial chymase are 
found in the aortic wall of older donors.94 Activation of these components not only leads to 
elevated blood pressure, but also results in harmful effect on the vasculature. These results 
are consistent with findings in postmenopausal women, and in men mentioned above, 
when compared to premenopausal women. Though it is known that aging exerts different 
effects on males compared to females, the precise actions of aging on the RAS and gender 
in different tissues are not well-established yet, and should be further elucidated. 
3. ThERAPEuTIC APPRoAChES To TARgET RAS In VASCuLAR DISEASE
Current medical therapies for managing Ang II-associated vascular diseases include 
β–blockers, statins, diuretics, calcium channel blockers and RAS inhibitors. In recent 
years, components of the RAS have become important targets in cardiovascular disease. 
Inhibition of the RAS is recommended for managing most of the cardiovascular diseases, 
such as hypertension, heart failure, acute myocardial infarction and stroke. Therapeutic 
interventions that control the effects of the RAS are often used for treatment of high blood 
pressure, particularly in young patients. In addition to their blood pressure-lowering ef-
fects, RAS inhibitors are also suggested to have additional cardioprotective effects. Both 
animal and human studies show that RAS blockade not only lowers blood pressure but 
may also prevent age-related structural and functional alterations in several organs.130 
3.1 Current RAS-related therapeutic interventions for age-related vascular disease
There are several classes of RAS inhibitors available, including ACE inhibitors, angiotensin 
receptor blockers, direct renin inhibitors and mineralocorticoid receptor antagonists. All 
four of these inhibitors interrupt the formation or block the effect of Ang II and/or aldo-
sterone. Monotherapy using ACE inhibitors cannot completely block the persistent activa-
tion of the RAS, due to either renin upregulation and/or the existence of ACE-independent 
pathways that convert Ang I to Ang II. Therefore, dual RAS blockade, in particular by com-
bining ACE inhibitors and angiotensin receptor blockers, has been proposed in patients 
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with cardiovascular and renal disease, to obtain a more complete blockade of the RAS. 
Because of the reported deleterious effects of Ang II on cardiovascular tissue, it seems 
logical to target the RAS and thereby reduce the development of cardiovascular damage.
Several studies already demonstrated that ACE inhibitors might inhibit atherosclero-
sis in animal models independent of blood pressure lowering.131-133 Additionally, renin inhibi-
tion and angiotensin receptor blockers reduced atherosclerotic lesion size in cholesterol fed 
mice susceptible for atherosclerosis.134-137 Moreover, research in aneurysmal mouse models 
has shown that inhibition of the RAS reduces the formation and progression of aortic an-
eurysms. Inhibition and/or blockade of the RAS reduces the incidence, progression and 
mortality in mouse models of abdominal aortic aneurysms.138, 139 Especially in mouse models 
of thoracic aortic aneurysms, inhibition of the RAS by AT1 receptor blockade (by losartan) 
or TGF-b-signaling (by TGF-b-neutralizing antibodies) effectively blocks the production of 
downstream TGF-β and thereby inhibits aortic root dilatation and aneurysm formation.46-48 
This new mechanism of decreased TGF-b-signaling by blocking the RAS has initiated 
numerous clinical trials and different aneurysmal mouse model studies to investigate the 
potency of RAS blockade.140, 141 Yet, the efficacy of several Ang II receptor blockers varies 
between different animal models and patients with aneurysm disease142, 143, indicating that 
further investigation into the role of RAS targeting in cardiovascular disease is warranted. 
Controversy remains as research has shown that dual RAS blockade gave conflict-
ing results in different patient populations and was associated with adverse side effects. 
Combination of ACE inhibitors with angiotensin receptor blockers in the elderly with 
cardiovascular complications, is linked to an increased risk of adverse renal outcomes 
with higher rate of hyperkalemia, renal dysfunction and no observed benefit with respect 
to overall mortality.144-147 Additionally, several clinical studies on dual RAS blockade were 
terminated early due to adverse side effects, implying that dual RAS blockade is not rec-
ommended. This might relate to the fact that a certain level of RAS activity is still required 
for proper physiological functioning of tissues, e.g., in the kidney148, and that blockade of 
the RAS should be optimal rather than maximal. Moreover, some patients fail to respond 
positively to these treatments. As described above, variation exists in RAS between men 
and women but also at different ages, which complicates the prediction of how elderly will 
react to therapeutic intervention strategies for vascular disease. Thus, blocking and/or 
inhibiting the RAS should take disease, age and gender into account.149 
Although the standard therapeutic interventions to control the effects of RAS 
activation, i.e. ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors and 
mineralocorticoid receptor antagonists, are effective in controlling the progression of 
vascular disease in some patients, they are not effective in preventing the onset of new 
cardiovascular diseases, and vascular disease still persists as a leading cause of illness 
and death. Moreover, many RAS inhibiting therapies are not 100 percent effective in all 
patients and additionally give adverse side effects. Thus, it is necessary to identify bet-
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ter therapeutic targets and strategies, which more successfully prevent and/or slow the 
progression of age-related vascular disease.
3.2 Indirect modulation of RAS in vascular disease: caloric restriction and anti-
oxidants
One of the best anti-aging strategies so far has been shown to be associated with diet intake. 
Research has discovered that our diet has a great impact on life span and age-related diseases. 
Caloric restriction, defined as a reduction of 70% in calorie intake without malnutrition, has 
been shown to be the most potent strategy to slow the aging process and it extends life span 
in different short lived species, such as mice and rats. Moreover, caloric restriction has as 
number of beneficial effects on the aging cardiovascular system (reviewed by Weiss and 
Fontana).150 In rhesus monkeys it has been shown that caloric restriction delays the onset 
of age-associated pathologies, which not only prolongs lifespan but also protects against 
the onset of cardiovascular disease.151 The biological mechanisms that induce the beneficial 
effects include modifications in energy metabolism and insulin sensitivity, increased oxida-
tive stress resistance, reduced production of mitochondria-derived reactive oxygen species 
and reduced inflammation.152-154 In the vasculature, caloric restriction also enhances endo-
thelial function and reduces the size and progression of atherosclerotic plaque formation 
in apolipoprotein E-deficient mice.155 Furthermore, in the aorta it was shown that caloric 
restriction not only attenuates the production of reactive oxygen species and oxidative dam-
age, but it also increases levels of the endogenous antioxidant glutathione and ascorbate.156 
Additionally, Finckenberg et al. showed that caloric restriction effectively ameliorates Ang 
II-induced mitochondrial remodeling and cardiac hypertrophy in transgenic rats expressing 
human renin and angiotensin genes, leading to a reduction in overall mortality.157 This study 
also showed that caloric restriction attenuates fibrosis and cardiomyocyte apoptosis. Even 
though not much is known about the effect of caloric restriction on Ang II-induced vascular 
damage, it is suggested that caloric restriction may have beneficial effects as it attenuates 
oxidative damage, enhances endothelial function and preserves mitochondrial function, 
processes known to be negatively influenced by Ang II signaling. 
Still, a caloric restriction diet does not have the same impact on life span in humans, 
possibly due to the fact that most people would not submit to such a rigorous dietary 
program. Therefore, research is aimed at determining the feasibility and efficacy of caloric 
restriction mimetics, both drugs and natural compounds, without lowering caloric intake. 
Resveratrol is one of the compounds that mimics the cardiovascular protective effects of 
calorie restriction, including the attenuation of mitochondrial oxidative stress in coronary 
arterial endothelial cells.158, 159 Currently, several studies are in progress investigating the 
effect of caloric restriction and different caloric restriction mimetics in humans.160, 161 
Regardless of the results of these studies, a healthy, balanced and sensible diet combined 
with enough physical activity, is still very important to maintain overall health.162
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Additionally, to improve current medical therapies for managing Ang II-associated 
cardiovascular disease, attention has been placed on antioxidant-based therapies and 
reactive oxygen species scavenging molecules to decrease oxidative stress associated with 
vascular damage. Overproduction of reactive oxygen species has been shown to be an im-
portant factor in the development of age-related cardiovascular diseases. As mentioned, 
reactive oxygen species plays a central role in cellular signaling when maintained at normal 
tissue levels, while during times of cell stress, excessive amounts of reactive oxygen spe-
cies cause harmful effects on the vasculature. Increased levels of reactive oxygen species 
have been implicated in the pathogenesis of diverse diseases including cancer, diabetes 
mellitus, atherosclerosis and aging. During aging, the production of reactive oxygen spe-
cies is increased, while some of the endogenous defense mechanisms decrease, leading 
to progressive damage of cellular structures and eventually an aging phenotype. As men-
tioned, especially mitochondrial-derived reactive oxygen species play an important role in 
aging and age-related cardiovascular disease.163, 164 Therefore, it is logical to suggest that 
application of antioxidants or reactive oxygen species scavengers could be useful in the 
treatment of age-related vascular disease. Research already demonstrated that several RAS 
inhibitors have an antioxidant effect. In clinical studies, it is shown that administration of 
AT1 receptor blocker candesartan mediates an antioxidant effect, resulting in less oxidative 
stress and inflammation, independent from its effect on blood pressure.165
Antioxidant therapies or reactive oxygen species scavengers may have an additional 
advantage over the current RAS therapies, because they can prevent vascular damage by 
direct interaction with reactive oxygen species, not only those produced by Ang II, but 
also by inflammatory cells or through the regulation of reactive oxygen species-dependent 
molecular signaling cascades. Several clinical trials and animal models of cardiovascular 
diseases have focused on antioxidant-based therapies to decrease oxidative stress. Strate-
gies to deliver antioxidants include gene therapy, dietary sources, low-molecular-weight 
free radical scavengers, polyethylene glycol conjugation, and nanomedicine-based 
technologies, as reviewed recently by.22 Although many studies have shown therapeutic 
benefits for monotherapy with antioxidant use on vascular disease, others have failed to 
show any beneficial effects. This might be because of incorrect dosing, the lack of interac-
tion between the antioxidant and reactive oxygen species or due to the fact that a state 
of ‘antioxidative’ stress can occur, in which the antioxidants attenuate or block adaptive 
stress responses.166 Thus, specific targeting of cells and locations where oxidative stress 
occurs might improve the efficacy of antioxidant therapies.  
3.3 Combining RAS blockade with reactive oxygen species inhibition
Considering the above, combined inhibition of reactive oxygen species and RAS would 
be expected to have further beneficial effects on vascular damage, to a greater degree 
than RAS inhibition alone. Not only reactive oxygen species produced by Ang II signaling 
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via the AT1 receptor will be reduced, but also reactive oxygen species produced by other 
sources which are independent of RAS signaling, including inflammatory cells and high 
pressure-derived reactive oxygen species. Indeed, recently it was shown that combining a 
mitochondria-targeted antioxidant, MitoQ10, with an angiotensin receptor blocker, losar-
tan, has an additive therapeutic benefit on attenuating development of hypertension and 
reducing left ventricular hypertrophy in stroke-prone spontaneously hypertensive rats.167 
Thus, combined RAS/reactive oxygen species blocking therapy might be a new strategy to 
prevent cardiovascular events. 
4. ConCLuSIon
Clearly, the RAS plays a critical role in the pathogenesis of many types of age-related vascu-
lar diseases. This review discussed that the RAS is involved in components that contribute 
to the development and progression of vascular disease; i.e. extracellular matrix defects, 
atherosclerosis and aging. Oxidative stress seems to be related to all of these components, 
subsequently contributing to the onset of vascular disease. Though, the precise mecha-
nisms by which these components induce vascular damage still need further study. 
Yet, it is not entirely clear which pathogenic mechanism should be targeted and 
which treatments should be used in prevention of cardiovascular events. Although 
numerous RAS inhibiting therapies have been developed and used in clinical settings 
for treatment of cardiovascular disease, they are not 100 percent effective in all patients 
and, particularly when given in combination, give rise to adverse side effects, including 
hyperkalemia and renal dysfunction. Moreover, the regulation of the RAS in the elderly 
is not fully understood yet and should be further explored, as many vascular diseases are 
age-related. Thus, it is necessary to further explore optimal strategies of (combined) RAS 
blockade to prevent or stop the progression of vascular disease. It would be particularly in-
teresting to test the efficacy of combined RAS/reactive oxygen species suppressing therapy 
on cardiovascular disease in animal models of aging, as it might give further beneficial 
effects on the vasculature. 
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ABSTRACT
Objective: Extracellular matrix degradation plays an important role in aortic aneurysm 
formation. In Fibulin-4R/R mice, deficiency of the extracellular matrix protein Fibulin-4 
induces upregulation of matrix metalloproteinases (MMP) and elastin irregularities, 
resulting in early thoracic aortic aneurysms. In humans, aneurysms usually develop in the 
abdominal aorta with increasing age and are often associated with atherosclerosis. To in-
vestigate the molecular mechanisms of the interaction between aneurysm formation and 
atherosclerotic disease we crossbred Fibulin-4+/R mice, with minor extracellular matrix 
(ECM) abnormalities such as increased ECM deposition and slight MMP activation in the 
thoracic aorta, but without aortic dilation yet, onto an atherosclerotic Apolipoprotein E 
knockout (ApoE-/-) background.
Approach: Double ApoE-/-/Fibulin-4+/R mutant mice were fed a high fat diet (HFD) 
for 10, 20 or 30 weeks and compared to ApoE-/-Fibulin-4+/+ control mice. MMP activity 
in the aorta was determined using protease-activatable near-infrared fluorescent probes. 
Thoracic and abdominal aortic diameters were assessed using high-frequency ultrasound. 
After sacrifice, atherosclerotic burden in the aorta was evaluated.
Results: Interestingly, after 10 weeks of HFD, ApoE-/-Fibulin-4+/R mice displayed 
increased MMP activity in the abdominal aorta and after 20 weeks of diet thoracic and 
abdominal aortic dilations were observed as compared to ApoE-/-Fibulin-4+/+ mice. In ad-
dition, ApoE-/-Fibulin-4+/R mice showed increased plaque formation after 10 weeks of HFD 
and histological plaque analysis showed a distinct plaque architecture. Moreover, part of 
the ApoE-/-Fibulin-4+/R mice developed symptoms of paralysis between 20 and 30 weeks of 
HFD and 30% did not survive beyond 30 weeks. 
Conclusions: These results indicate that a subtle defect in the extracellular matrix of 
the aortic wall predisposes to the development of thoracic and abdominal aortic dilation 
upon atherosclerosis, and induces altered plaque morphology.
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INTROduCTION
Aortic aneurysm and dissections account for 1-2% of all deaths in the developed countries.1 
According to their location, aneurysms can be categorized in two main groups: thoracic 
aortic aneurysms (TAA) and abdominal aortic aneurysms (AAA). Aneurysms of the tho-
racic aorta, in particular the aortic arch, are characterized by necrosis of the medial layer 
of the aortic wall, also called cystic medial necrosis. TAAs usually occur due to a genetic 
mutation, for example aneurysms in Marfan’s disease. Aneurysms of the distal aorta, in 
particular AAAs, are much more common and are thought to be caused by a multifactorial 
process.2 Interestingly, recent clinical studies report a high frequency of TAAs in patients 
with aneurysms of the abdominal aorta.3, 4 Important risk factors for aortic aneurysm 
formation are age and atherosclerosis, and these risk factors are similar for patients with 
aneurysms and those with arterial occlusive disease, which is characterized by narrowing 
of the arteries due to atherosclerosis.5 However, the molecular mechanisms underlying 
aneurysm formation and the relation with atherosclerosis are largely unknown. 
It is known that extracellular matrix degeneration plays an important role in TAA for-
mation. Elastin is a crucial component of the extracellular matrix that is responsible for 
maintaining vessel wall elasticity.6 Fibulin-4 is an extracellular matrix protein, which 
plays an important role in elastic fiber assembly and function and is a regulatory factor in 
elastogenesis.7, 8 Indeed, Fibulin-4 deficient patients described so far present with TAAs, 
due to homozygous or compound heterozygous mutations, which usually develop to a 
severe stage of the disease within the first months or years of their life.9-15 A proportion 
of these patients also presented with abdominal tortuosity and/or dilation on further 
examination.12, 15
Similar to Fibulin-4 deficient patients, previously developed mutant mice with a systemic 
4-fold (Fibulin-4R/R) reduced expression of Fibulin-4 present with aortic wall degeneration 
and thoracic aortic aneurysm.16-18 Additionally, they develop impaired vascular contractil-
ity and increased arterial stiffness. Interestingly, a 2-fold reduced expression of Fibulin-4, 
in Fibulin-4+/R mice, also induces aortic disease but in a milder form. Although they do not 
develop aortic aneurysms spontaneously at adult age, they present with aortic wall degen-
eration, including elastic fiber fragmentation and slightly increased TGF-β signaling.17, 19 
Additionally, destruction of the extracellular matrix in the aortic wall of these Fibulin-4 
mice is associated with increased expression and activation of matrix metalloprotease 
(MMPs), which are involved in degradation of the extracellular matrix.17, 19 Molecular 
imaging using a near-infrared in vivo imaging probe for MMP activity (MMPsense680™) 
shows a graded increase in MMP activity in aneurysmal lesions of the aortic arch of 
Fibulin-4+/R and Fibulin-4R/R mice, showing that MMP activity is a leading indicator in 
these hypomorfic Fibulin-4 mice for aneurysm formation.19
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To study whether and how a primary extracellular matrix defect can be involved in aortic 
dilation and atherosclerosis, we developed a mouse model in which we combined the subtle 
defect in the extracellular matrix of the Fibulin-4+/R mouse with the most commonly used 
model for atherosclerosis, the apolipoprotein E knockout (ApoE−/−) mouse. At the age of 
9 weeks, the double mutant mice were fed a high fat diet (HFD) to induce atherosclerotic 
plaque formation. Since MMP-induced elastin and collagen degradation are known to 
affect atherosclerotic plaque morphology20, 21, we additionally analyzed whether plaque 
morphology in ApoE-/- mice is affected by Fibulin-4 deficiency. This model mimics the 
human situation as it combines the clinically observed association between (thoracic and 
abdominal) aortic dilation and atherosclerosis by combining an atherosclerosis mouse 
model (ApoE) and a subtle inherited defect present in the aortic wall  (Fibulin-4+/R) that 
might predispose these animals for the development of atherosclerosis associated aortic 
disease. 
MATERIAL ANd METhOdS
Mouse model
Mice containing the Fibulin-4R allele were generated as previously described.2 All mice 
used were bred in a C57BI/6J background and were kept in individually ventilated cages to 
keep them consistently micro-flora and disease free. Fibulin-4R mice were crossbred with 
ApoE-/- mice (C57BI/6J background) to obtain ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R 
mice. Female and male ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R mice were fed either a 
normal chow diet (Standard CRM (P), Special Diets Services, UK), a HFD containing 16% 
fat (Purified diet W 4021.06, AB diets Animal Nutrition, Woerden, the Netherlands) or a 
control fat diet (CFD) containing 5% fat (Purified diet W control 4021.69, AB diets Animal 
Nutrition, Woerden, the Netherlands) starting at the age of 9 weeks. Hind limb paralyses 
was observed by dragging of the limbs, and facial paralyses by loss of eye blink reflects, a 
bulging eye and abnormal vibrissae orientation with fibers flattened posterior against the 
head. Animals were housed at the Animal Resource Center (Erasmus University Medical 
Center), which operates in compliance with the “Animal Welfare Act” of the Dutch govern-
ment, using the “Guide for the Care and Use of Laboratory Animals” as its standard. As 
required by Dutch law, formal permission to generate and use genetically modified animals 
was obtained from the responsible local and national authorities. All animal studied were 
approved by an independent Animal Ethical Committee (Dutch equivalent of the IACUC).
MMP imaging 
Per 25 grams of body weight 2 nmol specific MMP activatable NIRF probes, MMPSense680™ 
(Perkin Elmer Inc., Akron, Ohio, USA), was injected into the tail vein of anesthetized mice 
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after 10 and 20 weeks of HFD or normal chow diet. Intact aortas were harvested 24 hours 
after injection for ex vivo fluorescence imaging, and analyzed using the Odyssey Imag-
ing system (LI-COR® Biosciences, Lincoln, Nebraska, USA). Near-infrared images were 
obtained in the 700 nm channel. 
ultrasound imaging 
Animals were sedated with 4% isoflurane and maintained on 1-3% isoflurane for anaesthe-
sia, adjusted to the vital parameters of the mouse (heart rate > 400 bpm, breath rate 30 
strokes/min). Mice were placed on a heating pad to maintain body temperature at 37oC. 
In vivo ultrasound imaging of the aortic arch, abdominal aorta and left ventricle (LV) was 
performed with a Vevo2100 (Visualsonics Inc., Toronto, Canada) using a 40-MHz linear 
interfaced array transducer (MS550S). B-mode and M-mode images of the aorta were 
captured. Diameters of the aortic arch were measured from the parasternal window at the 
level of the ascending aorta. Distensibility of the aortic arch was measured as the systolic 
to diastolic aortic diameter ratio in M-mode image data (calculated as systolic diameter 
minus diastolic diameter, divided by the diastolic diameter).
Analysis of plaque area and composition
To quantify the surface area affected by atherosclerosis, aortas were stained with Oil-red-
O after 10 and 20 weeks of HFD and macro photographs of en face preparations were 
made (n=minimal 5 mice in each group). The Oil-red-O stained surface areas in the aortic 
arch, descending and abdominal aorta were quantified using ImageJ (Fiji). Additionally, 
plaque size and morphology were histologically analyzed after 10 and 20 weeks of HFD 
(n=minimal 5 mice in each group). The aortas with the branching brachiocephalic artery, 
left carotid artery and left subclavian artery of mice on 10 weeks of HFD were perfusion 
fixed with 1% paraformaldehyde after PBS flush, dehydrated and embedded in paraffin. 
Serial longitudinal sections of the aortic arch and cross sections of the abdominal aorta 
(5 µm) were prepared for histological analysis. Total plaque size in the inner curvature of 
the aortic arch and in the brachiocephalic artery was measured on haematoxylin-eosin 
stained slides using BioPix iQ 2.0 imaging software (BioPix, Göteborg, Sweden). Aortic 
wall structure and plaque morphology were additionally analyzed by histochemical stain-
ing with Resorcin-Fuchsin (elastin). Elastin content was analyzed on elastin stained slides 
with ImageJ (Fiji).
To further determine differences in plaque phenotype, including lipid content, 
cryosections were made of mice on 20 weeks HFD. After PBS flush aortic arches were 
embedded in Tissue-Tek (O.C.T. compound) and serial longitudinal cryosections were 
made (5 µm). Plaque size in the aortic arch and brachiocephalic artery was quantified on 
haematoxylin-eosin stained slides using Biopix. Oil-red-O staining was used to determine 
lipid content of the plaques. 
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Statistical analysis
All results are expressed as mean ± SEM (continuous results) or median (lower to upper 
limit) (aortic arch diameters). The unpaired 2-tailed Student t-test was performed to ana-
lyze the specific sample groups for significant differences. A p-value <0.05 was considered 
to indicate a significant difference between groups. All analyses were performed using IBM 
SPSS Statistics version 20.0 (SPSS Inc., Chicago, IL, USA).
RESuLTS
Abdominal aorta of ApoE-/-Fibulin-4+/R mice shows increased MMP activity
We have previously shown that extracellular matrix degeneration in Fibulin-4+/R and 
Fibulin-4R/R mice is associated with increased MMP activity in the thoracic aorta.19 In this 
study, we tested whether extracellular matrix degeneration in the aortic wall of Fibulin-4 
deficient mice could contribute to abdominal aortic lesions. Measurements of MMP activ-
ity in the abdominal aorta using the MMPsense probe indeed revealed a mild increased 
activity of 1.2 fold in Fibulin-4+/R abdominal aortas as compared to Fibulin-4+/+ mice (Fig. 
1A). However, these Fibulin-4+/R mice do not yet develop abdominal aortic dilations. 
As atherosclerosis can be associated with aortic aneurysms, we next tested whether 
the induction of atherosclerosis in Fibulin-4R heterozygous mice, which have minor 
extracellular matrix defects in the aortic wall, could lead not only to thoracic, but also 
abdominal aortic dilation. To induce atherosclerosis, Fibulin-4+/R mice were crossbred 
with ApoE-/- mice, which develop atherosclerosis spontaneously after 12 weeks.22-24 Start-
ing from the age of 9 weeks the double mutant ApoE-/-Fibulin-4+/R and ApoE-/-Fibulin-4+/+ 
littermate controls were fed a HFD for 10 or 20 weeks to accelerate atherosclerotic plaque 
formation. ApoE+/+Fibulin-4+/+ and ApoE+/+Fibulin-4+/R mice on a HFD for 10 or 20 weeks 
did not develop atherosclerosis and did not show additional vascular abnormalities as 
compared to Fibulin-4+/+ and Fibulin-4+/R mice.
Interestingly, after 10 weeks of HFD, MMP activity measurement on whole aortas 
revealed a strongly increased MMP activity in the abdominal aortas of ApoE-/-Fibulin-4+/R 
mice of 2.7 fold as compared to ApoE-/-Fibulin-4+/+ mice, and also compared to ApoE-/-Fib-
ulin-4+/R mice on a chow diet, which had a 1.6 fold increase compared to ApoE-/-Fibulin-4+/+ 
mice on chow diet (Fig.1B). This highly increased MMP activity in the abdominal aortas of 
ApoE-/-Fibulin-4+/R mice was further increased after 20 weeks of HFD. ApoE-/-Fibulin-4+/R 
mice on 20 weeks of HFD had a 13 fold increase as compared to ApoE-/-Fibulin-4+/+ mice. 
This indicates that induction of atherosclerosis in ApoE-/-Fibulin-4+/R mice enhanced 
the already slightly increased MMP activity observed in the abdominal aorta of Fibulin-
4+/R mice, which suggests that abdominal aortic wall lesions worsened progressively in 
ApoE-/-Fibulin-4+/R mice on a HFD.
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Figure 1. Increased MMP activity in ApoE-/-Fibulin-4+/R abdominal aortas after 10 and 20 weeks of HFD. 
(A) Ex vivo imaging of isolated aortas shows 1.2 fold higher MMP activity in the abdominal aortas of 
Fibulin-4+/R mice (n=6) as compared to Fibulin-4+/+ abdominal aortas (n=4). (B) Ex vivo imaging of aor-
tas after 10 and 20 weeks of HFD and chow diet shows a further increase in MMP activity in the abdomi-
nal aorta of ApoE-/-Fibulin-4+/R mice (n=3) with a 2.7 fold increase after 10 weeks of HFD as compared 
to ApoE-/-Fibulin-4+/+ aortas (n=3), and a 13 fold increase after 20 weeks of HFD in the abdominal aortas 
of ApoE-/-Fibulin-4+/R mice (n=5) as compared to ApoE-/-Fibulin-4+/+ aortas (n=5) as well as compared 
to ApoE-/-Fibulin-4+/R mice after 20 weeks of chow diet (n=5), which had a 1.6 fold increase compared 
to ApoE-/-Fibulin-4+/+ aortas (n=3). Horizontal lines depict the level of the diaphragm, indicating the 
transition of the thoracic into the abdominal part of the aorta.
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ApoE-/-Fibulin-4+/R aortas display increased thoracic and abdominal aortic diameters 
To subsequently determine whether the combination of atherosclerosis and an extracel-
lular matrix defect can result in aortic dilation in ApoE-/-Fibulin-4+/R mice, we measured 
thoracic and abdominal aortic diameters using in vivo ultrasound imaging of ApoE-/-Fibu-
lin-4+/+ and ApoE-/-Fibulin-4+/R mice after 10 and 20 weeks of HFD and after 10 or 20 weeks 
of CFD, which has a similar nutrient composition as HFD, but a lower fat percentage. We 
also included mice after 20 weeks of chow diet and mice of 9 weeks old (without starting 
a diet: 0 weeks HFD/CFD) as controls. Interestingly, significantly increased thoracic aortic 
diameters were observed in ApoE-/-Fibulin-4+/R mice after 20 weeks of CFD compared to 
ApoE-/-Fibulin-4+/+ mice, but no difference was observed between the two genotypes on 
HFD or chow diet (Fig. 2A and Supplemental Fig. 1A). The thoracic aortic diameters of 
the ApoE-/-Fibulin-4+/R mice on 20 weeks CFD were also significantly larger compared to 
ApoE-/-Fibulin-4+/R mice on 10 weeks CFD and ApoE-/-Fibulin-4+/R mice on 20 weeks chow 
diet. ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R mice on 10 and 20 weeks of HFD displayed 
similar distributions with large variations in aortic arch diameters, which seemed to show 
some dilation in both ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R mice. Since increased 
aortic arch diameters were also observed in ApoE-/-Fibulin-4+/+ mice on HFD, this prob-
ably indicates that HFD induces aortic arch dilations in both ApoE-/-Fibulin-4+/+ and 
ApoE-/-Fibulin-4+/R mice. Aortic arch diameter measurements at 0 weeks of diet or after 20 
weeks of chow diet, showed no difference between ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-
4+/R mice. In short, after a subtle increase in fat diet (CFD) ApoE-/-Fibulin-4+/R mice devel-
oped thoracic aortic dilations compared to ApoE-/-Fibulin-4+/+ mice, while a diet with even 
more fat (HFD) results in a large variation in thoracic aortic diameters between animals in 
both the ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R group. 
Additionally, to determine the effect of atherosclerosis on the stiffness of the aortic 
wall, we performed calculations on the distensibility of the aortic arch, which is an elastic-
ity index of the aorta and inversely correlates with aortic wall stiffness. A slight reduction 
was already observed in adult Fibulin-4+/R aortas compared to Fibulin-4+/+ aortas (Supple-
mental Fig. 2A). A similar slight reduction was observed in ApoE-/-Fibulin-4+/R mice after 
10 and 20 weeks of CFD as compared to ApoE-/-Fibulin-4+/+ mice (data not shown). The 
same measurements in ApoE-/-Fibulin-4+/R mice after 10 and 20 weeks of HFD revealed a 
further decreased distensibility as compared to ApoE-/-Fibulin-4+/+ mice (Supplemental 
Fig. 2B). This decrease was significant after 10 weeks of HFD, whereas after 20 weeks of 
HFD ApoE-/-Fibulin-4+/+ aortas also showed a slight decrease in aortic arch distensibility. 
In conclusion, these results indicate that CFD, probably inducing modest atherosclerosis 
formation, results in aortic arch dilation in extracellular matrix defective ApoE-/-Fibulin-
4+/R mice, while a HFD leads to an equal distribution of aortic arch diameters in both 
ApoE-/-Fibulin-4+/R and ApoE-/-Fibulin-4+/+ mice, (including aortic arch dilations in some 
of both). This could point to the fact that under the same conditions Fibulin-4+/R animals 
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Figure 2. Increased thoracic and abdominal aortic diameters in ApoE-/-Fibulin-4+/R mice. (A) Aortic 
arch diameter measurements by ultrasound imaging in M-mode show signifi cant increased systolic 
aortic arch diameters in ApoE-/-Fibulin-4+/R mice after 20 weeks of CFD (n=5) compared to ApoE-/-Fib-
ulin-4+/+ mice after 20 weeks of CFD (n=5), ApoE-/-Fibulin-4+/R mice after 10 weeks of CFD (n=5), and 
compared to ApoE-/-Fibulin-4+/R mice after 20 weeks of chow diet (n=6). Aortic arch diameters after 10 
and 20 weeks HFD appear to be equally distributed in ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R mice, 
with an increased variation in diameters. No diff erences are observed in mice fed a chow diet for 0 
or 20 weeks. (B) Abdominal aortic measurements at the level of the iliac artery bifurcation also show 
signifi cantly increased aortic diameters in ApoE-/-Fibulin-4+/R mice after 20 weeks of CFD compared 
to ApoE-/-Fibulin-4+/R mice after 10 weeks of CFD and 20 weeks of chow diet. Furthermore, increased 
abdominal aortic diameters are observed in ApoE-/-Fibulin-4+/R mice after 20 weeks of HFD compared to 
ApoE-/-Fibulin-4+/R mice after 20 weeks of chow diet (*p<0.05). Open symbols indicate aortic diameters 
of ApoE-/-Fibulin-4+/+ mice, closed symbols indicate aortic diameters of ApoE-/-Fibulin-4+/R mice.
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are more susceptible than Fibulin-4+/+ animals to atherosclerosis induction, which is 
therefore already apparent on a low fat diet.  In addition, HFD leads to increased aortic 
wall stiffness in ApoE-/-Fibulin-4+/R mice.
Interestingly, assessment of abdominal aortic diameters at the level of the iliac artery 
bifurcation showed significantly increased diameters in ApoE-/-Fibulin-4+/R mice after 20 
weeks on CFD as compared to 10 weeks on CFD, and also compared to ApoE-/-Fibulin-4+/R 
mice after 20 weeks chow diet (Fig. 2B and Supplemental Fig. 1B). Moreover, significantly 
increased abdominal diameters were observed in ApoE-/-Fibulin-4+/R mice on 20 weeks of 
HFD compared to ApoE-/-Fibulin-4+/R mice on 20 weeks of chow diet. Abdominal aortic 
diameters in ApoE-/-Fibulin-4+/+ mice were not increased when compared among different 
diets and diet durations. Altogether, these data suggest that Fibulin-4 deficient ApoE-/- 
mice already develop thoracic and abdominal aortic dilation on a low fat diet, while in 
addition HFD induces abdominal aortic dilation in ApoE-/-Fibulin-4+/R mice and increases 
aortic arch stiffness.
ApoE-/-Fibulin-4+/R aortas present increased plaque area in the thoracic and 
abdominal aorta
Next, we investigated the effect of a primary extracellular matrix defect on atherosclerotic 
plaque formation after 10 or 20 weeks of HFD feeding. Plaque area was quantified on en 
face preparations of Oil-red-O stained aortas. The descending and abdominal aorta of 
ApoE-/-Fibulin-4+/R mice after 10 weeks of HFD showed significantly increased plaque area 
as compared to ApoE-/-Fibulin-4+/+ mice (Fig. 3A and C). However, the plaque area in the 
aortic arch was similar between ApoE-/-Fibulin-4+/R and ApoE-/-Fibulin-4+/+ mice at this 
age. After 20 weeks of HFD increased plaque area was detected in the aortic arch and 
abdominal aorta of ApoE-/-Fibulin-4+/R mice compared to ApoE-/-Fibulin-4+/+ mice, but 
this was not significant due to large variability in plaque area between ApoE-/-Fibulin-4+/+ 
mice (Fig. 3B and D). This suggests that Fibulin-4 deficiency accelerates plaque forma-
tion such that these are present after 10 weeks of HFD, while plaque occurrence after 20 
weeks of HFD also increases in ApoE-/-Fibulin-4+/+ mice. Interestingly, increased plaque 
area in individual ApoE-/-Fibulin-4+/+ mice significantly correlated with increased aortic 
arch diameter (Fig. 4), while plaque area in ApoE-/-Fibulin-4+/R mice did not correlate with 
aortic arch diameter. These data indicate that the observed dilation in ApoE-/-Fibulin-4+/+ 
aortas is due to progression of atherosclerosis. However, in ApoE-/-Fibulin-4+/R mice this 
correlation is absent, which is probably due to the fact that aortic dilation is already pres-
ent at an earlier stage or with mild atherosclerosis, which means that in these mice the 
extracellular matrix defect is the underlying cause of the aortic dilation. At the same time, 
these results together indicate that the extracellular matrix defect in ApoE-/-Fibulin-4+/R 
mice contributes to the increase in plaque area observed in thoracic and abdominal aortas.
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Figure 3. Increased plaque deposition in thoracic and abdominal aortas of ApoE-/-Fibulin-4+/R mice. 
Oil-red-O staining and en face preparations of ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R aortas after 
(A) 10 and (B) 20 weeks of HFD show increased plaque areas in the thoracic and abdominal aortas 
of ApoE-/-Fibulin-4+/R mice. Images in B represent aortas from ApoE-/-Fibulin-4+/R mice, which show 
increased plaque areas as compared to their littermate ApoE-/-Fibulin-4+/+. Arch= aortic arch, D Ao= 
descending aorta, A Ao= abdominal aorta. (C) Quantifi cation of the Oil-red-O stained en face prepa-
rations of ApoE-/-Fibulin-4+/R aortas after 10 weeks of HFD (n=5) shows signifi cantly increased plaque 
areas in the descending and abdominal aortas as compared to ApoE-/-Fibulin-4+/+ aortas (n=5). (D) After 
20 weeks of HFD no signifi cant diff erences could be observed between ApoE-/-Fibulin-4+/R mice (n=10) 
and ApoE-/-Fibulin-4+/+ mice (n=5), as some ApoE-/-Fibulin-4+/+ aortas also displayed an increase in 
plaque areas (* p<0.05, **p<0.01).
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ApoE-/-Fibulin-4+/R aortas show altered plaque morphology 
Results of the en face Oil-red-O staining of the aortic arches were confi rmed by quantifi ca-
tion of plaque size on haematoxylin-eosin stained sections of the aortic arch, showing no 
signifi cantly increased plaque size in ApoE-/-Fibulin-4+/R animals after 10 and 20 weeks of 
HFD as compared to ApoE-/-Fibulin-4+/+ mice. Although a small increase in plaque size and 
lipid content was observed after 20 weeks of HFD in histological sections of aortic arches 
of ApoE-/-Fibulin-4+/R mice, this increase was not signifi cant due to the low amount of 
samples (Supplemental Fig. 3). Interestingly, a diff erent plaque morphology was observed 
in aortic arches of ApoE-/-Fibulin-4+/R mice after just 10 weeks of HFD; ApoE-/-Fibulin-4+/R 
aortas showed either 1) partially loose plaques (which will be referred to as disconnected 
plaques) or 2) plaques grown over existing plaques (which will be referred to as overly-
ing plaques) or 3) a combination of both, in the brachiocephalic artery and in the inner 
curvature of the aortic arch (Fig. 5A and C). Out of the eight ApoE-/-Fibulin-4+/R animals 
examined, all displayed either disconnected plaques or overlying plaques, or both, in the 
brachiocephalic artery, whereas one out of eight ApoE-/-Fibulin-4+/+ mice displayed a dis-
connected plaque and one an overlying plaque (Table 1). To determine whether this altered 
plaque morphology is associated with elastin abnormalities due to Fibulin-4 defi ciency, 
we performed histological elastin analysis. This revealed a signifi cantly decreased elastin 
content in plaques of the brachiocephalic artery of ApoE-/-Fibulin-4+/R animals (Fig. 5B). 
In the inner curvature of the aortic arch, three out of seven ApoE-/-Fibulin-4+/R animals 
had either a disconnected or an overlying plaque, or both, as compared to one out of 
eight ApoE-/-Fibulin-4+/+ mice with a disconnected plaque, which is the same animal that 
showed the disconnected plaque in the brachiocephalic artery (Table 1). Plaques of the 
inner curvature of the aortic arch of ApoE-/-Fibulin-4+/R animals additionally contained a 
Figure 4. Increased plaque formation correlates with aortic arch dilation in ApoE-/-Fibulin-4+/+ mice. 
After 20 weeks of HFD, ApoE-/-Fibulin-4+/+ mice signifi cantly develop increased aortic arch diameters 
with increased plaque formation, whereas no such correlation is present in ApoE-/-Fibulin-4+/R mice 
(*p<0.05).
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decrease in elastin content (Fig. 5D). Histological analysis on cross-sections of abdominal 
aortas showed thickening of the abdominal aortic wall with increased spaces between 
the elastic laminae in ApoE-/-Fibulin-4+/R animals after both 10 and 20 weeks of HFD, 
which is also observed at sites of plaque formation in the abdominal aorta as compared to 
Table 1. Amount of disconnected and overlying plaques found in the inner curvature of the aortic arch 
and in the brachiocephalic artery of ApoE-/-Fibulin-4+/R mice as compared to ApoE-/-Fibulin-4+/+
Genotype Inner curvature Brachiocephalic artery
Disconnected 
plaque
Overlying 
plaque
Total Disconnected 
plaque
Overlying 
plaque
Total
ApoE-/-Fibulin-4+/R 1/8 -/8 1/8 1/8 1/8 2/8
ApoE-/-Fibulin-4+/R 2/7 3/7 3/7 5/8 6/8 8/8
*One arch could not be analyzed
Figure 5. Plaque morphological changes in ApoE-/-Fibulin-4+/R aortic arches after 10 weeks of HFD. HE 
analysis points to more disconnected and overlying plaques in (A) the brachiocephalic artery and (C) 
inner curvature of the arch of ApoE-/-Fibulin-4+/R aortas after 10 weeks of HFD compared to ApoE-/-Fib-
ulin-4+/+ aortas. (B and D) Elastin staining and quantifi cation of the elastin content in plaques revealed 
signifi cantly less elastin in plaques in (B) the brachiocephalic artery of ApoE-/-Fibulin-4+/R mice. (D) 
Plaques of the inner curvature of the aortic arch of ApoE-/-Fibulin-4+/R mice also show a tendency to-
wards less elastin (*p<0.05).
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ApoE-/-Fibulin-4+/+ animals (Supplemental Fig. 4 and 5). This was also previously observed 
in the thoracic aortas of homozygous Fibulin-4R/R mice and is associated with degenera-
tion of the aortic wall.17 No diff erences in plaque morphology could be observed in the 
abdominal aorta. Altogether, these results suggest that a defi ciency in the extracellular 
matrix protein Fibulin-4 leads to the formation of morphologically diff erent atheroscle-
rotic plaques in the thoracic aorta.
Decreased survival of atheroscleroti c ApoE-/-Fibulin-4+/R mice between 20 and 30 
weeks of hFD
Interestingly, approximately 30% of ApoE-/-Fibulin-4+/R animals that were fed a HFD with 
the aim to be analyzed at 30 weeks, died suddenly between 20 and 30 weeks on the diet 
as compared to a 100% survival of ApoE-/-Fibulin-4+/+ control animals (Fig. 6). Moreover, 
symptoms of paralysis were observed after handling of 4 out of 16 ApoE-/-Fibulin-4+/R 
animals that survived between 20 and 30 weeks of CFD or HFD, while none of these symp-
toms were observed in ApoE-/-Fibulin-4+/+ mice (n=9) (Table 2). These results indicate that 
atherosclerotic Fibulin-4 defi cient ApoE-/-Fibulin-4+/R animals display a worsened survival 
outcome, possibly due to atherosclerosis-induced events, which may cause the paralysis 
symptoms.
Figure 6. Decreased survival of ApoE-/-Fibulin-4+/R mice between 20 and 30 weeks of HFD. After 30 
weeks of HFD approximately 30% of ApoE-/-Fibulin-4+/R mice (n=10) did not survive as compared to 
100% survival of ApoE-/-Fibulin-4+/+ mice (n=3). 
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dISCuSSION
In this study we demonstrate that a genetic defect leading to subtle changes in the ex-
tracellular matrix structure of the aortic wall, in combination with atherosclerosis, may 
predispose for thoracic and abdominal aortic disease, including morphologically altered 
atherosclerotic plaques, and a worsened survival outcome. Atherosclerosis induction in 
the double mutant ApoE-/-Fibulin-4+/R mice results in increased abdominal MMP activ-
ity, thoracic and abdominal aortic dilation and increased thoracic and abdominal plaque 
formation. Furthermore, ApoE-/-Fibulin-4+/R mice display altered plaque morphology and 
have a reduced survival rate after 20 weeks of HFD. These results indicate that an underly-
ing extracellular matrix defect promotes a bidirectional relation between atherosclerotic 
disease and aortic wall dilation.
On one side, atherosclerosis induction in Fibulin-4 deficient mice leads to en-
hanced aortic wall degeneration in Fibulin-4 deficient mice. ApoE-/-Fibulin-4+/R mice 
already develop both thoracic and abdominal aortic wall dilations after 20 weeks on CFD. 
Most probably 20 weeks of CFD induces mild atherosclerosis since ApoE-/- mice spontane-
ously develop atherosclerosis after 12 weeks on normal chow diet, which has a lower fat 
percentage and a different nutrient composition compared to CFD.22-24 Abdominal aortic 
dilations also occur after 20 weeks of HFD compared to chow diet, indicating that induc-
tion of both mild and high atherosclerosis results in increased abdominal aortic dilation 
in ApoE-/-Fibulin-4+/R mice. However, after 20 weeks of HFD both ApoE-/-Fibulin-4+/+ 
and ApoE-/-Fibulin-4+/R mice have a wide but equal distribution in thoracic aortic arch 
diameters. This might be explained by highly increased atherosclerotic plaque formation 
induced by the HFD, which probably overrules the effects of the extracellular matrix 
degeneration on the aortic wall.
On the other side the aortic wall degeneration in ApoE-/-Fibulin-4+/R mice on HFD 
leads to increased plaque formation and altered plaque morphology. Ten weeks of HFD 
induces significantly more atherosclerotic plaques in the thoracic and abdominal aorta of 
ApoE-/-Fibulin-4+/R mice, whereas 20 weeks of HFD induces increased plaque formation in 
both ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R mice. However, a slight increase in plaque 
formation in the aortic arch and abdominal aorta of ApoE-/-Fibulin-4+/R mice after 20 
weeks of HFD can be observed. This suggests that Fibulin-4 deficiency leads to enhanced 
atherosclerosis progression. In ApoE-/-Fibulin-4+/+ mice the increased plaque formation is 
associated with the observed increased diameters, which is in concordance with previous 
reports.25 However, ApoE-/-Fibulin-4+/R mice show increased plaque formation independent 
of changes in aortic diameters, probably because this dilation already occurs in an earlier 
stage at a lower percentage of fat. Histological analyses of aortic plaques of ApoE-/-Fibulin-
4+/R mice after 10 weeks of HFD show more disconnected plaques, more overlying plaques 
and less elastin content in plaques compared to ApoE-/-Fibulin-4+/+ aortic plaques. The 
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reduced elastin content in atherosclerotic plaques of ApoE-/-Fibulin-4+/R mice is likely to be 
a consequence of impaired elastogenesis since Fibulin-4 influences crosslinking of elastic 
fiber by affecting the recruitment of LOX.5, 7, 26, 27 A reduction in elastin content can make 
these plaques less stable. Additionally, ApoE-/-Fibulin-4+/R mice show symptoms of paraly-
sis and a reduced survival between 20 and 30 weeks of HFD. The histological observed 
alterations in plaque morphology together with the observed worsened survival outcome 
might indicate that Fibulin-4 deficiency increases atherosclerosis-induced events. 
Whether these events are caused by plaque rupture is unclear. Our data show overlying 
plaques, disconnected plaques, and plaques with reduced elastin content and high MMP 
activity in the double mutant ApoE-/-Fibulin-4+/R mice. These features coincide with the 
occurrence of paralysis and reduced survival outcome.
In this respect, it would be interesting to make whole body angiographies of these 
animals just before they succumb. However, this is complicated due to their unpredictable 
and sudden death. Strikingly, plaque rupture was observed in another atherosclerotic 
mouse model with a more severe ECM defect; the ApoE-/-Fibrillin-1+/- mouse.28 Fibrillin-1 is 
the major structural component of microfibrils, which provide the scaffold for the deposi-
tion and crosslinking of elastin. The C1039G mutated Fibrillin-1 mice used in these studies 
however are different from the Fibulin-4R mice used here, as the Fibrillin-1 mice spontane-
ously develop thoracic aneurysms thereby also affecting the hemodynamic parameters. 
Fragmentation of elastic fibers in these double knockout mice leads to increased vascular 
stiffness and promoted features of multifocal plaque instability. These mouse models 
with a structural defect in elastic fibers associated proteins provide insight into the role of 
extracellular matrix degeneration in the susceptibility for altered plaque morphology and 
its consequences.
The bidirectional interaction between aortic wall degeneration and atherosclero-
sis formation in our ApoE-/-Fibulin-4+/R mice may lead to a vicious circle, in which the 
observed increased MMP activity could play a prominent role. The MMPsense probe 
is activated by MMP2, -3, -9 and -13, of which MMP2 and MMP9 are known to play an 
important role in extracellular matrix degeneration and in aortic aneurysm formation. 
Increased MMP activity has indeed been observed in Fibulin-4 deficient mice with these 
probes.17, 19 Furthermore, MMPs, mainly MMP3, -9, -12 and -13, were shown to be involved 
in different stages of plaque formation.20 Therefore, the highly increased MMP activity 
observed in ApoE-/-Fibulin-4+/R mice might be due to aortic wall degeneration as well as 
increased atherosclerotic plaques, and might contribute to the altered plaque morphology 
in these mice.
This ApoE-/-Fibulin-4+/R mouse model with diet-induced atherosclerosis shows that 
subtle manifestations of aberrant elastin formation in heterozygous Fibulin-4+/R mice might 
predispose to thoracic and abdominal aortic disease as well as enhanced atherosclerotic 
disease. This combined mouse model provides the opportunity to unravel the biological 
Atherosclerosis & Aneurysms 93
4
processes underlying aortic wall degeneration and to identify markers that elucidate key 
events in the early stages of the pathogenic sequence that might culminate in an aneurysm. 
In fact, the ApoE-/-Fibulin-4 mouse model therefore indicates that a haploinsufficiency 
for Fibulin-4 leads to a pathogenic outcome in combination with fat diets, and therefore 
might resemble patients that experience late-onset ‘sporadic’ and barely detectable forms 
of aneurysms. Additionally, this model provides insight in the effect of mild extracellular 
matrix defects, as observed during aging, on the progression of atherosclerosis. 
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Supplemental Figure 1.Increased diastolic thoracic and abdominal aortic diameters in ApoE-/-Fibulin-
4+/R mice. (A) M-mode aortic diameter measurements in diastole by ultrasound imaging show signifi -
cant dilation of the aortic arches of ApoE-/-Fibulin-4+/R mice after 20 weeks of CFD (n=5) compared to 
ApoE-/-Fibulin-4+/+ mice after 20 weeks of CFD (n=5), ApoE-/-Fibulin-4+/R mice after 10 weeks of CFD 
(n=5) and ApoE-/-Fibulin-4+/R mice after 20 weeks of chow diet (n=6). Aortic arch diameters after 10 or 20 
weeks of HFD seem to be evenly distributed in ApoE-/-Fibulin-4+/+ and ApoE-/-Fibulin-4+/R mice, with an 
increased diameter variation. No diff erences are observed in mice fed a chow diet for 0 or 20 weeks. (B) 
Abdominal aortic measurements in diastole show signifi cantly increased diameters in ApoE-/-Fibulin-
4+/R mice after 20 weeks of CFD compared to ApoE-/-Fibulin-4+/R mice after 10 weeks of CFD and 20 weeks 
of chow diet. Furthermore, increased abdominal aortic diameters are observed in ApoE-/-Fibulin-4+/R 
mice after 10 and 20 weeks of HFD compared to ApoE-/-Fibulin-4+/R mice after 20 weeks of chow diet, 
and ApoE-/-Fibulin-4+/R mice after 20 weeks of HFD compared to ApoE-/-Fibulin-4+/R mice after 10 weeks 
of CFD (*p<0.05, **p<0.01). Open symbols indicate aortic diameters of ApoE-/-Fibulin-4+/+ mice, closed 
symbols indicate aortic diameters of ApoE-/-Fibulin-4+/R mice.
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Supplemental Figure 2. Decreased distensibility of aortic arches from ApoE-/-Fibulin-4+/R mice. (A) 
Calculations of aortic wall displacements in M-mode during systole and diastole indicate a slight non-
signifi cant reduced distensibility of 15 weeks old Fibulin-4+/R aortas on a chow diet compared to Fibu-
lin-4+/+ aortas. (B) A signifi cantly reduced distensibility is observed in calculations of aortic wall dis-
placements in B-mode of ApoE-/-Fibulin-4+/R (n=5) aortas after 10 weeks of HFD, which further decreases 
after 20 weeks (n=10) of HFD compared to ApoE-/-Fibulin-4+/+ aortas (n=5) (*p<0.05). 
Supplemental Figure 3. Quantifi cation of plaque area on histological sections of ApoE-/-Fibulin-4 aor-
tas after 10 and 20 weeks of HFD. (A) Plaque area quantifi ed in the inner curvature of the aortic arch 
shows no diff erence between ApoE-/-Fibulin-4+/R mice (n=8) and ApoE-/-Fibulin-4+/+ mice after 10 weeks 
of HFD (n=8), while a slight increase is observed in the brachiocephalic artery. (B) Quantifi ed plaque 
area and percentage lipid content in plaques show a slight increase in ApoE-/-Fibulin-4+/R mice after 20 
weeks of HFD (n=5) compared to ApoE-/-Fibulin-4+/R mice (n=3). IC= inner curvature, Brachio= bra-
chiocephalic artery.
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Supplemental Figure 4. Histological analysis of abdominal aortas after 10 weeks of HFD. HE and 
elastin analysis of the abdominal aorta revealed (A) thickened abdominal aortic wall with increased 
spaces between the elastic laminae in ApoE-/-Fibulin-4+/R mice after 10 weeks of HFD as compared to 
ApoE-/-Fibulin-4+/+ mice, (B) which is also observed at sites of plaque formation.
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Supplemental Figure 5. Histological analysis of abdominal aortas after 20 weeks of HFD. HE and 
elastin analysis of the abdominal aorta after 20 weeks of HFD points to a thickened abdominal aor-
tic wall with increased spaces between the elastic laminae in ApoE-/-Fibulin-4+/R mice as compared to 
ApoE-/-Fibulin-4+/+ mice.
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ABSTRACT
Aims: Increasing evidence supports a role for the angiotensin (Ang) II-AT1 receptor axis 
in aneurysm development. Here we studied whether counteracting this axis via stimula-
tion of AT2 receptors is beneficial. Such stimulation occurs naturally during AT1 receptor 
blockade with losartan, but not during renin inhibition with aliskiren. 
Methods and Results: Aneurysmal homozygous Fibulin-4R/R mice, displaying 
a 4-fold reduced fibulin-4 expression, were treated with placebo, losartan, aliskiren, or 
the b-blocker propranolol from day 35-100. Their phenotype includes cystic media de-
generation, aortic regurgitation, left ventricular (LV) dilation, reduced ejection fraction, 
and fractional shortening. While losartan and aliskiren reduced hemodynamic stress and 
increased renin similarly, only losartan increased survival. Propranolol had no effect. No 
drug rescued elastic fiber fragmentation in established aneurysms, although losartan did 
reduce aneurysm size. Losartan also increased ejection fraction, decreased LV diameter, 
and reduced cardiac pSmad2 signaling. None of these effects were seen with aliskiren or 
propranolol. Longitudinal microCT measurements, a novel method in which each mouse 
serves as its own control, revealed that losartan reduced LV growth more than aneurysm 
growth, presumably because the heart profits both from the local (cardiac) effects of 
losartan and its effects on aortic root remodeling.  
Conclusions: Losartan, but not aliskiren or propranolol, improved survival in 
Fibulin-4R/R mice. This most likely relates to its capacity to improve structure and function 
of both aorta and heart. The absence of this effect during aliskiren treatment, despite a 
similar degree of blood pressure reduction and renin-angiotensin system blockade, sug-
gests that it might be due to AT2 receptor stimulation.
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INTROduCTION
Thoracic aorta aneurysms (TAA) show degeneration of the medial layer of the aortic 
wall, characterized by elastic fiber fragmentation, loss of smooth muscle cells, and the 
accumulation of amorphous extracellular matrix.1 Such aortic wall degeneration is often 
a consequence of inherited connective tissue disorders. The most common inherited TAA 
disease, Marfan syndrome (MFS), is due to a mutation in the FBN1 gene, which encodes 
the extracellular matrix (ECM) glycoprotein fibrillin-1. FBN1 mutations result in a disorga-
nized ECM assembly in the aortic wall2, leading to all above described key features of TAA 
in MFS patients. Mice heterozygous for a cysteine substitution in an epidermal growth 
factor-like domain of fibrillin-1 (Fbn1C1039G/+ mice), i.e., a mutation which is prototypical for 
the FBN1 mutations in humans, similarly develop TAA.3
Another factor in the elastic fiber assembly of the vessel wall, heart valves and 
myocardial interstitium, is the ECM protein fibulin-4, encoded by the FBLN4 gene.4, 5 
In humans, a mutation in this gene causes cutis laxa syndrome, that besides cutis laxa 
(loose skin), bone fragility and lung emphysema is characterized by vascular tortuosity 
and aneurysms similar to those observed in MFS.6-11 Moreover, mice with a systemic 4-fold 
reduced fibulin-4 expression (Fibulin-4R/R) share similar key features as seen in MFS and 
cutis laxa syndrome, i.e., cystic media degeneration, aortic regurgitation, and impaired 
cardiac morphology and function12, 13, while complete fibulin-4 gene knock-out mice (Fibu-
lin-4-/-) die perinatally from aortic rupture.14
Recent studies have shown that transforming growth factor (TGF)β signaling 
is upregulated in TAAs of MFS.13, 15, 16 While direct regulators of TGFβ signaling include 
TGFβ and bone morphogenetic protein ligands, indirect stimulation of TGFβ signaling is 
accomplished by angiotensin (Ang) II, via its type 1 receptor (AT1R). In support of this con-
cept, both TGFβ-neutralizing antibodies and the AT1R blocker losartan exerted beneficial 
effects in rodent TAA models, including Fibulin-4R/R mice when treated prenatally.13, 15 Yet, 
clinical studies with losartan in MFS did not yield uniformly positive results.17, 18 Blocking 
AT1R results in a counterregulatory rise in renin, thereby increasing Ang II levels. This Ang 
II cannot stimulate the blocked AT1R, but it may still bind to the unoccupied Ang II type 2 
receptors (AT2R), which antagonizes AT1R-mediated effects.19, 20 Such AT2R stimulation is 
potentially beneficial in TAA20, and will not occur during other forms of renin-angiotensin 
system (RAS) blockade, i.e., inhibition of the enzymes that generate Ang I (renin) or Ang 
II (ACE). 
In the present study, we hypothesized that losartan outperforms the renin inhibitor 
aliskiren in the treatment of Fibulin-4R/R mice, given its additional AT2R-stimulating ef-
fects. Both drugs were compared with placebo and the b-blocker propranolol, a MFS drug 
that is often used in the clinic because it is expected to reduce heart rate, blood pressure 
and dP/dt. ACE inhibitors were not included, since such drugs, in addition to suppressing 
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Ang II, also increase bradykinin, thus introducing interference with yet another hormonal 
system. Treatment started postnatally at a clinically relevant age: day 35, when the aneu-
rysm is already present, and lasted up to 100 days. Moreover, we used a novel in-vivo μCT-
technique allowing longitudinal measurement that monitors the therapeutic treatment 
effects on both aneurysm progression as well as cardiac growth in time simultaneously.
Our data show that losartan, but not aliskiren or propranolol, independently of its 
blood pressure-lowering effect, improved survival in Fibulin-4R/R mice. The absence of this 
effect during aliskiren treatment suggests that it might involve AT2R stimulation. 
MATERIAL ANd METhOdS
Experimental animals
Generation of Fibulin-4R/R mice has been described previously.12 Heterozygous (Fibulin-
4+/R) mice in a mixed C57Bl/6x129 background were mated to obtain Fibulin-4+/+ (wild-type) 
and Fibulin-4R/R littermates. Animals were housed in the institutional animal facility. Both 
males and females were included in the study, and since no apparent sex-related differ-
ences were observed, data from both sexes were pooled. All experiments were performed 
under the regulation and permission of the Animal Care Committee of the Erasmus MC, 
Rotterdam, The Netherlands (protocol number 139-11-09 and 139-13-11). The investigation 
conforms to the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication, revised 2011).
Treatment
Fibulin-4R/R mice and wild-type mice were treated postnatally from the age of 35 days up to 
100 days with placebo, losartan (60 mg/kg p.o. per day; a kind gift of MSD, Haarlem, The 
Netherlands), aliskiren (62.5 mg/kg p.o. per day; a kind gift of Novartis Pharmaceuticals, 
Basel, Switzerland), or propranolol (50 mg/kg p.o. per day; Sigma, St. Louis, USA) in 
drinking water, as described before.13, 15, 21, 22
histology 
Mice (age 100 days) were weighed, euthanized by an overdose of CO2, and necropsied 
according to standard protocols. Perfusion-fixed aortas and hearts were isolated and 
paraffin-embedded. Next, 4 μm-aorta sections were haematoxylin and eosin (HE)-
stained, stained for elastin (Verhoeff van Gieson), glycosaminoglycans (Alcian Blue) or 
vascular smooth muscle cells (VSMCs, a-smooth muscle actin). Immunohistochemistry 
for phosphorylated Smad2 (pSmad2) was performed as described previously23, using 
rabbit antiphospho-smad2 antibodies (Cell Signaling Technology, Danvers, USA). Posi-
tively stained pSmad2 nuclei were divided by the total number of nuclei to obtain relative 
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amounts. HE-stained aorta slides were scanned with a nanozoomer (Hamamatsu, Almere, 
The Netherlands), and subsequently aortic wall diameter and aortic wall area were 
analyzed with NanoZoomer Digital Pathology view (Hamamatsu). Finally, 5-μm heart 
sections were stained with Gomori’s silver staining to visualize individual cardiomyocytes 
of the left ventricle (LV).24 Only transversally cut cells showing a nucleus were used to 
determine the cardiomyocyte area. 
biochemical measurements 
RAS components were measured in kidneys (Ang II) and blood plasma (renin). Blood 
was collected from the left ventricle immediately prior to euthanization in heparin-coated 
tubes, centrifuged at 5500 RPM, and plasma was stored at -80°C. Kidneys were removed 
after the animals had been euthanized, frozen in liquid nitrogen, and stored at -80°C. 
Tissue Ang II was measured by radioimmunoassay, after SepPak extraction and reversed-
phase HPLC separation as previously described.25, 26 Plasma renin concentration (PRC) 
was determined by enzyme-kinetic assay in the presence of excess angiotensinogen as 
described before.26 Additionally, B-type natriuretic peptide-45 (BNP-45) was measured in 
plasma, making use of a commercially available enzyme immuno-assay (Phoenix Pharma-
ceuticals Inc., Karlsruhe, Germany).
ultrasound and hemodynamic measurements 
To evaluate the treatment of the different compounds on aneurysm formation and cardiac 
function, cardiac geometry, echocardiographic and hemodynamic measurements were 
performed in 100-days old Fibulin-4+/+ (wild type) and Fibulin-4R/R mice. Mice were anes-
thetized with 2.5% isoflurane and ventilated with 35% O2. Anesthesia did not affect heart 
rate (data not shown). Echocardiography of the ascending aorta and LV was performed us-
ing a Vevo2100 (VisualSonics Inc., Toronto, Canada). Ascending aorta and LV lumen diam-
eter, aortic distensibility, ejection fraction and fractional shortening were obtained from 
M-Mode images. Ejection fraction and fractional shortening were defined as the relative 
differences between end-diastolic and end-systolic volumes and diameter, respectively.13 
Subsequently, a 1.4-Fr microtipped manometer (Millar Instruments, Houston, USA) was 
inserted into the right carotid artery to measure aortic pressure.27 Hemodynamic data were 
recorded and digitized using an online 4-channel data acquisition program (ATCODAS, 
Dataq Instruments, Akron, USA), analysis was performed with a program written in Mat-
lab.28 Ten consecutive beats were selected for determination of systolic and diastolic blood 
pressure, subsequent mean arterial pressures (MAP) were calculated. 
Western blot
LV tissue samples were used for immunoblotting of extracellular signal-regulated kinases 
(ERK1/2), phosphorylated ERK1/2 (pERK1/2), Smad2 and pSmad2 (Cell Signaling Technol-
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ogy). Ratios of phosphorylated protein levels to loading control β-actin were calculated 
and corrected for the ratios in wild-type mice.
Quantitative real-time reverse transcription polymerase chain reaction
Expression of angiotensin II type 1a, type 1b and type 2 receptors (AT1aR, AT1bR and AT2R) 
was analyzed in LV tissue. Total RNA was isolated using RNeasy Fibrous Tissue Mini Kit 
(Qiagen, Hilden, Germany) and reverse transcribed using iScript cDNA Synthesis Kit 
(Bio-Rad, Veenendaal, The Netherlands). cDNA samples were subjected to 40 cycles real-
time PCR analysis using SYBR Green qPCR Master Mix 2x (Bio-Rad) and primers; β-actin 
5’-AGCCATGTACGTAGCCATCCA-3’, 5’-TCTCCGGAGTCCATCACAATG-3’; β2-microglobin 
5’-CTCACACTGAATTCACCCCCA-3’, 5’-GTCTCGATCCCAGTAGACGGT-3’; AT1aR 
5’-CCCACGTGTCCCTGTTACTAC-3’, 5’-TTTGGGGACAGTACAGGTTTC-3’; AT1bR 5’-CTGT-
GAAATTGCGGACGTAGT-3’, 5’-AAGCCATAAAACAGAGGGTTCAG-3’; AT2R 5’-TACCCGT-
GACCAAGTCCTGA-3’, 5’-TACCCATCCAGGTCAGAGCA-3’. Gene expression was calculated 
using β-actin and β2-microglobin as housekeeping genes and the comparative Ct method 
(ΔΔCt) was used for relative quantification of gene expression.
FMT-CT Imaging
We used vascular Computed Tomography (CT) and fluorescent mediated tomography 
(FMT)-CT imaging with near-infrared fluorescent protease activatable probes as previ-
ously described.29 In short, mice subjected to FMT-CT were shaved and depilated to 
remove all hair that otherwise would absorb light and interfere with optical imaging. 
Mice subjected to vascular CT and FMT-CT mice received 5 mL/kg body weight Exia 160 
contrast agent (Binitio Biomedical Inc., Ottawa, Canada) through injection in the tail vein 
for subsequent CT analysis. Mice only subjected to vascular CT imaging were anesthetized 
(2.5% isoflurane) and scanned directly with the microCT scanner (Quantum FX system, 
Perkin Elmer Inc., Akron, USA). The thoracic aorta diameter, thoracic aortic volume and 
left ventricular volume were analyzed with a rendering program ‘microCT Tools by Analyze 
11.0 software’ (AnalyzeDirect Inc., Overland Park, USA). Fibulin-4 mice which were also 
subjected to FMT imaging, were scanned with an FMT 2500 system (Perkin Elmer Inc.) at 
680 nm excitation and emission wavelengths, at 24 hours after tail vein injection of 5 nmol 
of MMPSense680™ (Perkin Elmer Inc.). Mice were anesthetized (2.5% isoflurane) and 
fixed into the portable animal imaging cassette that lightly compressed the anesthetized 
mouse between optically translucent windows, thereby preventing motion during FMT 
and CT imaging. After FMT imaging, anesthetized mice were scanned with the microCT 
scanner to identify heart and aortic root region of the animals. After FMT-CT imaging, 
complete aortas were harvested and fluorescence was quantified using the FMT 2500 and 
Odyssey imaging systems (LI-COR Inc.). Near infrared images were obtained in the 680 
nm channel.
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Data analysis
Normally distributed data are presented as mean±SEM. One-way ANOVA was applied for 
the analysis between groups, followed by a post-hoc Dunnett’s test when appropriate. All 
statistical tests were two-sided and P<0.05 was considered statistically significant. 
RESuLTS
Losartan increases survival of adult Fibulin-4R/R animals independently of its effect 
on blood pressure and the degree of RAS blockade
Reduced fibulin-4 expression resulted in severe TAA, cardiac hypertrophy, and diminished 
survival (Fig. 1A-1B), in full agreement with previous observations.12, 13 Losartan, but not 
aliskiren treatment, significantly improved survival (Fig. 1C). Propranolol even tended to 
diminish survival (P=0.25), and no animal survived up to 100 days with this treatment. As a 
consequence, blood pressure data could not be obtained in propranolol-treated mice, and 
in only 3 surviving aliskiren-treated mice versus 5 losartan-treated mice. MAP tended to 
be diminished in Fibulin-4R/R mice (P=0.17). Both RAS blockers similarly reduced MAP at 
100 days (Fig. 1D). PRC and renal Ang II were higher in fibulin-4R/R mice than in wild-type 
animals (Fig. 1E-1F). Losartan and aliskiren comparably increased PRC versus placebo, 
suggesting a similar degree of RAS blockade. Losartan, but not aliskiren, additionally 
suppressed renal Ang II.
Losartan improves aneurysm size and aortic distensibility without affecting 
structural changes and matrix metalloproteinases (MMPs) 
At the age of 100 days, the ascending aortic diameter in Fibulin-4R/R mice was almost 3 
times enlarged compared to wild-type mice (Fig. 2A). This widening was accompanied by 
an approximately 50% decrease in distensibility (Fig. 2B) and an increased wall thickness 
(Fig. 2C). Losartan improved diameter and distensibility without affecting thoracic aortic 
wall thickness, whereas aliskiren had no significant effect on any of these parameters (Fig. 
2A-2C). For reasons discussed above, similar data could not be obtained for propranolol. 
Neither losartan nor aliskiren affected the disturbed aortic wall morphology, the severe 
alterations in elastic fiber organization, or the increased glycosaminoglycan deposition in 
Fibulin-4R/R mice (Fig. 2D-2F). These drugs also did not significantly improve the reduced 
VSMC content, or diminish the increased pSmad2-signaling in these animals (Fig. 2G-
2H). Non-canonical (pERK) TGFβ signaling was similarly unaffected (data not shown). 
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Figure 1. (A-B) Reduced fibulin-4 expression results in thoracic aorta aneurysms and cardiac hyper-
trophy in 100-day old Fibulin-4R/R mice (white bars represent 4 mm). (C) Kaplan-Meier survival curves 
of WT and treated Fibulin-4R/R mice (n=7-19). *P<0.05 vs. placebo. (D-F) Mean arterial pressure (MAP; 
n=3-5), plasma renin concentration (PRC; n=10-18), and renal angiotensin II levels (n=5) in Fibulin-4R/R 
mice treated for 65 days with placebo, losartan, aliskiren or propranolol vs. untreated age-matched WT 
mice. Data are mean±SEM. *P<0.05, **P<0.01, ***P<0.001.
In vivo MMP activity, measured by 3D FMT-CT, was undetectable in aortas of 
wild-type mice, but greatly increased in the aortic arch of placebo- or losartan-treated 
Fibulin-4R/R mice (Fig. 3A). Abdominal aorta MMP measurements were inaccurate due to 
the high fluorescent signal from the liver. Removal of the aortas after sacrifice allowed ex-
vivo imaging at much great sensitivity (Fig. 3B), and confirmed the in-vivo observations. 
Losartan did not affect MMP activity as compared to placebo (Fig. 3C). Consequently, 
MMP activity was not determined in aliskiren-treated mice. 
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Figure 2. (A-C) Aortic diameter, distensibility and wall diameter in Fibulin-4R/R mice treated for 65 days 
with placebo, losartan or aliskiren vs. age-matched untreated WT mice (mean±SEM of n=6-10) (black 
bars represent 100 µm); *P<0.05 vs. placebo. Treatment did not affect aortic wall morphology (D), elas-
tic fiber fragmentation (E), extracellular matrix deposition (Alcian Blue) (F), a-smooth muscle actin 
(SMA) deposition (G), or pSmad2-signaling (H). 
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Losartan improves cardiac morphology and function 
Transthoracic echocardiography in placebo-treated Fibulin-4R/R mice revealed a tripling 
of LV mass and a doubling of LV diameter versus wild-type mice (Fig. 4A-4B) at the age 
of 100 days. Ejection fraction and fractional shortening were both greatly reduced (Fig. 
Figure 3. (A) In-vivo three-dimensional FMT-CT co-registration of heart and aorta in Fibulin-4R/R mice 
treated for 65 days with placebo or losartan vs. age-matched untreated WT mice, after injection of 
MMPSense 680 to determine matrix metalloproteinase (MMP) activity. (B) MMP activity determined 
ex vivo in whole aortas, and (C) its quantification (mean±SEM of n=2). 
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4C-4D). Losartan improved all parameters, although significance was not reached for LV 
mass. Aliskiren affected none of these parameters. Data for propranolol in 100-day old 
mice could not be obtained. 
Figure 4. (A-D) Left ventricular (LV) mass, LV diameter, ejection fraction and fractional shortening de-
termined by in-vivo transthoracic echocardiography in Fibulin-4R/R mice treated for 65 days with place-
bo, losartan or aliskiren vs. age-matched untreated WT mice (mean±SEM of n=6-10). *P<0.05, **P<0.01.
Losartan prevents cardiomyocyte hypertrophy and reduces canonical TgFb signaling
Cardiomyocyte area doubled in Fibulin-4R/R versus wild-type mice, and losartan (but not 
aliskiren) fully prevented this hypertrophic response (Fig. 5A-5B). As expected, changes 
in plasma BNP paralleled this pattern, although no significant differences were observed 
for this parameter (Fig. 5C). Both canonical (pSmad2) and non-canonical (pERK) TGFβ 
signaling were upregulated in hearts of Fibulin-4R/R mice, but losartan reduced only the 
former to wild-type levels (Fig. 5D-5E). Smad2 and ERK levels were identical under all 
conditions (data not shown). LV AT1aR -, AT1bR -, and AT2R expression were downregulated 
in Fibulin-4R/R mice versus wild-type mice, and losartan treatment exclusively normalized 
AT1aR expression (Fig. 5F). Unfortunately, due to scarcity of available tissue, similar data 
could not be obtained in aliskiren- or propranolol-treated mice. 
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Figure 5. (A-B) Cardiomyocyte area (n=5-12; panel A shows a representative example) and (C) plasma 
brain natriuretic peptide (BNP; n=10-18) levels in Fibulin-4R/R mice treated for 65 days with placebo, 
losartan or aliskiren vs. age-matched untreated WT mice. Data are mean±SEM, **P<0.01, ***P<0.001 vs. 
WT or placebo. (D-E) pSmad2, pERK, and β-actin protein levels in hearts of Fibulin-4R/R mice treated 
for 65 days with placebo or losartan vs. age-matched untreated WT mice (n=3-4). *P<0.05 vs. WT. (F) 
Relative gene expression of LV Ang II receptors (n=3-10). *P<0.05 vs. WT.
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Losartan prevents LV and aneurysm growth rate 
We used a novel microCT method in combination with the vascular contrast agent Exia160, 
yielding longitudinal 3D data sets in which each animal serves as its own baseline control 
(Fig. 6A). At the start of treatment, both aortic volume and LV volume were not different 
in placebo- and losartan-treated Fibulin-4R/R mice (Fig. 6B-6C). Both volumes increased 
Figure 6. (A) 3D overview of CT-angiography with contrast agent Exia160. (B-C) Aortic and LV volume 
of placebo and losartan treated Fibulin-4R/R mice at baseline. (D-E) Percentage growth of ascending 
aortas and left ventricle (LV). Data are mean±SEM of n=4-6. *P<0.05, ***P<0.001 vs. placebo.
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by approximately 60% during placebo treatment, and losartan largely (aortic volume), if 
not completely (LV volume) prevented this (Fig. 6D-6E).
dISCuSSION
The present study shows that losartan, but not aliskiren or propranolol, increased survival 
in Fibulin-4R/R mice, and that this predominantly related to its capacity to improve cardiac 
function and structure. Although losartan also stabilized aortic growth, these effects were 
more modest than its effects on LV growth, and they did not result in any change in aortic 
wall morphology, TGFβ-signaling, or MMP-activity. Nevertheless, there was an improve-
ment in aortic distensibility. The larger effects on the heart most likely reflect the fact that 
the heart profits both from the local (cardiac) effects of losartan and its effects on aortic 
root remodeling. Since none of these effects were seen with aliskiren, despite the fact that 
this RAS blocker lowered blood pressure and inhibited the RAS to the same degree as 
losartan, we conclude that they are blood pressure-independent, and that losartan exerts 
effects beyond blockade of the classical Ang II-AT1R axis. This most likely concerns its 
unique capacity to induce AT2R stimulation. A second possibility would be activation of 
the angiotensin-(1-7)-Mas receptor axis. However, a study making use of Fbn1C1039G/+ mice 
(an alternative, albeit less severe, TAA model) supports the former only, since it observed 
no effect of an ACE inhibitor, although such a drug, like an AT1R blocker, activates the 
angiotensin-(1-7)-Mas receptor axis.20, 30 Our study is the first to directly compare renin 
inhibition and AT1R blockade in a mouse TAA model. 
RAS activation, both in the circulation and at the tissue level, is an established 
characteristic of Fibulin-4R/R mice.13, 31 Given the low Ang II levels in the aorta and its 
relatively small size32, we measured Ang II in renal tissue to confirm the upregulated tissue 
RAS activity in this model. Increased Ang II levels will facilitate TGFβ-signaling, which is 
known to be enhanced in patients and mice with MFS.29, 33-36 In fact, increased serum TGFβ 
levels correlated directly with aortic root dilation.33 In agreement with the causative role 
of Ang II, we showed in an earlier study that prenatal treatment with losartan successfully 
improved elastic fiber fragmentation and reduced vessel wall thickness in Fibulin-4R/R 
mice.13 Moreover, in mice that lack fibulin-4 in VSMCs (Fbln4SMKO mice), aneurysm for-
mation could be prevented completely when RAS blockade was started within a narrow 
therapeutic window during the first month of life.31 In this latter study, ACE inhibition 
with captopril and losartan treatment were equally effective. Yet, in contrast with our 
study, no cardiac phenotype was reported in Fbln4SMKO mice. 
The present study in Fibulin-4R/R mice now evaluated postnatal losartan versus 
aliskiren treatment, started on day 35, i.e., when aneurysm formation is already present. 
This is not only more clinically relevant, as treatment in TAA patients usually starts in 
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the presence of an aneurysm, but also more realistic given the fact that such blockade 
is contraindicated during pregnancy. Propranolol, a classical MFS drug, was used as a 
comparator, but exerted no effect, in agreement with its lack of effect at the same dose (50 
mg/kg p.o. per day) in Fbn1C1039G/+ mice.15 All drugs were given orally, since the fragility of 
our model, resulting in a very low survival, was not compatible with the operation required 
to implant osmotic minipumps. Although aliskiren displays a low bioavailability37, and is 
highly species-specific38, it blocks mouse renin at the same concentration range as human 
renin.39 Consequently, by applying oral doses that were over 10 times higher than those 
used in humans (62.5 mg/kg p.o. per day versus 150-300 mg/day in humans), we were able, 
as in previous studies21, 22, to achieve a degree of RAS blockade that yielded the same blood 
pressure-lowering effects as losartan at 60 mg/kg p.o. per day. Importantly, as an indication 
of RAS blockade, losartan and aliskiren increased circulating renin similarly. Probably as a 
consequence of this rise in renin release, aliskiren did not significantly decrease renal Ang 
II. Similar observations were made previously in the rat kidney.40 Yet, losartan decreased 
renal Ang II, in agreement with the fact that tissue Ang II largely reflects Ang II that is 
bound to, or has been internalized via, AT1R.41, 42 Therefore, during losartan treatment, the 
reduction in tissue Ang II is an indication of the degree of AT1R blockade. Unfortunately, we 
were unable to obtain comparable data for propranolol-treated mice, since none of these 
mice survived until the age of 100 days, i.e., the day of sacrifice for our RAS component 
measurements, at which timepoint blood pressure was measured. Nevertheless, it might 
be speculated that propranolol, given its modest renin-suppressing effects43, did reduce 
Ang II. Long-term treatment with propranolol was feasible in Fbn1C1039G/+ mice, in which 
aneurysm formation starts only at the age of 2 months.3, 44 Propranolol affected blood 
pressure in Fbn1C1039G/+ mice to the same extent as losartan.15 Even if this had also been the 
case in our model, e.g., based on Ang II reduction, this effect would have resembled that of 
aliskiren, i.e., it could not have resulted in enhanced AT2R stimulation. Thus, once TAA are 
established, both renin suppression with propranolol and renin inhibition with aliskiren 
lack the beneficial effects of losartan. In contrast, when treatment is started before the 
onset of TAA, like in the Fbln4SMKO mice model described above31, captopril yielded the 
same effects as losartan. Since captopril does not allow AT2R stimulation, these data sug-
gest that, at a very early stage of TAA, AT1R are predominant, while at a later stage AT2R 
may additionally come into play. This correlates well with the widely accepted phenom-
enon that AT2Rs normally display low-to-undetectable levels, which increase only under 
pathological conditions, e.g., post-myocardial infarction, during hypertension-induced 
remodeling, and in heart failure.45-47 Clearly, timing of treatment is of utmost importance, 
and different ages at the start of treatment (e.g. children/adolescents versus adults) may 
explain the success (or lack thereof) of different RAS blockers in clinical trials.17, 18, 48 
Moreover, when classifying FBN1 mutations into ‘haploinsufficiency’ (decreased amount 
of normal fibrillin-1), and ‘dominant negative’ (normal fibrillin-1 abundance with mutant 
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fibrillin-1 incorporated in the matrix), Franken et al. observed that Marfan patients with 
haploinsufficient FBN1 mutations were more responsive to losartan.49 Since the Fbn1C1039G/+ 
and Fibulin-4R/R TAA models closely correspond with the haploinsufficiency situation, 
it appears that the underlying mutation is an additional determinant of the success of 
AT1R blockade in Marfan patients. Taken together, simultaneous AT2R stimulation may 
not always offer an additional advantage, and thus selective AT2R agonists should not by 
definition be preferred over AT1R antagonists. 
Given the predominant effects of losartan on the heart, we focused on canonical 
(pSmad2) and non-canonical (pERK) TGFβ signaling in cardiac tissue. Both were upregu-
lated in Fibulin-4R/R mice, comparable to their upregulation in aortic tissue in Fbln4SMKO 
and Fbn1C1039G/+ mice.20, 31 Yet, although losartan suppressed both types of signaling in aortic 
tissue in these latter models, in the hearts of our mice only the canonical signaling was 
found to be suppressed after losartan, while no pSmad2 suppression was seen in the aortic 
wall (Fig. 5E). These findings concur with the heart-specific effect of this AT1R antagonist 
in our model, and suggest that the AT2R stimulatory effects, if occurring, result in reduced 
canonical TGFβ signaling in the heart. Studies in transgenic animals support the concept 
that AT2Rs are antihypertrophic and prevent remodeling.50, 51 The lack of effect on pERK 
signaling in our Fibulin-4R/R mice is in agreement with a recent study by Cook et al.52, 
who demonstrated that ERK1/2 activation peaks at a very early stage of the disease only, 
while pSmad2 remains elevated throughout the disease. From this perspective, effects of 
losartan on pERK1/2 are no longer expected after 100 days, simply because pERK1/2 is not 
activated anymore at that stage.   
Gene expression studies in LV tissue revealed a reduction of all Ang II receptor types 
in Fibulin-4R/R mice compared to wild type mice. It should be noted that mice, unlike 
humans, display two AT1R subtypes, AT1aR and AT1bR, and that losartan blocks both AT1Rs 
equally well. AT1R downregulation is also known to occur in heart failure patients.53 It 
was not observed in the aortic arch or kidney of our Fibulin-4R/R mice13, implying that 
its downregulation was cardiac-specific. Importantly, although the raw Ct values for the 
AT1bR, the AT2R and the housekeeping genes β-actin and β2-microglobin were identical in 
LV tissue and aorta (B.S. van Thiel, data not shown), the raw Ct values for the AT1aR in the 
LV were approximately 6 cycles lower than in the aorta. This suggests that AT1aR expression 
in the heart greatly exceeds that in the aorta. Losartan treatment exclusively normalized 
cardiac AT1aR expression in Fibulin-4R/R mice. Such upregulation is a well-known physi-
ological response to receptor antagonism, once again supporting effective AT1aR blockade 
by losartan in the heart. Yet, it does not imply that AT1aR activation had now normalized 
(due to the simultaneous presence of losartan), and thus predominant AT2R stimulation 
by the elevated levels of Ang II during losartan treatment is still highly likely.
Our data are the first to show the losartan-induced stabilization of LV growth over 
time with longitudinal microCT measurements. Using each animal as its own baseline 
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control, this novel approach enabled us to conclude that the effects of losartan on LV 
growth exceeded those on aortic growth. Combined with the FMT to co-registrate MMP-
activity, this approach allows monitoring of cardiac and aortic remodeling in a unique, 
non-invasive manner. It would also reduce the required number of animals. Given the 
major limitation of our animal model, i.e. a complicated breeding scheme and a high 
death rate resulting in low n-numbers, this is an important advantage. 
In conclusion, losartan, but not aliskiren or propranolol, improved survival in 
Fibulin-4R/R mice, by simultaneously stabilizing aortic growth, reducing aortic distensibil-
ity, and improving cardiac function and structure. The absence of these effects during 
aliskiren treatment, despite a similar reduction in blood pressure and degree of RAS 
blockade, suggests that it might be due to AT2R stimulation and/or activation of the 
angiotensin-(1-7)/Mas receptor axis. Future studies, making use of AT2R/Mas receptor 
knockout animals, AT2R/Mas receptor antagonists (e.g., PD123319 and A779, respectively) 
or AT2R/Mas receptor agonists (e.g., C21 and AVE0991, respectively) may help to substanti-
ate this view. However, given the non-specific effects of the latter types of drugs54, 55, the 
possibility that AT2R heterodimerize with Mas receptors56, and the consequences of AT2R 
deletion on cardiac development and remodeling57, the results of such studies may not be 
straightforward. In addition, none of these approaches is currently feasible in humans. 
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ABSTRACT
DNA damage is an important contributor to endothelial dysfunction and age-related 
vascular disease. Recently, we demonstrated in a DNA repair-deficient, prematurely ag-
ing mouse model (Ercc1d/- mice) that dietary restriction (DR) strongly increases life- and 
health span, including ameliorating endothelial dysfunction, by preserving genomic 
integrity. In this mouse mutant displaying prominent accelerated, age-dependent en-
dothelial dysfunction we investigated the signaling pathways involved in improved 
endothelium-mediated vasodilation by DR, and explore the potential role of the renin-
angiotensin system. Ercc1d/- mice showed increased blood pressure and decreased aortic 
relaxations to acetylcholine in organ bath experiments. Nitric oxide (NO) signaling was 
compromised. DR improved relaxations by increasing prostaglandin-mediated responses, 
and cyclo-oxygenase 1 and decreased phosphodiesterase 4B were identified as potential 
mechanisms. DR also prevented loss of NO signaling in vascular smooth muscle cells 
and normalized angiotensin II vasoconstrictions, which were increased in Ercc1d/- mice. 
Ercc1d/- mutants showed a loss of Angiotensin II type 2 receptor-mediated counterregula-
tion of Angiotensin II type 1 receptor-induced vasoconstrictions. Chronic losartan treat-
ment effectively decreased blood pressure, but did not improve endothelium-dependent 
relaxations. This result might relate to the aging-associated loss of treatment efficacy of 
renin-angiotensin system blockade with respect to endothelial function improvement. 
In summary, dietary restriction effectively prevents endothelium-dependent vasodilator 
dysfunction by augmenting prostaglandin-mediated responses, whereas chronic Ang type 
1 receptor blockade is ineffective. 
Vasodilator dysfunction in aging 127
6
INTROduCTION
Age is a major risk factor for the development of cardiovascular diseases (CVD), indepen-
dently from traditional risk factors.1 An important factor that contributes to organismal 
aging, including vascular aging, is genomic instability.2, 3 We recently demonstrated that 
mutation of the DNA repair endonuclease excision repair cross complementing 1 in mice 
(Ercc1d/- mice) accelerates important characteristics of vascular aging-related vasomotor 
dysfunction.4, 5 In general, Ercc1d/- mice rapidly and faithfully mimic natural human ag-
ing compared to aged wild-type (WT) mice.6 Accordingly, mouse models of accelerated 
vascular aging due to genomic instability can be used as tools complementary to models 
representing the impact of classical risk factors, such as hypertension and dyslipidemia.
We demonstrated that dietary restriction (DR, 30% reduced food intake without 
malnutrition), a universal intervention extending lifespan in numerous species, tripled 
remaining lifespan and strongly improved health span in Ercc1d/- animals, by far exceeding 
the relative lifespan extension in WT mice. We found that this dramatic anti-accelerated 
aging effect in the mutant was at least in part due to preserving genomic integrity by reduc-
ing DNA damage accumulation.2 The improvement of health span included prevention of 
endothelial dysfunction, which in humans is one of the major contributors to morbidity 
and mortality due to a decline in vascular function.1 In humans, DR has a beneficial effect 
on cardiovascular risk, which is attributed to the reduction in diet-related risk factors 
such as dyslipidemia, high blood pressure (salt intake), and hyperglycemia.7 This in turn 
reduces oxidative stress and augments the nitric oxide (NO)  – cGMP pathway, an impor-
tant endothelial signaling axis involved in blood flow, blood pressure and cardiovascular 
growth regulation.7 Our results in Ercc1d/- mice have added a novel paradigm, namely that 
DR preserves genomic integrity and thus in this manner protects against vascular aging.
In this new paradigm it is not known which vasodilatory signaling pathway is 
improved. In our previous studies we have shown that, comparable to human aging, Er-
cc1d/- mice display a reduction of NO – cGMP signaling and increased oxidative stress.4, 5 
Therefore, we here set out to identify which vasodilatory signaling pathway is improved by 
DR in Ercc1d/- mice. In addition, the impact of DR on endothelium-independent relaxation 
was investigated.
A potential mediator of blood pressure increase and decreased endothelium-
dependent relaxation caused by DNA damage is activation of the renin-angiotensin sys-
tem (RAS). Angiotensin (Ang) II, the main bioactive hormone of this system, is strongly 
involved in hypertension, arteriosclerosis, vascular DNA damage and cell senescence, 
inflammation, oxidative stress, longevity and health span.8 Also, Ang II inhibits eNOS 
- NO - cGMP signaling.9 Given that the RAS is sensitive to salt and LDL cholesterol, it 
may also respond to DR.10, 11 However, it is not known how genomic instability influences 
RAS activity, let alone whether RAS activation would mediate its detrimental effects on 
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the vascular wall. Therefore, we additionally studied the vasoconstrictor responses of 
the Ercc1d/- mouse vasculature to Ang II under ad libitum (AL) feeding and DR. Also, we 
evaluated the effect of chronic AT1 receptor blockade on endothelial function and blood 
pressure in AL-fed Ercc1d/- mice.
MATERIAL ANd METhOdS
Animals and interventions
Animal experiments were performed at RIVM and Erasmus MC in accordance with the 
Principles of Laboratory Animal Care and with the guidelines approved by the Dutch Ethi-
cal Committee in full accordance with European legislation.
Dietary	restriction	studies	
Ercc1d/- mice and their wild-type littermates (WT) (Bl6/FVB F1 hybrids) underwent DR 
intervention from resp. 7 and 11 weeks after birth until sacrifice as described extensively in 
our previous publication, and in the Methods supplement.2
Losartan	intervention	study
From 5 weeks of age, Ercc1d/- and WT mice (Bl6/FVB F1 hybrids) were divided into two 
groups per strain, which were either treated with losartan (100 mg/kg/day) in drinking 
water, or drinking water only until the age of 12 weeks when the animals were sacrificed. 
Blood pressure was measured by tail cuff at the age of 11 weeks. The study rationale and 
animal numbers are described in the Methods supplement.
organ bath experiments
Tissue harvesting and preparation procedures, and detailed description of the organ bath 
experiments can be found in the Methods supplement.
In short, thoracic aorta and iliac arteries were collected and tested in small wire 
organ bath setups. Vasodilations to cumulative concentrations of acetylcholine (ACh) 
and sodium nitroprusside (SNP) were measured in vessels preconstricted with U46619 
to construct concentration-response curves (CRCs). When sufficient aortic tissue was 
available, the involvement of nitric oxide (NO) and prostaglandins in ACh responses was 
investigated by performing the experiments in the presence of the endothelial nitric oxide 
synthase (eNOS) inhibitor NG-Methyl-L-Arginine acetate salt (L-NMMA, 10-5 mol/L), the 
cyclo-oxygenase (COX) inhibitor indomethacin (INDO, 10-5 mol/L) or both inhibitors. In 
iliac arteries Ang II (10-10-10-7 mol/L) CRCs were constructed. PD123319 (10-7 mol/L) was 
used to test the involvement of Ang II type 2 (AT2) receptors, and the guanylyl cyclase 
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inhibitor 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10-5 mol/L) to test the role of 
NO-cGMP signaling. Inhibitors were added 15 minutes prior to U46619 or Ang II.
Quantitative real-time PCR
Total RNA was isolated and cDNA was prepared, which was amplified by real-time PCR 
to perform ΔΔCt quantification, either with the use of SYBR green or Taqman analysis. 
Further details are in the Methods supplement.
Plasma renin concentration
Blood was collected from 12-wk-old WT and Ercc1d/- mice by cardiac puncture and trans-
ferred to EDTA coagulation vials. Blood samples were centrifuged at 4600 rpm for 10 min-
utes to collect plasma. Plasma renin concentration was determined by an enzyme-kinetic 
assay as described previously.12
Statistical methods
Data are presented as mean±SEM. SNP-corrected ACh responses were calculated as fol-
lows: (response to ACh as % of U46619 preconstriction / response to 10-4 mol/L SNP as % of 
U46619) x 100 (to indicate as a percentage) x -1 (to indicate that it is a relaxation). Statisti-
cal testing for differences between single values expressed in bar graphs was performed 
by t-test or 1-way ANOVA followed by appropriate post-hoc tests. Differences in CRC were 
tested by general linear model for repeated measures (GLM-RM, sphericity assumed). 
Differences were considered significant at p<0.05.
RESuLTS
The effect of DR on acetylcholine responses in WT and Ercc1d/- mice 
We first investigated the effect of genomic instability and DR on the diminished ACh 
response at different ages in Ercc1d/- and WT mice. As previously reported, AL-fed Er-
cc1d/- mutants showed a lifespan of 19 weeks (median age), which was extended by DR 
to a median age of 44 weeks.2 ACh responses in the Ercc1d/- aorta of AL-fed animals age-
dependently decreased between the age of 7 to 16 weeks (Fig. 1A), and at the latter age 
were significantly decreased compared to 20-wk old WT. WT aortas did not show any 
change in ACh response between 11 to 20 weeks (data not shown). To explore if DR would 
protect against endothelial dysfunction until an age at which AL-fed Ercc1d/- mice have 
already succumbed (predominantly occurring from neurodegeneration), we proceeded 
to an age of 30 weeks in DR-fed animals. In our initial publication on the effect of DR 
on general health2 we demonstrated that DR improved the response to ACh in 16-wk-old 
Ercc1d/- mice. Here we show that the improvement of ACh responses persisted in 30-wk-old 
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DR-fed Ercc1d/- mutants (Fig.1B), well after the AL mice had died. In WT animals DR had 
no effect on ACh-induced relaxation (Fig. 1B). Thus, Ercc1d/- mice showed decreased aortic 
relaxations to ACh with increasing age, which could partly be prevented by DR. 
Endothelial vs. non-endothelial responses
Ercc1d/- aortas displays a pronounced decrease of endothelium-independent responses to 
NO.4, 5 We therefore investigated the effect of DR on responses to SNP, which entirely 
rely on direct release of NO and subsequent cGMP production in vascular smooth muscle 
cells (VSMC), as evidenced by the complete blockade of this response by the guanylyl 
cyclase inhibitor ODQ (data not shown). Dilatory responses to 10-4 mol/L SNP, which was 
given on top of ACh, progressively decreased in AL-fed Ercc1d/- mice, reaching statistical 
significance in 16-wk-old mice as compared to 7-wk-old mice (Fig. 1C, p<0.05 one-way 
ANOVA on 7-, 11- and 16-wk AL-fed mice with Dunnett post-hoc test). DR significantly 
prevented the age-dependent decline in dilator responses in 11- and 16-wk-old mice (Fig. 
1C, p<0.05, t-test). Even 30-wk-old DR-fed Ercc1d/- mutants still displayed a better SNP 
response as compared to 16-wk AL-fed Ercc1d/- mice (p<0.05, t-test). In WT animals no 
age- or diet-related changes were observed (Fig. 1D, 11-wk animals not shown), and SNP 
responses were similar to those in 7-wk AL-fed and DR-fed Ercc1d/- mice, which is expected 
as WT mice at 20 weeks of age do not (yet) display an aging-phenotype
To exclude any influence of ACh on SNP responses and to explore dose-related ef-
fects of SNP, we generated SNP CRCs in 16-wk-old Ercc1d/- and in 20-wk-old WT animals 
(Fig. 1E). The data confirmed that in AL-fed Ercc1d/- mice SNP responses were strongly re-
duced, and that they were fully restored to the level of WT animals by DR. In WT animals 
no significant changes occurred.
The response to ACh depends on the amount of relaxing factors that is released 
from the endothelium as well as the responsiveness of the VSMC to these factors. The pres-
ent observation that responses of VSMC to NO are fully restored by DR (Fig. 1C, E) while 
the responses to ACh are not (Fig. 1B), suggests that the release of endothelial-derived 
relaxing factors is compromised. Therefore, we studied the contribution of these factors 
to vasodilation. 
The role of endothelial signaling compounds in genotype- and diet-related effects
Dilations in AL-fed vs. DR-fed WT mice did not differ and results were therefore pooled. 
ACh responses were almost completely dependent on NO in WT animals since adding the 
eNOS inhibitor L-NMMA blocked the response to ACh (Fig. 2A). As expected from our 
previous study4, NO also mediated a large part of the vasodilation to ACh in AL-fed Ercc1d/- 
mice (Fig. 2B). The residual response suggests the emergence of an endothelium-derived 
hyperpolarizing factor (EDHF), which did not appear to be COX-dependent, since it was 
not affected by indomethacin (Fig. 2B). This result, together with the observation that 
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Figure 1. (A) Age-dependent acetylcholine (ACh)-induced vasodilation in aortic segments from ad libi-
tum (AL) fed wildtype (WT) and Ercc1d/- mice as measured ex vivo in small wire organ baths. (B) Eff ect of 
diet restrictions (DR) on the ACh responses. (C - E) age-dependent sodium nitroprusside (SNP)-induced 
vasodilations and the eff ect of diet restriction (DR). SNP was either given as a bolus concentration of 10-4 
mol/L SNP after constructing ACh concentration response curves (C, D) or administered in cumulative 
concentrations immediately after preconstriction (E). Cumulative concentrations of ACh and SNP were 
applied after preconstriction with the thromboxane analogue U46619. Responses are expressed as % 
relaxation of the U46619 in panels A-E. Error bars: S.E.M. *:p<0.05, general linear model for repeated 
measures (GLM-RM). &: p<0.05 16-week (16-wk) vs. 7-week (7-wk) Ercc1d/-AL, one-way ANOVA, Dun-
nett post-hoc test, #: p<0.05 t-test, †: p<0.05, 16-wk Ercc1d/-AL compared to all other groups, GLM-RM.
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inhibition of vasodilation by L-NMMA was much more pronounced in WT confi rms the 
specifi c loss of NO signaling in Ercc1d/- aorta’s. Remarkably, the DR-induced facilitation of 
the ACh response in Ercc1d/- mice appeared to be due to an upregulation of a vasodilator 
prostaglandin pathway, since now indomethacin did further reduce the response of ACh 
on top of L-NMMA, while the eff ect of L-NMMA alone was unaltered (Fig. 2C).
Figure 2. Contribution of nitric oxide (NO) and prostaglandins to ACh-induced vasodilation of aortic 
segments from 20-wk-old AL- and DR-fed wild-type (WT) (A), and 16-wk-old AL-fed (B) and DR-fed 
(C) Ercc1d/-mice measured in organ baths. L-NMMA (10-5 mol/L) and INDO (10-5 mol/L) resp. inhibit NO 
and prostaglandin synthesis, and were added to the organ baths 10 minutes before U46619. Responses 
are expressed as % relaxation of the U46619 preconstriction. (D) Vasoconstriction to Ang II expressed 
as % of contraction to 100 mM KCl. Error bars: S.E.M. *:p<0.05 vs. non-pretreated segments. #:p<0.05 
vs. L-NMMA-treated segments.
Prostaglandins are produced by COX-1 or 2, and exert their vasodilator eff ects 
through the IP receptor using adenylyl cyclase (AC) 5/6 – cAMP signaling as a second mes-
senger system. cAMP is prone to degradation by phosphodiesterase type 4B/D (PDE4).13-15 
Vasodilator dysfunction in aging 133
6
To investigate which of these components could be responsible for the upregulated 
prostaglandin response we quantifi ed their expression in blood vessel-rich lung tissue. 
Ct values for the IP receptor, PDE4D and AC6 mRNA levels were on average >34, and 
therefore we considered these levels too low for reliable detection. COX-1 mRNA showed a 
trend to increase (p<0.05 one-way ANOVA for all 4 groups) after DR in WT and in Ercc1d/- 
mice, and did signifi cantly increase in DR-fed Ercc1d/- mice as compared with AL-fed WT 
mice (Fig. 3A). PDE4B mRNA was decreased in both Ercc1d/- mouse groups compared with 
AL-fed WT mice (Fig. 3A). COX-2 and AC 5/6 mRNA did not show signifi cant changes 
among the groups. The results suggest that both an increase of prostaglandin production 
by COX1 and decreased metabolism by PDE4B underlie the improved vasodilation after 
DR in Ercc1d/- mice.
Figure 3. (A) Relative mRNA expression levels in lung tissue of COX-1, COX-2, AC 5/6, and PDE4B in 
16-wk-old Ercc1d/- mice and 20-wk-old wild-type (WT) littermates from the diet intervention study. (B) 
Relative mRNA expression levels of AT1a-, AT1b- and AT2-receptors in abdominal aortic tissue, of ACE in 
lung tissue and of renin in renal tissue of 12-wk-old Ercc1d/- mice and WT littermates from the losartan 
treatment study. All values are corrected for β-actin and normalized to WT expression levels. Results 
were similar when corrected for HPRT-1 (data not shown). (C) Plasma renin concentration in Ercc1d/- 
mice and WT littermates from the losartan treatment study. Error bars: S.E.M. †=P<0.05 vs. WT-AL 
(one way- ANOVA followed by Dunnett’s post-hoc test vs. WT-AL); *:p<0.05 vs. WT, t-test.
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Eff ects of genomic instability and DR on Ang II responses
To explore a possible role of the renin-angiotensin system we fi rst investigated vasocon-
striction to Ang II in a subset of the diet intervention mice. Ang II responses were in 
general highly variable within each strain, and tended to be higher in AL-fed Ercc1d/- vs. 
AL-fed WT mice (Fig. 2D), although this did not reach signifi cance over the entire CRC 
(GLM-RM). DR-fed Ercc1d/- animals showed a trend for a decreased response to Ang II as 
compared to AL-fed Ercc1d/- mutants (GLM-RM, p=0.059). The results suggest a genomic 
instability-induced upregulation of the Ang II response, which is normalized by DR.
The losartan interventi on study
In a separate cohort of Ercc1d/- and WT mice we evaluated the eff ect of chronic AT1 receptor 
blockade on blood pressure and vascular function. In agreement with our previous study4 
blood pressure tended to be slightly higher in Ercc1d/- mice, mainly refl ected by systolic 
blood pressure (SBP), and to a lesser extent by diastolic blood pressure (DBP) (Fig. 4). The 
diff erence reached borderline signifi cance for SBP (p = 0.076, t-test). Chronic AT1 receptor 
blockade by losartan signifi cantly lowered SBP and DBP in both mouse strains. 
Figure 4. (A) Systolic and (B) diastolic blood pressure in conscious Ercc1d/- and wild-type (WT) mice of 
the losartan intervention study as measured by the tail cuff  method. *: p<0.05, t-test
Vasomotor responses to Ang II in the losartan interventi on study
In the losartan intervention cohort, Ercc1d/- mice displayed an exaggerated response to Ang 
II as compared to WT mice (Fig. 5A). Vasoconstrictions are mediated by AT1 receptors and 
we therefore explored other indicators of increased AT1 receptor activity such as negative 
feedback on renin activity and ACE expression. Plasma renin activity was reduced (Fig. 
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3C). This was not due to a change in mRNA level in the kidney (Fig. 3B). ACE mRNA in 
the lung was reduced (Fig. 3B). Both findings are in agreement with increased AT1 receptor 
activity. 
To further explore mechanisms leading to increased Ang II vasoconstrictions we 
studied vascular AT1 and AT2 receptor expression and function. We and others previously 
reported that AT2 receptor stimulation counteracts AT1 receptor-mediated vasoconstric-
tion.16 To explore the effect of genomic instability on AT2 receptor activity, Ang II responses 
in Ercc1d/- and WT animals in the presence of AT2 receptor antagonist PD123319 were com-
pared to those in the absence of this antagonist. PD123319 did not change in Ercc1d/- mice, 
but tended (p=NS) to increase the Ang II response in WT (Fig. 5A). Chronic treatment 
with losartan, starting from week 5 after birth until the end of week 12, normalized this 
exaggerated response in the Ercc1d/- mice (Fig. 5B), but had no effect on the Ang II response 
in WT mice (data not shown). Therefore, genomic instability leads to loss of counterregu-
lation of AT1 receptor-mediated vasoconstriction by AT2 receptor, and not due changes in 
receptor expression.
To explore the possible involvement of counterregulation of Ang II-induced 
constriction by NO-cGMP signaling, which can be the result of endothelial AT2 receptor 
stimulation, Ang II responses were studied in the presence of the guanylyl cyclase inhibitor 
ODQ. This approach, rather than adding an eNOS inhibitor, was chosen because Ercc1d/- 
mice show both changes in endothelial NO production as well as in cGMP responses of 
VSMC. Although the presence of ODQ tended to increase Ang II responses, the increase 
was very modest and did not reach significance in Ercc1d/- animals (Fig. 5B), nor in WT (not 
shown). Apparently, the loss of NO-cGMP signaling cannot entirely explain the increase 
Ang II vasoconstrictions.
Since increased AT1 receptor signaling is believed to be involved in vascular disease 
related to endothelial dysfunction, a role that might both provoke as wells as be medi-
ated by increased blood pressure, we tested the effect of chronic losartan treatment on 
vasodilator function in Ercc1d/- mice.
Effect of chronic losartan treatment on accelerated age-related vasodilator 
dysfunction
In the 12-wk-old Ercc1d/- mutants vasodilator responses to ACh were significantly decreased 
as compared to WT animals (Fig. 5C). The dilation response to a SNP concentration-
response curve was also decreased in Ercc1d/- mice (Fig. 5D). Chronic AT1 receptor block-
ade with losartan in vivo did not significantly change any of the responses. Our findings 
indicate that the observed vasodilator dysfunction (persistent after losartan) was not 
blood pressure-dependent and that the detrimental effect of genomic instability cannot 
be opposed by chronic AT1 receptor blockade with Losartan.
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dISCuSSION
In the present study we explored potential mechanisms that lead to DR-mediated improve-
ment of vasodilator dysfunction caused by DNA damage. Loss of vasodilation was entirely 
due to loss of NO-cGMP signaling, both as a result of decreased endothelial NO release 
and decreased VSMC responsiveness to NO. In previous publications we showed that the 
decreased NO function was due to decreased eNOS expression and activation, increased 
PDE1 and possibly also PDE5 activity, and for a small part due to increased ROS produc-
tion.4, 5 The present results indicate that DR improves vascular dilations up to an age of at 
least 30 weeks. This is because DR enables aortic tissue to recruit endothelium-derived 
vasodilatory prostaglandins, which are normally absent. In addition, the responsiveness of 
VSMC to NO is improved. A possible explanation for the emerging prostaglandin response 
is the increase in COX-1 combined with a decreased in PDE4B, which together should lead 
Figure 5. Vasoconstriction to angiotensin II (Ang II) of isolated iliac arteries from mice of the (A) diet 
intervention study, and (B) the losartan intervention study. (C, D) Vasodilation in isolated aortic tissue 
of the mice from the losartan intervention study to the endothelium-dependent vasodilator acetylcho-
line (ACh) and the endothelium-independent vasodilator, NO-donor sodium nitroprusside (SNP). All 
responses were measured ex vivo in small wire organ baths. Aortic tissue used to measure vasodilator 
responses was preconstricted with thromboxane analogue U46619. Error bars: S.E.M. *:p<0.05, general 
linear model for repeated measures. #: p<0.05, t-test on individual concentrations of Ang II of ad libitum 
(AL) fed Ercc1d/-mice vs. wild-type (WT) littermates.
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to improved vasodilator cAMP signaling. We have also explored the possible involvement 
of Ang II. Although defective DNA repair increased vasoconstrictive responses to Ang II, 
chronic blockade of AT1 receptors with losartan did not rescue vasodilator responses. Also, 
blood pressure is not a driving mechanism in the observed vasodilator dysfunction, since 
blood pressure-lowering did not affect this dysfunction. Ang II-induced vasoconstriction 
most likely increased due to the loss of counterregulatory action of AT1 receptor by AT2 
receptor when Ercc1d/- mutants age. 
Preservation of endothelium-dependent responses by DR has been previously re-
ported in aging WT rodents, involving nuclear factor erythroid-2-related factor-2 (Nrf2)-
mediated upregulation of antioxidants.17 In various tissues of AL-fed Ercc1d/- mice Nrf2-
related antioxidants are already increased as a protective mechanism (2 and unpublished 
observations), but ex vivo aortic vasodilator responses are still improved by the oxygen 
radical scavenger N-acetylcysteine due to an interaction in VSMC.2, 4 After DR,Nrf2 is fur-
ther activated2 and SNP responses are totally normalized (Fig. 1), establishing the potential 
role of Nrf2. The present study now demonstrates that DR recruits yet another system 
to enhance endothelial function, namely vasodilatory prostaglandin signaling, acting 
through cAMP. To achieve this, COX-1 expression increased in DR-fed Ercc1d/- mice, on top 
of already decreased PDE4B expression in those mice. Potentially, this points at the geno-
protective effect of DR improving transcriptional output in Ercc1d/-, as was demonstrated 
in our previous publication.2 Although the fate of COX products in the aging vasculature 
is certainly not uniform in diverse studies in rodents and humans18, our results confirm 
the observation that DR prevents the decline of plasma and renal prostacyclin levels in 
aging rats.19, 20 Another study shows rather diverse changes, claiming lower levels of both 
vasoconstrictive and vasodilatory COX products after DR in the aging rat aorta.21 Although 
both findings indicate the participation of COX products in DR-induced changes, this 
topic has attracted little attention until now. Nevertheless, the combined improvement 
of VSMC responses to NO-cGMP and increased prostaglandin-cAMP by the endothelium 
explains the effect of DR.
Ang II responses increased in AL-fed Ercc1d/- mice compared to WT, whereas plasma 
renin activity decreased. The latter result is in agreement with the observation that renin 
levels decrease with age.22, 23 Although renin levels start decreasing already when approach-
ing middle age, our present findings indicate that the aging process might contribute to this 
decrease. With respect to the effect of aging on AT1 receptor-mediated vasoconstrictions 
many contrasting findings have been described, depending on the species or the vessels 
that have been used.24-28 Nevertheless, our observation is in agreement with findings show-
ing that in older persons blood pressure and blood flow responses to Ang II are elevated, 
especially in the presence of diabetes or the absence of counterregulation by AT2 recep-
tors.26, 29-31 Counterbalancing of AT1-mediated pathogenesis is the basis for development 
of AT2 receptor agonists as clinical drugs against cardiovascular diseases.32, 33 Conversely, 
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increased Ang II activity via AT1 receptors due to a loss of counterregulation by AT2 recep-
tor is a mechanism observed in various disease models and in aging wild-type rats.32, 34 The 
counterbalancing effect by AT2 receptors is often ascribed to endothelial NO release, or 
might relate to a change in dimerization of the two Ang II receptor subtypes.35 Loss of NO 
signaling clearly does not play a role in Ercc1d/- mutants nor their WT littermates given the 
absence of an effect of ODQ, leaving receptor interaction as the alternative mechanism. 
The endothelial dysfunction observed in the present study was clearly not related 
to Ang II and increased blood pressure. In patients, the effect of chronic AT1 receptor 
blockade on preservation of vasodilator function is variable, having either a protective ef-
fect or not.36 It was assumed that this might depend on the underlying disease or the vessel 
type that is investigated. However, our study suggests that the aging process might explain 
such variation. Unfortunately, most of the human studies exploring the effect of chronic 
AT1 receptor blockade focus on patients around 60 and younger, and not on the oldest old. 
Nevertheless, there are clues that aging affects the effectiveness of AT1 receptor blockade. 
It has been shown that losartan becomes gradually less effective in aging rats, especially in 
the presence of hypertension and after loss of endothelium-independent NO function.37 
Clinical observations show that losartan/antihypertensive treatment can lead to adverse 
cognitive effects in elderly, which is ascribed to perfusion problems.38 However, the same 
study suggests that this perfusion problem is a result of both blood pressure lowering and 
a persisting vascular dysfunction, at least in the brain. This implicates that vasodilator 
function is not improved. More dedicated studies in the oldest patients are necessary to 
resolve this paradox. There are mechanistic explanations available for this paradigm. In 
patients or in models of heart failure, hypertension, diabetes etc. Ang II blockade largely 
improves endothelial function due to an acute reduction of ROS formation by NAPH 
oxidase, increasing NO bioavailability.9 DNA damage largely lowers NO independently 
from ROS4, and apparently this undermines the treatment efficacy of AT1 antagonists in 
our mouse model. It is therefore relevant to find tools to investigate this possibility in 
humans. Suboptimal effectiveness of and treatment response variability to RAS inhibition 
are well-known phenomena, but remain largely unexplained, and therefore drive studies 
that attempt to find prediction markers for therapy effectiveness. 39, 40 
CLINICAL PERSPECTIvES 
DR is a very efficient intervention to prevent vasodilator dysfunction caused by genomic 
instability. In this study we set out to identify potential mechanisms that lead to DR-
mediated improvement of vasodilator dysfunction caused by DNA damage.
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•	 Improvement of prostaglandin-mediated endothelium-dependent signaling and 
of VSMC responses to NO were identified as mechanisms. Endothelial dysfunction 
induced by genomic instability is not reversible with chronic losartan treatment.
•	 Mouse models of genomic instability appear to represent the RAS blockade-resistant 
part of aging-related vascular disease, and might be tools to further explore this 
clinically relevant issue. Further study on the effect of genomic instability might offer 
a novel source of mechanistic explanations and markers with potential for clinical 
translation.
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ABSTRACT
In this study, we tested the use of functional micro-Computed Tomography (microCT) 
imaging combined with near infrared fluorescent (NIRF) probes to directly report the in 
vivo activity of key biomarkers of age-related cardiac failure using progeroid Ercc1 mouse 
models. Mutations in the ERCC1 gene causes diminished DNA damage repair and an ac-
celerated aging phenotype in mice, including cardiovascular aging. We tested the effect 
and kinetics of diminished DNA damage repair on protease activity and apoptosis and 
possible subsequent cardiac failure in vivo. 
Full body Ercc1d/-, cardiomyocyte-specific Ercc1c/- and their Ercc1-proficient controls 
were imaged with contrast enhanced microCT for anatomical reference and to assess car-
diac morphology and function. The NIRF probes MMPSense680™ and Annexin-Vivo750™ 
were used to image matrix metalloprotease activity and apoptosis, respectively. Functional 
microCT analysis was compared to ultrasound imaging and results were validated by 
histology.
Ercc1d/- deficiency resulted in changes in left ventricular geometry and function-
ing at 24 weeks of age; an increase in left ventricular end-diastolic and left ventricular 
end-systolic volume was observed, thereby leading to an overall decrease in stroke volume 
and a substantial reduction in left ventricular ejection fraction. Ercc1-proficient mice 
showed relative stable volumes over time. Moreover, Ercc1d/- deficiency leads to increased 
myocardial apoptosis at 12 and 24 weeks of age, and a gradual increase of MMP activity 
already starting at 6 weeks, suggesting that these processes precede cardiac failure in these 
progeroid Ercc1 mice. Cardiomyocyte-specific inactivation of Ercc1 also led to impaired 
cardiac functioning and increased myocardial apoptosis and MMP activity, indicating that 
Ercc1 deficiency in cardiomyocytes is associated with adverse cardiac remodeling and poor 
cardiac functioning. 
In conclusion, combined microCT and optical imaging allows simultaneous analy-
sis of molecular and functional changes in mouse models for accelerated aging and shows 
that gradual increases in matrix metalloprotease activity is followed by apoptosis and 
cardiac functional decline in progeroid Ercc1 mice. 
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INTROduCTION
Cardiovascular diseases (CVDs) persist as one of the leading causes of morbidity and 
mortality in the elderly population worldwide. The incidence and prevalence of numerous 
CVDs, including heart failure, myocardial infarction, atherosclerosis and hypertension, 
increase tremendously after the age of 50 years.1, 2 Many hypotheses have been proposed to 
explain the aging process, but neither appears to be fully satisfactory.3, 4 The accumulation 
of unrepaired DNA damage over time is regarded as one of the driving forces of accelerated 
aging and age-related diseases, as exemplified in mice and patients with genetic defects 
in DNA repair pathways.5, 6 A variety of these genetically altered mice with affected DNA 
repair pathways, demonstrate a strict correlation between the severity of the DNA repair 
defect and the extend of aging pathology and reduced lifespan, suggesting that the load 
of DNA damage directly relates to the rate of aging.6 Several lines of evidence, in experi-
mental as well as clinical studies, support the notion that accumulation of DNA damage, 
secondary to oxidative stress, is involved in the development of age-related CVDs.7 Yet, 
the precise role of DNA damage and related aging on the manifestation of CVDs remains 
elusive and needs further exploration.
One of the most widely studied mouse models of accelerated aging as a consequence 
of increased DNA damage is the Ercc1d/- mouse model. These mice contain one knockout 
allele of the Excision Repair Cross Complementation group 1 (ERCC1) gene, and one pro-
tein truncating mutation, in which the last seven amino acids at the C-terminus of the 
Ercc1 protein are deleted.8 Due to this effect, these animals are deficient in multiple DNA 
repair mechanisms including global genome-and transcription-coupled nucleotide exci-
sion repair, interstrand crosslink repair and homologous recombination.9 Consequently, 
DNA damage accumulation causes these mice to display an accelerated aging phenotype, 
including growth retardation, neurological degeneration and a shortened lifespan. In 
addition, Ercc1d/- mutants display accelerated age-dependent vasodilator dysfunction, in-
creased vascular stiffness, increased blood pressure and vascular cell senescence.10 Hence, 
these mice are useful to explore why DNA damage and aging are crucial components in 
CVD etiology. 
Cardiac aging is a complex process in which many cellular and molecular changes 
occur in the heart, including increases in cardiomyocyte apoptosis, interstitial fibrosis 
and cardiomyocyte hypertrophy. At a functional level, aging is associated with an altered 
left ventricular (LV) diastolic function, diminished LV systolic reserve capacity, decreased 
blood flow and an increased prevalence of atrial fibrillation, eventually leading to a 
reduction in cardiac output and ejection fraction.11 Loss of myocytes, through necrosis 
and apoptosis, has been demonstrated in the aging heart and is thought to contribute 
to the progressive loss of cardiac functioning.12-14 Apoptosis is a tightly regulated cell 
death process that is an important contributor to the development of the cardiovascular 
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system as well as to the adaptation of the cardiovascular system to the continuous chang-
ing environment.15, 16 Progressive apoptosis may lead to a dysbalance between cell death 
and cell renewal, eventually leading to cardiac decline and failure.12, 13 It has been shown 
that unrepaired DNA damage is a trigger for a cell to undergo apoptosis, however, how 
this process contributes to a decline in cardiac performance remains to be elucidated. 
In addition to apoptosis, matrix metalloproteinases (MMPs) are found to participate in 
cardiac tissue remodeling in several CVDs, including myocardial infarction, heart failure 
and development of dilated cardiomyopathy (DCM).17-20 MMPs are a family of proteolytic 
enzymes with the capacity to cleave components of the extracellular matrix, including 
elastin and collagen and thereby promote extracellular matrix turnover and degradation 
of the myocardial wall.21 Clinical evidence suggests that MMP-9 has a significant role in LV 
remodeling and thus can serve as a novel prognostic biomarker for individuals at increased 
risk for CV mortality.22-25 In this study, we therefore focused on apoptosis and MMP activity 
as potential biomarkers of age-related cardiac failure. 
The most commonly used modality to evaluate cardiac functioning is echocar-
diography. However, functional analysis is performed in a 2D-view, and this generates a 
potential risk of inaccurate measurements of the whole heart, especially in small animals. 
In addition, assessment of right ventricular volumes and function remains challenging 
because of the particular shape of the right ventricle wrapped around the LV. This has 
been shown to be particularly unsatisfying in patients with non-standard ventricular 
size and anatomy.26-28 Thus, there is a need for other noninvasive imaging techniques to 
evaluate CVDs. Contrast enhanced micro-Computed Tomography (microCT) imaging has 
been shown to be useful to investigate cardiac function and structure in small animals, 
as it has a high resolution and allows 3D imaging of heart and associated structures, 
providing reliable information about ventricular structure and function.29 Moreover, the 
introduction of in vivo multimodality molecular imaging plays an increasingly pivotal role 
in biomedical and clinical research. MicroCT imaging can be combined with fluorescence 
molecular tomography (FMT) and near infrared fluorescent (NIRF) probe(s), which not 
only provides anatomical and functional data but also allows non-invasive studying of 
molecular targets involved in the development and progression of disease, including CVD, 
in small animals.30-33 NIRF optical molecular imaging offers a new approach to evaluate 
processes involved in cardiac disease and provide valuable insights into different aspect of 
disease development and progression. 
As Ercc1 plays an important role in several DNA damage responses, we hypoth-
esized that intact DNA repair in cardiomyocytes is critical for maintaining normal cardiac 
function and that complete or partial loss of Ercc1 would provoke induced DNA damage, 
apoptosis and subsequent cardiac aging and failure. Furthermore, we tested the use of 
functional microCT imaging combined with NIRF probes targeting apoptosis and MMP 
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activity to directly report on the in vivo activity of these markers of age-related cardiac 
failure.
MATERIAL ANd METhOdS
Mouse model
All animal procedures were performed in accordance with the Principles of Laboratory 
Animal Care and Guidelines approved by the Dutch Animal Ethical Committee in full 
accordance with European legislation. As required by Dutch law, formal permission to 
generate and use genetically modified animals was obtained from the responsible local 
and national authorities. Animals were housed in individual ventilated cages under spe-
cific pathogen free conditions and maintained in a controlled environment (20-22˚C, 12 
h light: 12 h dark cycle). They were given ad libitum access to food (maintained on either 
AIN93G synthetic pellets (Research Diet Services B.V.; gross energy content 4.9 kcal/g dry 
mass, digestible energy 3.97 kcal/g) or standard chow diet) and water. 
Male and female animals were used in this experiment. The generation of Ercc1d/- 
and Ercc1+/+ mice has been described previously.8 Ercc1d/- mutants (15% expression of 
the mutant Ercc1 allele), and their wild-type Ercc1+/+ littermates (WT), in an F1 hybrid 
FVB/NJ x C57BL/6J background, were studied at 6, 12 and 24 weeks of age. Mice with 
a cardiomyocyte-specific deletion of ERCC1 (αMHC-Ercc1c/-) were generated using the 
Cre-loxP technology on a similar mixed background. Briefly, a floxed allele of Ercc1 was 
generated by inserting loxP sites in intron 2 and 5, such that Cre recombinase excises 
exons 3–5 of the Ercc1 locus.34-36 Mice harboring two floxed alleles of Ercc1 were crossed 
with hemizygous mice expressing Cre-recombinase under the control of the α-myosin 
heavy chain (αMHC-Cre) promotor. αMHC-Ercc1c/- and their control (cre-) littermates 
were studied at 8 and 16 weeks of age.
In	vivo microCT-FMT imaging of MMP activity and apoptosis
Mice were imaged with contrast enhanced Quantum FX Micro-computed Tomography (mi-
croCT) (Perkin Elmer Inc., Akron, Ohio, USA) for anatomical reference and to assess cardiac 
morphology and function. The NIRF probes MMPSense680™ and Annexin-Vivo750™ (Per-
kin Elmer Inc.) were used to image matrix metalloprotease (MMP) activity and apoptosis, 
respectively and imaged with the FMT 2500 fluorescence tomography in vivo imaging system 
(Perkin Elmer Inc.). The MMPsense probe is optically silent in a non-active state and becomes 
highly fluorescent following protease-mediated activation by MMPs, including MMP-2, -3, 
-9 and -13, whereas Annexin-Vivo binds to phosphatidylserine, which is exposed on the outer 
leaflet of the cell membrane lipid bilayer during the early stages of apoptosis. Briefly, mice 
were injected intravenously with MMPSense680™ (2 nmol/25 gram bodyweight in 100µl 
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PBS) 24 hours before microCT-FMT imaging. Mice were anaesthetized (1.5-2.5% isoflurane, 
O2 1 L/min) and depilated to minimize the interference of fur on the fluorescent signal. 
2 hours before FMT imaging, mice were injected intravenously with Annexin-Vivo750™. 
Before microCT imaging (Perkin Elmer Inc.), mice were injected in the tail vein with the 
iodinated contrast agent eXIA160 (Binitio Biomedical Inc., Ottawa, Canada), positioned 
in the imaging cassette and restrained to prevent movement during imaging. Mice were 
scanned using intrinsic cardiac respiratory gating to reduce artifacts caused by breathing or 
cardiac motion. After microCT imaging, mice remained under anesthesia and the cassette 
was transferred to the FMT 2500 fluorescent tomography in vivo imaging system (Perkin 
Elmer Inc.). FMT imaging was performed using 680 and 700 nm excitation and emission 
wavelengths, respectively, 24 hours after injection of MMPSense680™. The multimodal ani-
mal cassette facilitates the coregistration of FMT and CT data through fiducial landmarks. 
FMT and microCT data were merged using the Amide software and in vivo fluorescence was 
quantified. Functional parameters were calculated from the 3D microCT images with the 
help of the software ANALYZE® 12.0 (AnalyzeDirect Inc., Overland Parks, KS, USA).  
Ex	vivo fluorescent imaging of excised hearts
After in vivo microCT-FMT imaging, mice were euthanized using an overdose of inhalant 
anesthetic isoflurane. Hearts were excised, emersion fixed in formalin and assessed for ex 
vivo tissue epifluorescence using the FMT system and the Odyssey® CLx imaging system 
(LI-COR® Biosciences, Lincoln, Nebraska, USA). 
Statistical analysis
Data are expressed as the mean±SEM. Differences between groups were evaluated by Stu-
dent’s t-test or ANOVA, and corrected for multiple testing by post-hoc Bonferroni analysis 
when needed. P<0.05 was considered significant. All analyses were performed using IBM 
SPSS Statistics version 20.0 (SPSS Inc., Chicago, IL, USA).
RESuLTS
Ercc1 deficiency results in changes in LV geometry and functioning 
As previously described, Ercc1d/- mice showed reduced growth, declined body weight and a 
shortened lifespan (of approximately half a year) compared to their control littermates (Fig. 
1a and 1b, and Table 1).37 To investigate the effect of Ercc1d/- deficiency on heart geometry 
and function, anesthetized mice were injected with an iodinated contrast agent and imaged 
with the use of microCT. Imaging revealed an enlargement of the heart chambers in Ercc1d/- 
animals at 24 weeks of age compared to Ercc1d/- animals at 6 and 12 weeks of age. This was 
in striking contrast to the relatively stable volumes in the WT group over time, shown by a 
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volumetric 2D representation of the heart in end-diastole (Fig. 1c). To investigate whether 
normal cardiac function is maintained in Ercc1d/- mice, LV parameters were analyzed. Ercc1d/- 
mice showed an increase in left ventricular end-diastolic (LVED) volume (24-week-old Er-
cc1d/- 33+/-1 mm3 versus 6-week-old Ercc1d/- 27+/-2 mm3; p<0.05; n=22 and n=6, respectively), 
suggesting that the LV chamber is 24% dilated in diastole at 24 weeks of age compared to 
the earlier time points (Fig. 1d and Table 1). In addition, an increase in left ventricular end-
Figure 1. Ercc1 defi ciency results in a shortened lifespan and a deterioration in left ventricular function 
(LV) at 24 weeks of age. a. Lifespan is reduced in Ercc1d/- mice compared to control littermates. b. Repre-
sentative pictures of WT and Ercc1d/- mice and hearts at the age of 24 weeks. c. Representative microCT 
images of the heart in left ventricular end-diastole from WT and Ercc1d/- mice at 24 weeks of age. d. 
MicroCT functional imaging revealed a deterioration in LV function in Ercc1d/- at 24 weeks of age. Data 
is presented as mean±SEM. Statistical signifi cance *P<0.05 and **P< 0.001. 
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systolic (LVES) volume was observed, leading to an overall decrease in stroke volume at 24 
weeks (24-week-old Ercc1d/- 22+/-1 mm3 versus 6-week-old Ercc1d/- 14+/-2 mm3; p<0.05; n=22 
and n=6, respectively). WT mice showed stable volumes over time. Because stroke volume 
decreased while LVED volume increased in Ercc1d/- mice at the age of 24 weeks, there is a sub-
stantial reduction in left ventricular ejection fraction (LVEF) (24-week-old Ercc1d/- 33%+/-2 
versus WT 44%+/-1; p<0.05; n=22 and n=10, respectively). 
Table 1. Left ventricular volumes and global functional indices measured in 6- and 24-week-old WT 
and Ercc1d/- mice. Data represents mean±SEM. Statistical significance *P<0.05 and **P< 0.01. LVEDV, 
left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular 
stroke volume; LVEF, left ventricular ejection fraction; LVMV, total left ventricular myocardial volume; 
LVMM, left ventricular myocardial mass; BPM, beats per minute.
Control WT Mutant Ercc1∆/-
6 weeks 24 weeks ∆ % 6 weeks 24 weeks ∆ %
Body weight (g) 26.1 ± 1.38 M
20.7 ± 0.20 F
43.4 ± 1.01 M
28.6 ± 1.42 F
+16
-2
17.3 ± 0.89 M
13.7 ± 0.50 F
13.5 ± 0.32 M
13.3 ± 0.23 F
-13
-10
Heart weight (g) 0.139 ± 0.005 0.148 ± 0.008 +6 0.087 ± 0.003 0.077 ± 0.001 -12
LVEDV (mm3) 54.69 ± 1.53 64.71 ± 2.27 +18 26.68 ± 1.69 33.00 ± 0.55 +24**
LVESV (mm3) 26.74 ± 1.50 36.02 ± 1.39 +35 14.25 ± 1.52 22.16 ± 0.80 +55**
LVSV (mm3) 27.94 ± 2.39 28.69 ± 1.12 +3 12.43 ± 1.26 10.84 ± 0.69 -13
LVEF (%) 50.87 ± 3.35 44.35 ± 0.85 -13 46.82 ± 4.36 32.87 ± 2.10 -30*
LVMV (mm3) 81.92 ± 3.63 93.62 ± 9.30 +14 49.98 ± 2.59 46.25 ± 1.46 -7
LVMM (mg) 86.02 ± 3.81 93.30 ± 9.76 +14 52.48 ± 2.72  48.56 ± 1.53 -7
Cardiomyocyte-specific deletion of Ercc1 in the heart leads to impaired cardiac 
functioning
In order to investigate whether the observed cardiac impairment in the Ercc1d/- animals 
was due to loss of Ercc1 in the heart or due to overall age-related systemic organ failure, 
Ercc1 was deleted specifically in the cardiomyocytes of the heart. These αMHC-Ercc1c/- 
mice exhibited normal growth and body weight, similar to control (Table 2), but sub-
sequently showed a reduced lifespan of about 24 weeks (Fig. 2a). From 16 weeks on an 
overall decrease in health and survival was observed. Therefore, cardiac size and function 
were assessed with microCT in 8 and 16-week-old αMHC-Ercc1c/- and control mice. At 16 
weeks, αMHC-Ercc1c/- showed an increase in LVED volume (Ercc1c/- 73+/-6 mm3 versus WT 
57+/-3 mm3; p<0.05; n=4 both groups) as well as an increase in LVES volume (Ercc1c/- 51+/-5 
mm3 versus WT 29+/-3 mm3; p<0.05; n=4 both groups). This suggest that left ventricular 
dilation and systolic dysfunction were present in αMHC-Ercc1c/- at 16 weeks of age (Fig. 
2c). The deterioration of LV function in αMHC-Ercc1c/- mice preceded signs of heart failure 
(Ercc1c/- 30%+/-1 versus WT 50%+/-2; p<0.05; n=6 both groups) (Fig. 2c). These results 
indicate that Ercc1 deficiency in cardiomyocytes is associated with adverse cardiac remod-
eling and poor cardiac functioning. 
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Table 2. Left ventricular volumes and global functional indices measured in 8- and 16-week-old control 
and αMHC-Ercc1c/- mice. Data represents mean ± SEM. Statistical signifi cance *P<0.05 and **P< 0.01. 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left 
ventricular stroke volume; LVEF, left ventricular ejection fraction; BPM, beats per minute.
Control Cre- aMhC-Ercc1c/-
8 weeks 16 weeks ∆ % 8 weeks 16 weeks ∆ %
Body weight (g) 22.7 ± 1.2 27.8 ± 3.3 +22 21.3 ± 2.1 24.2 ± 2.2 +14
Heart weight (g) 0.111 ± 0.004 0.136 ± 0.007 +22 0.112 ± 0.008 0.130 ± 0.008 +16
LVEDV (mm3) 46.91 ± 1.59 57.26 ± 2.98 +22 50.55 ± 3.07 72.48 ± 5.76 +43
LVESV (mm3) 25.08 ± 1.12 28.85 ± 2.63 +15 29.49 ± 2.25 50.85 ± 4.43 +72
LVSV (mm3) 21.83 ± 1.47 28.42 ± 1.01 +30 21.06 ± 0.82 21.63 ± 1.18 +3
LVEF (%) 46.46 ± 2.14 50.10 ± 2.29 +8 41.76 ± 0.88 29.97 ± 1.18 -28
Figure 2. Specifi c deletion of Ercc1 in cardiomyocytes leads to early onset of left ventricular (LV) dys-
function. a. Specifi c loss of Ercc1 in cardiomyocytes (αMHC-Ercc1c/-) leads to a signifi cant reduction in 
lifespan compared to littermate controls. b. Representative microCT images of the heart from αMHC-
Ercc1c/- mouse and control littermates, showing an increase in size of the heart from the mutant animals 
at the age of 16 weeks. c. MicroCT functional imaging revealed that left ventricular function is impaired 
in αMHC-Ercc1c/- mice. Data is presented as mean±SEM. Statistical signifi cance *P<0.05 and **P< 0.001. 
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Ercc1 defi ciency causes a gradual decrease in LV myocardial mass over ti me
As a lot of patients diagnosed with heart failure have an underlying type of cardiomyopa-
thy, i.e. disease of the myocardium, we quantifi ed the myocardial wall volume and mass 
in Ercc1d/- hearts of 6, 12 and 24 weeks of age, using the microCT data (as indicated in Fig. 
3a). 3D-reconstructed myocardial wall images showed a gradual decrease in myocardial 
mass in Ercc1d/- hearts over time (Fig. 3b). Quantifi cation of the LV wall mass confi rmed 
LV myocardial wall thinning in Ercc1d/- hearts at 24 weeks of age compared to 6-week-old 
Ercc1d/- mice, whereas the LV myocardial wall mass of WT mice increased from 6 until 24 
weeks of age (Fig. 3c).
Ercc1 defi ciency leads to increased myocardial apoptosis and MMP acti vity
To investigate whether we could, non-invasively, detect apoptotic cells in the aging Ercc1d/- 
hearts, we injected these animals with the NIRF probe Annexin-Vivo750™ that binds to 
phosphatidylserine which is exposed on the outer leafl et of the cell membrane lipid bilayer 
during the early stages of apoptosis. MicroCT-FMT-reconstructed 3D images showed an 
increased intensity of Annexin-Vivo in Ercc1d/- compared to WT mice, at 24 weeks of age 
(Fig. 4a). Quantifi cation of the in vivo fl uorescent signal revealed signifi cantly increased 
myocardial apoptosis in Ercc1d/- mice at all ages when compared to WT (24 weeks 164+/-25 
Figure 3. Ercc1D/- mice causes a gradual decrease in LV myocardial mass over time. a. Representative 
microCT images of a WT heart in which the myocardial wall is selected (red) for analysis. b. 3D re-
constructed myocardial wall images of WT and Ercc1d/-hearts over time show a gradual thinning of the 
myocardial wall in 24-week-old Ercc1d/-hearts. c. Quantifi cation of the left ventricular (LV) wall mass 
confi rmed a trend in LV myocardial wall thinning in Ercc1d/- hearts at 24 weeks of age.  Data is presented 
as mean±SEM. Statistical signifi cance *P<0.05 and **P< 0.001.
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versus 16+/-3 pmol/g, respectively; p<0.001; n=8 vs n=5) (Fig. 4b). 2D tissue epifl uores-
cence imaging of excised hearts confi rmed the increased fl uorescence seen noninvasively 
by FMT in the Ercc1d/- mice (Fig. 4c and d). In addition, representative heart sections were 
Figure 4. Ercc1 defi ciency leads to increased myocardial apoptosis. a. In vivo fl uorescent imaging of 
apoptosis in the heart in Ercc1d/- mice compared to WT, at 24 weeks of age. Signal from the other tis-
sues is excluded for clarity. b. In vivo quantitative data, by dual fusion of FMT and CT imaging, revealed 
increased myocardial apoptosis in Ercc1d/- mice at 12 and 24 weeks of age. c. Epifl uorescence images of 
the heart, obtained with an odyssey imaging system, show an increase in apoptotic signal at 24 weeks 
of age in the Ercc1d/- mice compared to WT. d. Quantifi cation of 2D tissue epifl uorescence imaging of 
excised hearts confi rmed the increased fl uorescence in the Ercc1d/- mice. e. Representative heart sections 
showed that the NIRF fl uorescence of the injected Annexin-Vivo probe was detected on the membrane 
of cells. f. Immunohistochemistry confi rmed the presence of apoptotic cells in the myocardium of 12 
and 18 weeks old Ercc1d/- mice. Data is presented as mean±SEM. Statistical signifi cance *P<0.05 and 
**P< 0.001
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examined under a fl uorescent microscope, which showed that the NIRF fl uorescence of 
the injected Annexin-Vivo probe was detected on the membrane of cells (Fig. 4e). Im-
munohistochemistry confi rmed the presence of apoptotic cells in the myocardium of 12 
weeks old Ercc1d/- mice (Fig. 4f). TUNEL staining revealed a greater occurrence of apop-
totic myocytes in Ercc1d/- hearts, whereas only a few TUNEL-positive cells were detected 
in WT hearts. Apoptotic cells were located throughout the whole myocardium. As shown 
in Figure 4f, quantifi cation of cardiomyocyte apoptosis by TUNEL staining demonstrated 
an approximate 2-fold increase in Ercc1d/- hearts compared to WT hearts. Since MMPs 
participate in cardiac remodeling after acute injury and are involved in the breakdown of 
the myocardium, we injected the accelerated aging Ercc1d/- mice with the MMP-specifi c 
activatable NIRF probe MMPSense680™ to detect possibly increased MMP activity in 
the Ercc1d/- hearts. We subsequently determined tissue epifl uorescence levels in excised 
hearts using the Odyssey imaging system. At 6 and 24 weeks of age, Ercc1d- hearts showed 
increased MMP activity compared to WT hearts (Fig. 5a and b). 
dISCuSSION
Research focusing on age-related diseases in humans carries unique challenges, because 
of its complexity as well as the time involved, thus the need remains for preclinical studies 
based on animal models that resemble the clinical setting of age-related diseases at ac-
celerated pace. During the past few decades, many animal models to study certain aspects 
of cardiac aging and related disease have emerged, however, the precise role of DNA repair 
defi ciency and related accelerated aging on CVD remains largely elusive.38, 39 As accumula-
tion of DNA damage is regarded as one of the possible explanations of aging, in this study 
Figure 5. Ercc1 defi ciency results in a gradual increase of MMP activity in the myocardium. a. 2D Tis-
sue epifl uorescence imaging of excised hearts using the Odyssey imaging system. b. Quantifi cation of 
epifl uorescence imaging of excised hearts showed a signifi cant gradual increase of MMP activity at 24 
weeks of age, in the Ercc1d/- mice compared to WT. Data is presented as mean±SEM. Statistical signifi -
cance *P<0.05 and **P< 0.001. 
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we explored the effect of Ercc1 deficiency, leading to defects in DNA repair, on cardiac 
function.4 We evaluated cardiac performance starting at 6 through 24 weeks of age using 
non-invasive microCT imaging. Additionally, we tested the use of functional microCT 
imaging combined with NIRF probes to explore whether we could directly report on the in 
vivo activity of MMP and the occurrence of apoptosis in the aging heart, and investigated 
if these probes can serve as markers for age-related CVD. 
In the present study, we demonstrate that Ercc1 deficiency results in changes in 
geometry and functioning of the heart with age. Adult Ercc1d/- mice exhibited ventricular 
chamber enlargement and LV myocardial wall thinning, however decreased stroke volume/
ejection fraction only occurred at the end of their lifespan (24 weeks). The overall changes 
in the heart and myocardium of the 24-week-old Ercc1d/- mice suggest that Ercc1 deficiency 
contributes to the development of features consistent with progressive DCM, a common 
pathology seen in aged humans.40 DCM is a disease of the myocardium that is character-
ized by ventricular chamber enlargement with a reduction in cardiac performance, often 
accompanied by progressive thinning of the myocardial wall. Several studies have already 
indicated a link between DNA damage and DCM in humans as well animal models. Pa-
tients with DCM, exhibited elevated levels of 8-hydroxy-2-deoxyguanosine (8-OhdG) in 
their serum and myocardium, suggesting an increase in overall oxidative DNA damage 
in this type of cardiac disease.41 Moreover, mitochondrial DNA damage and dysfunction 
have been shown to activate apoptosis and cause DCM.42-44 DNA damage and aging are 
not limited to DCM, but also contribute to other types of CVDs, including heart failure 
and myocardial infarction.45-49 In addition, increasing evidence indicates that therapeutic 
radiation treatment causes various types of DNA damage and consequently can cause 
cardiovascular complications (reviewed within Ishida et al.).46 
The Ercc1d/- mouse model has been well recognized as a model of accelerated aging, 
and as such the pathology observed in these animals could be the result of accelerated sys-
temic organ aging and consequent failure.6, 37 However, as we showed that cardiomyocyte-
specific deletion of Ercc1 identically impaired cardiac functioning, we conclude that Ercc1 
deficiency in the heart results in adverse cardiac remodeling and poor cardiac functioning, 
independently of overall age-related systemic organ failure. Mice with cardiomyocyte-
specific deletion of Ercc1 had an overall lifespan approximately 20 weeks and likely died 
due to the decrease in cardiac performance. However, only at 24 weeks of age the Ercc1d/- 
mice showed a decrease in LVEF. We chose 24 weeks as our end-point because it has been 
previously reported that Ercc1d/-mice have an average lifespan of 24-28 weeks, as shown 
in Figure 1a.37, 50, 51 During their lifetime, these Ercc1d/- animals show numerous acceler-
ated aging features including loss of vision and hearing, dystonia and tremors, kyphosis, 
ataxia and progressive neurodegeneration.50, 52, 53 The exact cause of death in these mice is 
still unknown, but is probably related to the fact that the most vulnerable organ systems 
fail first, thus preventing information acquisition of the aging phenotype on other organ 
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systems, including the heart. Nevertheless, the vast amount on functional, histopatho-
logical, transcriptional, proteomic, metabolomics and ultrastructural data regarding the 
Ercc1d/- mice support the conclusion that these animals copy normal murine aging, and are 
a useful model to study the effect of aging and DNA repair defects on disease development 
and progression (reviewed within Gurkar et al.).54
Hybrid imaging optimized for small animals is very important because of the 
widespread use of genetically engineered mice resembling disease and the need to in vivo 
investigate the functional, anatomical and molecular phenotype of these mice. Imaging of 
the cardiovascular system, especially the right ventricle and the myocardial wall, has been 
quite challenging for a long time. The advances in new and existing imaging modalities 
for small animals, allow more accurate, high resolution, 3D, longitudinal imaging of the 
cardiovascular system and provides rapid translation of new knowledge to the clinic.55 
MicroCT imaging is frequently used for characterization of cardiac function and structure 
in small animals, and current systems now provide cardio-respiratory gating, to minimize 
movement interference.56, 57 The current study used microCT imaging not only to deter-
mine cardiac function but also explore the shape and anatomy of the myocardial wall. 
We could accurately measure the myocardial wall volume and mass, demonstrating that 
Ercc1d/- mice show myocardial wall thinning at 24 weeks of age. Moreover, representative 
microCT images of the Ercc1d/- hearts suggest that the right ventricle is also affected in 
these mice, and analysis and quantification thereof should give us more answers regarding 
the function and geometry of the right ventricle. The microCT is well suited for examina-
tion of cardiac disease in small animals.  
Fluorescent molecular imaging data presented in this study revealed that cardiac 
aging and subsequent failure in the progeroid Ercc1 mice is preceded by a gradual increase 
in MMP activity and an increase in apoptosis. Aging is linked to increased MMP activity 
and extracellular matrix turnover, which could lead to myocardial remodeling thereby 
affecting cardiac performance. Several different types of MMPs are detected in diseased 
hearts, in which MMP-9, in particular, is found to play a key role.24, 58, 59 However, the 
suggestion that MMP-9 can serve as potential plasma markers for cardiac aging might not 
be correct, as the age-associated increase of circulating MMP-9 in mice is in contrast with 
the decrease of circulating MMP-9 found in aging humans.60, 61 This highlights the com-
plexity of the presence and role of MMPs in age-related diseases. The MMPs found in the 
aging heart might be derived from senescent cells and due to the senescence-associated 
secretory phenotype.62 Numerous examples of increased cellular senescence involved in 
age-related pathology have been reported.63 DNA damage is a crucial mediator for cells to 
undergo apoptosis or enter senescence and it was shown that Ercc1 deficient cells undergo 
premature cellular senescence.8 Hence, the increased MMP activity observed in Ercc1d/- 
mice might also be derived from senescent cells, and the use of in vivo molecular imaging 
of MMP activity could help to follow changes in activity over time. Additionally, apoptosis 
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has been suggested to be responsible for a significant amount of cardiomyocyte death 
that contributes to the development and progression of heart failure. Indeed, apoptosis 
has been found in several cardiac diseases.64-66 However, whether there are increases in 
apoptotic cells in failing hearts remains controversial.67 One of the arguments is that the 
TUNEL technique, which detect apoptosis by identifying in situ DNA nicks, is not solely 
specific for programmed cell death but might also label cells that undergo DNA repair.68 
The apoptosis probe we used in this study, Annexin-Vivo750™, binds to phosphatidylser-
ines exposed on the outside of early apoptotic cells and does not detect DNA nicks, and 
therefore holds potential for in vivo identification of apoptosis. Fluorescent imaging of 
Annexin-Vivo in the Ercc1d/- mice, demonstrated that Ercc1 deficiency leads to increased 
myocardial apoptosis already starting at 6 weeks of age before changes in cardiac perfor-
mance occurred. Accordingly, this probe holds important potential for in vivo assessment 
of apoptosis involved in CVDs and can provide valuable insights into early disease detec-
tion. Prevention of cardiovascular disease requires early detection and risk stratification 
before the manifestation of disease. 
In conclusion, this is the first study to show that Ercc1 deficient accelerated aging 
mice develop cardiac pathology which starts with an in vivo gradual increase in MMP 
activity followed by apoptosis, leading to progressive ventricular enlargement, LV myocar-
dial wall thinning and reduction in cardiac performance. The use of microCT is a valuable 
imaging modality to establish cardiac function in small animals as well as explore 3D 
geometric changes throughout the heart. Moreover, combined CT and optical imaging 
allows simultaneous analysis of molecular and functional changes in mouse models for ac-
celerated aging and hold important potential for early disease detection, exploring disease 
progression and the assessment of therapeutic effects.   
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ABSTRACT
Changes in the renin-angiotensin system, known for its critical role in the regulation of 
blood pressure and sodium homeostasis, may contribute to aging and age-related dis-
eases. While the systemic renin-angiotensin system is suppressed during aging, little is 
known about its regulation and activity within tissues. Yet, this knowledge is required to 
successively treat and/or prevent renal disease in the elderly. In this study, we tested the 
use of the renin activatable near-infrared fluorescent probe ReninSense680™ to facilitate 
non-invasive imaging of renin activity in vivo. First, we validated the specificity of the 
probe, by detecting increased intrarenal activity after losartan treatment and the virtual 
absence of fluorescence in renin knock-out mice. Second, age-related kidney pathology, 
tubular anisokaryosis, glomerulosclerosis and increased apoptosis was confirmed in kid-
neys of 12, 18 and 24-week-old Ercc1d/- mice, while initial renal development was normal. 
Next, we examined the in vivo renin activity in these Ercc1d/- mice. Interestingly, increased 
intrarenal renin activity was detected by ReninSense in Ercc1d/- compared to WT mice, 
while plasma renin activity was lower. Hence, this study demonstrates that intrarenal RAS 
activity does not necessarily run in parallel with circulating renin in the aging mouse. In 
addition, our study supports the use of this probe for longitudinal imaging of altered RAS 
signaling in aging.
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INTROduCTION
Aging is a natural biological process that is associated with diverse detrimental changes in 
cells and tissues, ultimately leading to loss of organ function. Progressive deterioration of 
the renal structure is part of the normal aging process, including loss of renal mass, loss of 
tubules and increase in the incidence of glomerulosclerosis and tubulointerstitial fibrosis.1 
Besides sclerosis and loss of most of the glomeruli, the remaining glomeruli often exhibit 
impaired filtration ability. Accordingly, many elderly suffer from a decline in renal func-
tion, often shown as a progressive decrease in glomerular filtration rate and renal blood 
flow. These age-related structural and functional changes may predispose the kidney to 
acute kidney injury or progressive chronic kidney disease.2
The renin-angiotensin system (RAS) has long been recognized for its critical role in 
the regulation of blood pressure and fluid homeostasis. Changes in the responsiveness and 
activity of the RAS have been shown to play an important role in aging, as well as in renal 
disease as it predisposes the elderly to acute kidney injury and chronic kidney disease.3-7 
It is suggested that overexposure to the RAS hormone angiotensin (Ang) II causes DNA 
damage as well as cellular senescence and/or apoptosis; processes known to play a role in 
aging and disease.8, 9 Moreover, interference in the RAS system by using RAS blockers has 
been proposed to extend lifespan and to prevent age-associated changes.10 However, not 
all elderly respond well to RAS blockade and related adverse events include acute kidney 
injury, hyperkalemia and hypotension.11, 12 Thus, we need more insight into the regulation 
of the RAS during aging, in order to successively treat and/or prevent renal disease in the 
elderly population.
Although Ang II is considered to be the principal effector molecule of the RAS, 
renin is the rate-limiting enzyme in the cascade and plays an essential role in regulating 
RAS activity. Several classes of drugs blocking renin activity have been shown to have 
renoprotective actions.13 Currently, plasma renin activity is used as the clinical marker 
for systemic RAS activity, and previous studies have shown that circulating renin is sup-
pressed with advancing age.7, 14 However, multiple studies reported on the existence of 
so-called tissue RAS, which may act independently of the systemic RAS.15 Indeed, RAS 
components in the kidney did not always change in parallel with RAS components in the 
circulation.16 In fact, inappropriate activation of the intrarenal RAS might underlie the 
pathogenesis of hypertension and renal injury (reviewed within Kobori et al.).17 Thus, next 
to systematic plasma renin activity measurements more emphasis should be placed on 
quantifying tissue RAS activity. As it is difficult to measure tissue RAS components in vivo, 
non-invasive imaging of local renin activity would help to evaluate the possible role of 
tissue renin activity in disease development and progression. Moreover, the development 
of new non-invasive imaging methods with the use of near-infrared fluorescent (NIRF) 
probes could lead to better detection and treatment options in the future.  
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It has previously been shown that kidneys of the progeroid Ercc1d/- mouse model 
display severe tubular attenuation and degeneration with marked anisokaryosis.18, 19 More-
over, Schermer et al.20  showed that age-related transcriptional changes were present in 
the glomeruli of Ercc1d/- mice, thus suggesting that the progeroid Ercc1d/- mouse model 
is a valuable tool to study age-related glomerular pathologies. To investigate age-related 
changes in the intrarenal RAS in vivo, we applied the renin activatable NIRF probe Renin-
Sense680™ allowing non-invasive imaging of renin activity in the progeroid Ercc1d/- mouse 
model.21
MATERIAL ANd METhOdS
All animal experiments were performed under the regulation and permission of the 
Animal Care Committee, conforming to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 8523, 
revised 1985). As required by Dutch law, formal permission to generate and use genetically 
modified animals was obtained from the responsible local and national authorities (DEC 
118-11-05 and DEC 139-12-16). 
Experimental animals 
Animals used in this study were male and female Ercc1d/- mutants and their wild-type 
Ercc1+/+ littermates (WT) in an F1 hybrid FVB/N-C57BL/6J background. The generation of 
nucleotide excision repair-deficient Ercc1d/- mice has been previously described.22 Ren1c 
homozygous null mice (RenKO; 3 females and 1 male) were generated as described before 
(C57BL/6J background) and sacrificed at the age of 3-6 months.23 A separate group of WT 
mice were divided into two groups, which were either given losartan (100 mg/kg/day) in 
drinking water, or drinking water only from 5 weeks of age until the age of 12 weeks when 
the animals were sacrificed.  
All mice were housed under standard laboratory conditions (temperature 23±1°C, 
12-hour light-dark cycle) and maintained on standard chow (Special Diets Services, Essex, 
UK) with ad libitum access to water. Since Ercc1d/- mice are smaller, water bottles with long 
nozzles were used and food was administered within the cages from four weeks of age.
In	vivo microCT-FMT imaging of renin activity
Ercc1d/- and WT mice, treated with or losartan or placebo, were injected intravenously 
with ReninSense680™ (2 nmol/100µl per 25 gram bodyweight) (Perkin Elmer Inc., Akron, 
Ohio, USA) 24 hours post FMT imaging. Mice were anesthetized (1.5-2.5% isoflurane, O2 
1 L/min) and depilated to minimize the interference of fur on the fluorescent signal. To 
improve detection of intrarenal renin activity, mice were injected with the NIRF probe 
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Annexin-Vivo750™ (Perkin Elmer Inc.) 2 hours post FMT imaging to visualize the kidneys 
and/or imaged with the microCT to allow co-registration of anatomical data with the in 
vivo fluorescence. Before FMT imaging, mice were injected in the tail vein with the iodine 
contrast agent eXIA160 (Binitio Biomedical Inc., Ottawa, Canada) for microCT imaging. 
Mice were positioned in the animal imaging cassette, restrained to prevent movement 
during imaging and imaged by using the Quantum FX imaging system (microCT) (Perkin 
Elmer Inc.). After microCT imaging, mice remained under anesthesia and the cassette 
was transferred to the FMT 2500 fluorescence tomography in vivo imaging system (Perkin 
Elmer Inc.). FMT imaging was performed using 680 and 700 nm excitation and emis-
sion wavelengths, respectively, 24 hours after injection. The multimodal animal imaging 
cassette facilitates the co-registration of microCT and FMT data through fiducial land-
marks. Fusion of microCT and FMT images was done using the TrueQuant 4.0 software 
(Perkin Elmer Inc.). The position of the kidney was determined by the accumulation of 
the fluorescence of Annexin-Vivo750™ in the kidney and/or based on the distribution of 
the iodine contrast visualized with the microCT, which allowed quantification of in vivo 
fluorescence of ReninSense680™.
Tissue collection and ex vivo fluorescent imaging of excised kidneys
Mice were euthanized after in vivo microCT-FMT imaging by isoflurane overdose. Blood 
samples were harvested by cardiac puncture, transferred to EDTA coagulation vials and 
centrifuged at 4600 rpm for 10 minutes to collect plasma. Next, kidneys were excised, 
emersion fixated in formalin and assessed for ex vivo tissue epifluorecence using the FMT 
system and the Odyssey® CLx imaging system (LI-COR® Biosciences, Lincoln, Nebraska, 
USA). A separate group of Ercc1d/- and WT mice were sacrificed, kidneys were excised, snap 
frozen in liquid nitrogen and stored at -80°C. 
In	vitro fluorescent imaging of kidney and plasma renin activity
Activation of ReninSense680™ was determined in plasma (pooled plasma from C57Bl/6J 
mice, GeneTex, Irvine, CA, USA) and kidney lysates. Frozen kidneys of 2 WT and 4 RenKO 
mice were homogenised in PBS using mortar-pestle method. Protein concentration was 
determined using a Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Rockford, IL, 
USA). Samples were pre-incubated in the presence or absence of different concentrations 
of the renin inhibitor aliskiren (10-11 – 10-4 M) at 37°C for 30 minutes. Next, tissue fluores-
cence was assessed by incubation of plasma or kidney lysates with ReninSense680™ (end 
concentration 0.2 pmol/μl) at 37°C in a humidified incubator for 30 hours. Fluorescence 
was measured using the Odyssey® CLx imaging system (excitation settings 700 nm). For 
background subtraction, kidney lysates of RenKO mice together with denatured kidney 
and plasma lysates (by heating the sample for 10 min at 70°C) were incubated with and 
without ReninSense680™. 
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Plasma renin concentration measured by enzyme-kinetic assay
To determine the plasma renin concentration, Ang I generation was quantified in the pres-
ence of excess sheep angiotensinogen.24, 25
histological assessment
Emersion fixated kidneys were embedded in paraffin, sectioned at 5 µm, and mounted 
on Superfrost Plus slides. Cross-sections of the whole kidney including the cortex and 
medulla were stained for haematoxylin and eosin (HE), Periodic acid-Schiff stain (PAS), 
Jones 2 and terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling 
(TUNEL). The number of TUNEL-positive cells in the kidney was determined using 40x 
magnification. 
urine measurements relevant to renal function
Urine was collected and urinary protein, creatinine and urea level were measured accord-
ing to supplier instructions with Pierce BCA Protein Assay kit (Thermo Fisher Scientific, 
Rockford, IL, USA), QuantiChrome Creatinine Assay Kit (Gentaur, Brussels, Belgium) and 
QuantiChrome Urea Assay Kit (Gentaur, Brussels, Belgium), respectively. 
Statistical analysis
Data are expressed as the mean±SEM. Differences between groups were evaluated by Stu-
dent’s t-test or ANOVA, and corrected for multiple testing by post-hoc Bonferroni analysis 
when needed. P<0.05 was considered significant. All analyses were performed using IBM 
SPSS Statistics version 20.0 (SPSS Inc., Chicago, IL, USA).
RESuLTS 
Progeroid Ercc1d/- mice display age-related kidney pathology
We first set out to confirm the age-related kidney pathology in Ercc1d/- mice, for which we 
examined kidneys of 12 and 18-week-old mice. Indeed, from 12 weeks onwards Ercc1d/- mice 
display progressive kidney pathology including tubular degeneration and anisokaryosis 
(Fig. 1a). In addition, they present with signs of kidney aging, shown by reduced prolifera-
tion (data not shown) and increased apoptosis (Fig. 1b) already at 12 weeks of age, which 
was even more pronounced at 18 weeks. Moreover, at 18 weeks of age, hyaline protein-
aceous casts were present within the lumen of the tubules in kidneys of Ercc1d/- mice. 
Renal development of Ercc1d/- kidneys was found to be normal, as 12-week-old animals had 
normal kidney architecture including normal numbers of glomeruli (Fig. 1c). To rule out 
significant renal dysfunction due to the observed pathology, we confirmed that urinary 
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albumin, creatinine and urea levels were unaltered in Ercc1d/- mice compared to WT mice 
(Fig. 2a-c). 
Figure 1. Histopathological changes in the kidney of progeroid Ercc1d/- mice. a. Haematoxylin and eosin 
(HE), Periodic acid-Schiff  stain (PAS) and Jones 2 staining of the kidneys of 12 and 18-week-old Ercc1d/- 
mice and their wild-type (WT) littermates. Histological examination showed signs of kidney aging in 
Ercc1d/-, including anisokaryosis, tubular degeneration and glomerulosclerosis. Moreover, hyaline pro-
teinaceous casts were found within the lumen of the tubules in kidneys of Ercc1d/- mice at 18 weeks of age 
(indicated by the arrow in PAS staining). In all panels, scale bar = 50μm. b. TUNEL staining indicated 
increased apoptotic cell death in Ercc1d/- kidneys. c. The number of glomeruli confi rmed normal kidney 
development from birth in Ercc1d/-. ***P<0.01 vs. WT.
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ReninSense selecti vely detects renin acti vity in the kidney in vitro 
To assess the ability of ReninSense680™ to detect both kidney and plasma renin, 
activation of ReninSense was tested in kidney lysates and plasma from WT and Ren1c 
homozygous null (RenKO) mice, with and without co-incubation of the renin inhibitor 
aliskiren. As expected, ReninSense was rapidly activated in kidney lysates of WT mice 
assessed by fl uorescent measurements with the odyssey system. The microplate kidney 
extract fl uorescent assay showed <5% variation between duplicate wells. Aliskiren blocked 
ReninSense activation in a concentration-dependent manner by maximally ≈80% (Fig. 
3a). The half maximal inhibitory concentration (IC50) for aliskiren in kidney lysates was 
approximately 10-7.7 M as measured here with the ReninSense probe (Fig. 3b), i.e. close 
to the IC50 reported earlier for mouse renin.26 The remaining fl uorescent signal in the 
presence of the highest concentration of aliskiren was comparable to the fl uorescence seen 
in kidney extracts from RenKO mice and denatured kidneys, indicating that this is the 
background fl uorescent level of the ReninSense probe, in other words the detection limit 
of this system. When evaluating the ReninSense probe in mouse plasma, fl uorescence 
levels remained in this background range and were unaff ected by aliskiren, indicating that 
the probe cannot be used to measure renin activity in plasma using the odyssey system.   
In	vivo imaging of renin upregulati on shown by ReninSense 
To address the ability of ReninSense to be cleaved and used as a readout for in vivo renin 
activity, ReninSense activation was examined in WT mice treated either with vehicle or with 
the AT1 receptor antagonist losartan, which is known to increase renin levels. In addition, 
ReninSense activation was measured in RenKO mice. Animals were imaged tomographi-
cally by FMT 2500 24 h after ReninSense injection. To improve detection of intrarenal renin 
activity, mice were injected with the NIRF probe Annexin-Vivo750™ to visualize the kidneys 
Figure 2. Functional renal changes in progeroid Ercc1d/- mice. Urinary albumin (a), creatinine (b) and 
urea (c) was unaltered in Ercc1d/- mice compared to WT mice at 12 and 18 weeks of age.
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and, when possible, also imaged with the microCT to allow co-registration of anatomical 
data with the in vivo fl uorescence (Fig. 4a). Losartan-treated mice showed increased in 
vivo (Fig. 4b) and ex vivo (Fig. 4c) activation of ReninSense in their kidneys compared to 
vehicle treated mice. The increase in renin activity after losartan treatment was validated 
by quantifi cation of the in vivo results (Fig. 4d), increased plasma renin activity (Fig. 4e) 
and increased renin expression levels in the kidney (Fig. 4f). As expected, fl uorescence of 
ReninSense could not be detected in vivo or ex vivo in RenKO mice, which do not express the 
renin gene. These results validate the specifi city of the ReninSense probe for renin activity.
Increased renin acti vity in the kidney of progeroid Ercc1d/- mice in vivo
While it is generally accepted that circulating renin activity is suppressed during aging, 
little is known about the regulation and activity of renin within tissues with increasing 
age. In order to investigate in vivo kidney renin activity during aging, we injected progeroid 
Ercc1d/- mice and their WT littermates with ReninSense. Combined microCT and FMT 
imaging of ReninSense showed increased in vivo intrarenal renin activity in Ercc1d/- mice 
compared to WT mice already from 12 weeks of age onwards, which was signifi cantly 
diff erent at 24 weeks of age (Fig. 5a and b). Quantifi cation of the in vivo fl uorescence 
(Fig. 5b) and ex vivo imaging of the kidneys (Fig. 5c) confi rmed these results. We found 
no diff erences in in vivo renin activity between male and female mice (data not shown). 
Remarkably, plasma renin activity in the Ercc1d/- mice was signifi cantly lower compared to 
WT mice at 24 weeks of age (Fig. 5d), while normal plasma renin activity levels were found 
at 6 weeks of age. 
Figure 3. Specifi c in vitro enzymatic activation of ReninSense by kidney and plasma renin. a. Renin-
Sense was rapidly activated by kidney renin in WT mice. Low levels of fl uorescence were found in 
RenKO kidney lysates comparable to autofl uorescence of the probe. High concentrations of aliskiren 
completely blocked ReninSense activation. b. The half maximal inhibitory concentration (IC50) for 
aliskiren in kidney lysates was 10-7.7 M. Data are mean±SEM of duplicate samples. ***P<0.01 vs. control.
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Figure 4. In vivo activation of ReninSense in kidneys of WT mice, with and without losartan treatment. 
a. Mice were imaged tomographically by FMT 2500 and microCT 24 h after ReninSense injection. Micro 
CT imaging and FMT imaging of Annexin-Vivo allowed accurate localization of the kidneys. Combined 
microCT and FMT imaging of Annexin-Vivo and ReninSense showed in vivo renin activity in the kidneys 
and bladder (clearance of probe). b. Losartan-treated mice showed increased in vivo intrarenal renin 
activity, which was confi rmed by quantifi cation (c). d. Ex vivo imaging of the kidneys by the Odyssey® 
system confi rmed activation of the ReninSense probe in losartan-treated mice. Fluorescence of Renin-
Sense could not be detected in vivo of ex vivo in RenKO mice. e. Losartan treatment increased plasma 
renin activity. f. Increased expression levels of renin in the kidney were found in losartan-treated mice. 
ND, not detectable. Data are mean±SEM of n=3. *P<0.05, ***P<0.01 vs. WT. 
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dISCuSSION
Changes in the RAS are associated with the pathophysiology of various cardiovascular and 
renal diseases, and therefore targeting the RAS seems a logical therapeutic approach in 
treatment of these diseases. Indeed, pharmacological RAS blockade has been shown to 
eff ectively slow down the progression of renal disease. However, it is important to note 
that not all patients, e.g. elderly, respond well to RAS blockade. While the systemic RAS 
is suppressed with advancing age, the regulation and activity of tissue RAS during aging 
is not well defi ned. As such, previous reports showed that although the circulating RAS 
is suppressed during normal aging, some components of the intrarenal RAS are elevat-
ed.3, 16, 17, 27-29 Varying tissue RAS activity might, at least in part, explain why elderly respond 
Figure 5. In vivo imaging of renin activity by ReninSense in progeroid Ercc1d/- mice. a. Ercc1d/- mice 
display activated intrarenal renin activity at 24 weeks of age, as evidenced by increased fl uorescence de-
tected with the ReninSense probe when imaged with the microCT and FMT. b. Quantifi cation of the in 
vivo fl uorescence of ReninSense confi rmed increased renin activity in the kidney which was signifi cantly 
diff erent at 24 weeks of age. c. These results were further confi rmed by ex vivo by imaging of the kidneys 
with the Odyssey® system. d. Plasma renin activity measurements showed that Ercc1d/- mice (squares) 
tended to have lower plasma renin activity levels compared to WT mice (circles), which was signifi cantly 
lower at 24 weeks of age. No diff erence in in vivo renin activity was observed between male (blue) and 
female (red) mice. Data are mean±SEM of n=6-12. Diff erences were assessed by one-way ANOVA, fol-
lowed by correction for multiple testing by post-hoc Bonferroni analysis. **P<0.01, ***P<0.01 vs. WT.
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unpredictable to RAS blockade. Therefore, in this study we aimed to evaluate the use of 
the renin activatable near-infrared fluorescent probe ReninSense to facilitate non-invasive 
imaging of renin activity in vivo. In addition, we investigated the activity of plasma as 
well as intrarenal renin in progeroid Ercc1d/- mice with accompanying age-related kidney 
pathology. First, we showed that ReninSense specifically detects renin activity, as fluores-
cence of the probe was increased after losartan treatment, while virtually no fluorescence 
could be detected in RenKO mice. Secondly, this study demonstrated that intrarenal renin 
activity does not necessarily run in parallel with circulating renin in the progeroid aging 
Ercc1d/- mice. 
It is important to note that most of the clinical studies supporting the beneficial 
effects of RAS inhibition do not include participants older than 75 years of age or elderly 
patients that are frail with a high comorbidity burden.30, 31 Not all elderly respond well 
to RAS blockade, and related adverse events include acute kidney injury, hyperkalemia, 
hypotension  and a further decline in glomerular filtration rate.3, 11, 12, 32, 33 Additionally, com-
bination therapy with ACE inhibitors and angiotensin receptor blockers in patients with 
cardiovascular complications is linked to an increased risk of adverse renal outcomes with 
higher rates of hyperkalemia, hypotension, renal dysfunction and no observed benefit 
with respect to overall mortality.34-37 The occurrence of these side effects might be worse in 
the elderly population, as they are prone to develop acute kidney injury and hyperkalemia 
due to the risk of complete RAS inhibition as they already have low plasma renin levels. 
Therefore, caution and close monitoring are recommended when using these drugs in 
elderly patients with kidney dysfunction and the optimal RAS inhibition with respect to 
end organ protection has yet to be determined in the elderly.38 In this respect, it would be 
interesting to see how RAS inhibition would affect the aging kidney alone. In other words, 
study the effect of RAS inhibition in kidney-specific Ercc1 mutant mice, which would 
represent a healthy mouse with aging kidneys. This might answer important questions on 
how the RAS is regulated in the aging kidney, and whether this is a systemic effect or not.
Controversy remains as to whether all RAS components that are required to gener-
ate Ang II locally are produced locally, or are taken up from the circulation.15, 39, 40 In the 
present study, the opposing findings on intrarenal and plasma renin in progeroid Ercc1d/- 
mice supports an independent upregulation of intrarenal RAS. This might be very similar 
in the elderly as their circulating renin is lower with increasing age.7, 14 It remains to be 
seen whether kidney renin levels are increased with age in the elderly population. Interest-
ingly, low plasma renin levels with increased kidney renin levels have also been found 
in diabetic patients.13, 41 Animal models of early diabetic nephropathy identically showed 
decreased plasma renin activity and increases in kidney renin.42-45 Epidemiologic studies 
showed that with age, the incidence and susceptibility of abnormal glucose levels and 
diabetic disease increases, however the mechanisms linking aging and diabetes are not 
well understood.46, 47 It is suggested that increased intrarenal renin is responsible for the 
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development and progression of nephropathy in diabetes, through increased intrarenal 
AT1 receptor signaling.17, 42 Therefore, it would be interesting to investigate whether diabe-
tes is responsible for this increased intrarenal renin and accompanying kidney injury, or 
rather that this increased intrarenal RAS, like diabetes, is in fact an concomitant result of 
the aging process.41 
As the circulating RAS does not necessarily reveal the responsiveness of the RAS 
within tissues, there is a need for reliable methods to assess the RAS within tissues. Whether 
urinary angiotensinogen reflects intrarenal RAS activity is doubtful.48-50 In addition, renal 
plasma flow responses to infused Ang II are used as an indirect measure of intrarenal RAS 
activation in humans, as it correlates inversely with endogenous RAS activity.51-55 However, 
all these methods are indirect measurements of intrarenal RAS activity and currently there 
is no method to directly assess intrarenal RAS activity in humans. Thus, non-invasive 
imaging of the ReninSense probe holds considerable promise to improve the detection 
and localization of local renin activity, including intrarenal renin. Determining local renin 
activity would help to evaluate the complexity of RAS biology and the possible role of local 
renin activity in disease development and progression. Moreover, this method enables 
longitudinal imaging of altered RAS signaling, consequently, disease progression can be 
monitored over time and the effect of (new) interventions can be studied non-invasively. 
In the present study, the fluorescence levels of the ReninSense probe in mouse plasma 
remained in the background range and were unaffected by aliskiren, indicating that the 
probe cannot be used to measure renin activity with the odyssey system. These results are 
consistent with the results demonstrated by Zhang et al., as ReninSense fluorescence in 
mouse plasma in their hands was also unaffected by renin inhibition.21 Only when mice 
were treated with low salt diet, ReninSense fluorescence increased over time and L-810 
treatment in these mice reduced the fluorescence to a level similar to the fluorescence levels 
in untreated mouse plasma, indicating that these measured fluorescence in normal mouse 
plasma actually represented background. We did however, observe that ReninSense was 
rapidly activated in kidney lysates of WT mice and that aliskiren blocked ReninSense acti-
vation by maximally ≈80%. The remaining fluorescent signal in the presence of the highest 
concentration of aliskiren was comparable to the fluorescence seen in kidney extracts from 
RenKO mice and denatured kidneys. This implies that the remaining fluorescent signal 
either represents the background fluorescent level of the ReninSense probe, or represents 
activation of the probe ReninSense by renin-like enzyme (e.g. cathepsins), which might 
also be capable of reacting with the angiotensinogen sequence of the probe. Nevertheless, 
when comparing in vivo and ex vivo kidney activation of ReninSense in RenKO mice, fluo-
rescence did not reach the threshold value an thus could not be detected, while losartan 
significantly increased kidney fluorescence levels in vivo as well as ex vivo, verifying the 
specificity of the probe to measure renin activity in the kidneys of small animals. 
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In conclusion, we have demonstrated that the NIRF probe ReninSense can be used 
to non-invasively visualize and measure intrarenal renin activity. By using this method to 
identify local RAS activity, we might gain important insights into the changes in the RAS 
that occur with age as well as in other (age-related) diseases. Although further study is 
warranted, our observations in the progeroid Ercc1d/- mouse model provide evidence that 
circulating RAS activity does not necessarily run in parallel with intrarenal RAS activity 
during aging, which has important clinical consequences. As this increased intrarenal 
RAS activity, might contribute to the disturbed kidney pathology observed in these mice, 
future investigations should examine the effect of the observed age-dependent changes in 
intrarenal renin activity on kidney deterioration. 
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ABSTRACT 
Because of the presence of the blood-brain barrier, brain renin-angiotensin system activity 
should depend on local (pro)renin synthesis. Indeed, an intracellular form of renin has 
been described in the brain, but whether it displays angiotensin (Ang) I-generating activity 
(AGA) is unknown. Here, we quantified brain (pro)renin, before and after buffer perfusion 
of the brain, in wild-type mice, renin knockout mice, deoxycorticosterone acetate salt-
treated mice, and Ang II-infused mice. Brain regions were homogenized and incubated 
with excess angiotensinogen to detect AGA, before and after prorenin activation, using a 
renin inhibitor to correct for nonrenin-mediated AGA. Renin-dependent AGA was readily 
detectable in brain regions, the highest AGA being present in brain stem (>thalamus=
cerebellum=striatum=midbrain>hippocampus=cortex). Brain AGA increased marginally 
after prorenin activation, suggesting that brain prorenin is low. Buffer perfusion reduced 
AGA in all brain areas by >60%. Plasma renin (per mL) was 40x to 800x higher than brain 
renin (per gram). Renin was undetectable in plasma and brain of renin knockout mice. 
Deoxycorticosterone acetate salt and Ang II suppressed plasma renin and brain renin in 
parallel, without upregulating brain prorenin. Finally, Ang I was undetectable in brains 
of spontaneously hypertensive rats, while their brain/plasma Ang II concentration ratio 
decreased by 80% after Ang I type 1 receptor blockade. In conclusion, brain renin levels 
(per gram) correspond with the amount of renin present in 1 to 20 mL plasma. Brain renin 
disappears after buffer perfusion, and varies in association with plasma renin. This indi-
cates that brain renin represents trapped plasma renin. Brain Ang II represents Ang II 
taken up from blood rather than locally synthesized Ang II. 
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INTROduCTION
Since the discovery of renin in the brain nearly 50 years ago,1 numerous studies have pro-
posed that a so-called brain renin-angiotensin system (RAS) exists. Given the presence of 
the blood-brain barrier, brain RAS activity should depend on the local synthesis of renin 
or prorenin (together denoted as (pro)renin) in the brain rather than uptake from blood. 
In support of this concept, an intracellular, nonsecreted form of renin (icREN) has been 
shown to occur exclusively in the brain. This renin isoform is derived from an alternative 
transcript of the renin gene, lacking the signal peptide and part of the prosegment.2, 3 To 
what degree this truncated prorenin truly generates angiotensin (Ang) I remains elusive. 
Lee-Kirsch et al2 detected low Ang I-generating activity (AGA) levels in cell lysates of 
AtT20 cells transfected with icREN during incubation with excess angiotensinogen, but 
failed to demonstrate to what degree this AGA was renin-mediated (eg, by making use of a 
renin inhibitor). Peters et al4 showed increased AGA in cardiac homogenates of transgenic 
rats overexpressing icREN and were able to block this with the renin inhibitor CH732. Yet, 
unexpectedly, the AGA increase was observed only after prosegment removal with tryp-
sin, in disagreement with the fact that truncated prorenin does not require prosegment 
removal to display activity.5 Moreover, icREN overexpression in the heart, if anything, 
resulted in effects that were unrelated to angiotensin formation.6  
Deoxycorticosterone acetate (DOCA) salt treatment is widely believed to stimulate 
brain RAS activity. Confusingly, it lowers icREN expression, but increases the expression 
of the classical, secreted form of renin in brain tissue (sREN),7 possibly because, icREN, 
via an unknown mechanism, inhibits sREN expression.8 Li et al9, 10 proposed that DOCA-
salt selectively increases brain prorenin, which, in the absence of a prosegment-cleaving 
enzyme in the brain, requires interaction with the (pro)renin receptor to allow Ang I gen-
eration locally. The underlying assumption of this concept is that prorenin binding to the 
(pro)renin receptor results in a conformational change in the prorenin molecule, allowing 
it to display enzymatic activity without prosegment cleavage.11 Yet, the low (nanomolar) af-
finity of the (pro)renin receptor implies that high prorenin levels are required for receptor 
binding,11 for which there currently is no evidence.10   
Given these uncertainties, in the present study, we set out to re-evaluate the oc-
currence of (pro)renin in the brain. We quantified brain (pro)renin in a wide variety of 
brain regions, derived from control mice, mice exposed to DOCA salt or Ang II, and renin-
deficient mice. Under all conditions, a comparison was made with plasma (pro)renin, and 
the renin inhibitor aliskiren was applied in the assay to evaluate whether AGA was truly 
renin mediated. Mice were studied given the fact that their (pro)renin levels are several 
orders of magnitude higher than those in humans or rats, thereby facilitating the detec-
tion of renin-dependent AGA, even in areas with low (pro)renin levels. To obtain a more 
complete understanding of the brain RAS, we also quantified brain angiotensinogen, and 
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we studied the changes in brain angiotensin generation making use of brain stem tissue 
obtained from control spontaneously hypertensive rats (SHR) and SHR treated with the 
Ang II type 1 (AT1) receptor blocker olmesartan or the angiotensin-converting enzyme 
inhibitor lisinopril for 4 weeks. 
MATERIAL ANd METhOdS
Mouse and rat studies
Renin, prorenin and angiotensinogen were measured in plasma and brain regions (cer-
ebellum, brain stem, cortex, hippocampus, midbrain, striatum, and thalamus) obtained 
from wild-type mice, mice treated with deoxycorticosterone acetate (DOCA)-salt or 
angiotensin II, and renin-deficient mice (Ren1c-/-), either without and with transcardial 
perfusion with PBS to wash away blood from the brain vasculature. Renin expression in 
brain tissue was also explored by using Ingenuity Pathway Analysis, and angiotensinogen 
synthesis was additionally studied in rat primary cortical astrocytes. Angiotensins were 
measured in plasma and brain stem tissue obtained from SHR treated with vehicle, lisino-
pril or olmesartan. For further details, see the Methods section in the online-only Data 
Supplement.
Statistical Analysis
Data are expressed as mean±SEM. Univariate linear associations between plasma and 
brain renin levels were assessed by calculation of Pearson’s coefficient of correlation. Dif-
ferences between groups were evaluated by Student’s t test or analysis of variance and 
corrected for multiple testing by post hoc Bonferroni analysis when needed. P<0.05 was 
considered significant.
RESuLTS
Aliskiren Inhibits AgA in the Mouse brain
Aliskiren identically inhibited AGA in mouse plasma (n=2), mouse kidney homogenate 
(n=2) and mouse brain homogenate (n=3: Fig.1). The half maximal inhibitory concentra-
tion (IC50) was in the nanomolar range, as has been reported before for mouse renin.12, 13 
These data suggest that AGA in mouse brain homogenates is caused by renin. All subse-
quent AGA measurements were performed both in the absence and presence of 10 mmol/L 
aliskiren to correct for nonrenin (ie, nonaliskiren-inhibitable) AGA.   
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Figure 1. Concentration-dependent inhibition 
of angiotensin I-generating activity (AGA) by 
aliskiren in mouse plasma (n=2), mouse kidney 
homogenate (n=2) and mouse brain homogenate 
(n=3, representing pooled brain stem, cortex, and 
midbrain regions, respectively, from 3 to 4 mice 
each). 
buffer Perfusion Reduces Mouse brain Renin by >60%
Renin-dependent (ie, aliskiren-inhibitable) AGA was readily detectable in brain regions, 
the highest AGA being present in brain stem (>thalamus=cerebellum=striatum=midb
rain >hippocampus=cortex: Fig.2; n=5/group). AGA increased in each individual brain 
region after prorenin activation, but only when analyzing all brain regions together by 
multivariate analysis of variance did this increase reach significance (P<0.05). Applying 
the prorenin activation procedure to 3 mouse brain homogenates (cortex, midbrain, and 
brain stem, respectively) to which recombinant human prorenin had been added yielded 
values in a renin immunoradiometric assay (IRMA; 211±12 pg/mL) that were similar to 
those when activating the same amount of recombinant human prorenin in buffer with 
aliskiren14 (169±6 pg/mL). This confirms that our prorenin activation procedure was ap-
propriate. PBS perfusion of the mouse brain reduced AGA in all brain areas by >60% (Fig. 
2; P<0.01) and diminished the percentage of AGA that could be blocked by aliskiren (Table 
S2). These data suggest that blood removal predominantly washes away renin, but not 
Figure 2. Renin and total renin 
(=renin+prorenin) levels in plasma 
and brain regions of mice before and 
after buffer perfusion (wash) of the 
brain. Data are mean±SEM of n=5. 
Multivariate analysis of variance 
(ANOVA) showed that total renin 
levels were higher than renin levels 
(P<0.05) and that buffer perfusion 
reduced renin by >60% in all regions 
(P<0.01). 
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nonrenin enzymes that are also capable of reacting with angiotensinogen. Plasma renin 
(expressed per milliliter of plasma) was 40x to 800x higher than brain renin (expressed per 
gram of tissue), and, as expected, identical in mice that were exposed to buffer perfusion. 
Plasma prorenin levels were of the same order of magnitude as plasma renin levels, as 
demonstrated earlier in mice.15
Comparable Reductions in brain and Plasma (Pro)Renin after DoCA Salt Treatment, 
Ang II infusion, and Renin Deficiency
DOCA salt (n=6) and Ang II (n=7) suppressed plasma renin versus wild-type (n=6) mice, 
and parallel decreases were observed for brain stem, midbrain, and cortex renin (Fig. 3), 
although significance was not reached in all cases. Nevertheless, brain renin levels (ex-
pressed per gram of tissue) correlated significantly with plasma renin levels (expressed 
per milliliter of plasma) in all 3 brain regions (Fig. 4). The different slopes may reflect the 
different blood content of each brain region. Plasma prorenin levels were comparable to 
plasma renin levels, and prorenin activation in brain regions nonsignificantly increased 
brain AGA. Plasma renin and prorenin were undetectable in Ren1c-/- mice (n=4), and renin 
(ie, aliskiren-inhibitable AGA) was also undetectable in the 3 brain regions obtained from 
Ren1c-/- mice. However, low levels of aliskiren-inhibitable AGA were present in brain stem 
(1 out of 4), midbrain (3 out of 4), and cortex (2 out of 4) after prorenin activation in the 
Ren1c-/- mice. Because this cannot represent prorenin, these data imply that our prorenin 
activation procedure occasionally activated a renin-like enzyme, capable of reacting with 
angiotensinogen, the activity of which can be blocked by 10 mmol/L aliskiren. 
Figure 3. Renin and total renin 
(=renin+prorenin) levels in plasma 
and brain regions of untreated mice 
(wild-type [WT]), mice treated with 
deoxycorticosterone acetate (DOCA) 
salt, mice infused with Ang II, and 
Ren1c-/- mice. Data are mean±SEM of 
n=4 to 7. Differences in renin levels 
were assessed by 1-way analysis of 
variance (ANOVA), followed by cor-
rection for multiple testing by post 
hoc Bonferroni analysis. *P<0.05, 
#P<0.01, oP<0.001 vs WT.
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Renin Expression in the brain
Renin (secreted+intracellular), sREN, or icREN mRNA expression levels were undetect-
able in all brain regions in wild-type, DOCA salt-treated, and Ang II-infused mice. Primer 
specificity for renin (secreted+intracellular) and sREN was validated by measuring renal 
renin expression in Ren1c-/- mice (Fig. S1B). In the Ingenuity Pathway Analysis tissue ex-
pression data sets, renin expression was found in cerebellum, hypothalamus, and pituitary, 
but only in 3 out of 9 different datasets examined (data not shown). 
Despite Angiotensinogen Expression, Angiotensinogen Protein is undetectable in 
Mouse brain and Rat Astrocytes
Mouse plasma contained detectable levels of angiotensinogen (28±5 pmol/mL). Angio-
tensinogen mRNA expression was observed in different brain regions (Fig. 5), at Ct values 
Figure 4. Relationship between renin in plasma 
and renin in 3 different brain regions in untreat-
ed mice (wild-type [WT], n=6), mice treated 
with deoxycorticosterone acetate (DOCA) salt 
(n=6), and mice infused with angiotensin (Ang) 
II (n=7). 
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of 23 (cerebellum), 22 (thalamus), 25 (hippocampus), and 27 (striatum) versus ≈18 in the 
liver. Brain expression levels changed inconsistently after DOCA salt, Ang II, and renin 
deficiency: an increase was observed in the thalamus after DOCA salt (P<0.05), while 
decreases occurred in the cerebellum after DOCA salt (P<0.05), and in the hippocampus 
after Ang II (P<0.05). Yet, angiotensinogen protein was undetectable (<1 pmol/g) in mouse 
cortex and brain stem (n=4 of each). Angiotensinogen was also undetectable in the me-
dium of cultured rat astrocytes (<0.3 pmol/mL), cultured for 24, 48, 72 or 96 hours (n=4 
for each condition), or the accompanying cell lysates (<0.3 pmol/mg protein).
Figure 5. Angiotensinogen mRNA 
expression in different brain regions 
in untreated mice (wild-type [WT]), 
mice treated with deoxycorticosterone 
acetate (DOCA) salt, mice infused 
with angiotensin (Ang) II, and Ren1c-/- 
mice. Data, presented as fold change 
over TubG2 relative to WT levels, are 
mean±SEM of n=3-6. Differences were 
assessed by 1-way analysis of variance 
(ANOVA), followed by correction for 
multiple testing by post hoc Bonfer-
roni analysis. *P<0.05 vs WT.
Angiotensins in the ShR brain with and without RAS blockade
Ang I, Ang-(1-7), and Ang-(2-8) were below detection limit in brain tissue of untreated 
SHR (n=6), while Ang II could be detected in the rat brain at levels corresponding with 
≈25% of the Ang II levels in blood plasma (Table S3; Fig. 6). Ang I and Ang-(2-8), but not 
Ang-(1-7), were detectable in plasma in untreated SHR. Brain Ang-(1-7) and Ang-(2-8) 
remained undetectable after olmesartan (n=6) or lisinopril (n=4), while Ang I became 
detectable in the rat brain after both types of RAS blockade (P<0.001 for both). Because 
plasma Ang I increased ≈20-fold after olmesartan and lisinopril (P<0.001 for both), it 
could be calculated that during both types of RAS blockade, brain Ang I levels corre-
sponded with ≈1% of the Ang I levels in plasma. Olmesartan increased brain Ang II ≈5-fold 
(P<0.001) and plasma Ang II ≈25-fold (P<0.001), so that after AT1 receptor blockade, the 
brain/plasma ratio of Ang II decreased by ≈80% (P<0.05). Lisinopril decreased plasma 
Ang II by >90% (P<0.001), and diminished brain Ang II to undetectable levels (P<0.001). 
Lisinopril also decreased plasma Ang-(2-8) to undetectable levels and greatly increased 
plasma Ang-(1-7), while olmesartan increased both plasma Ang-(2-8) and plasma Ang-
(1-7). Taken together, given that brain Ang I levels correspond with ≈1% of the circulating 
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Ang I levels, 10 mL plasma per gram brain tissue is sufficient to explain the entire brain Ang 
I content. Brain Ang II levels, relative to plasma Ang II levels, are higher, suggesting either 
local synthesis or an active uptake mechanism. The massive decrease in the Ang II brain/
plasma ratio after olmesartan supports the latter.
Figure 6. Angiotensin (Ang) I and II levels in plasma and brain of SHR treated with vehicle (control), 
olmesartan, or lisinopril. Data are mean±SEM of n=4 to 6. Differences were assessed by 1-way analysis of 
variance (ANOVA), followed by correction for multiple testing by post hoc Bonferroni analysis. oP<0.001 
vs control. ND indicates not detectable.
dISCuSSION
The present study confirms that renin-dependent AGA can be detected in virtually every 
region of the mouse brain. Yet, as compared with plasma, brain renin levels were low, 
corresponding with the amount of renin in 1 to 25 mL blood plasma per gram brain tis-
sue (≈0.1%-2.5% [v/v]). This volume mimics the amount of blood plasma in various brain 
regions determined with tritiated inulin or Evans blue dye.16, 17 Moreover, perfusing the 
brain with PBS prior to the collection of the various regions reduced brain renin uniformly 
by >60%. Had local renin synthesis occurred in one or more specific brain regions, the 
washout percentage should have been much lower in these regions, similar to the fact that 
in the kidney one cannot wash away stored renin,18, 19 while this does happen in nonrenin 
producing organs like the heart.20 Furthermore, DOCA salt, like Ang II, reduced circulat-
ing renin and, contrary to our expectations, did not increase brain prorenin. In fact, if 
anything, both DOCA-salt and Ang II lowered brain renin in parallel with plasma renin. 
Aliskiren-inhibitable AGA was entirely absent in the brain of Ren1c-/- mice, supporting the 
validity of our brain renin measurement. Taken together, our data do not support the pres-
ence of kidney-independent (pro)renin synthesis in the brain, nor the concept that this 
occurs particularly in the DOCA salt model. In fact, brain renin levels are so low that the 
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accumulation of renin at brain tissue sites outside the blood compartment seems unlikely. 
This greatly differs from other organs (eg, the heart), where renin diffuses freely into the 
interstitium and/or binds to a receptor, thereby reaching tissue levels that are, on a gram 
basis, at least as high as the renin levels in blood plasma (on an mL basis).20-22 Clearly, the 
presence of the blood-brain barrier prevents such distribution.  
Prorenin activation resulted in modest AGA increases in all brain regions, and 
significance for this increase was only obtained by analyzing all regions together. Apply-
ing recombinant human prorenin to brain homogenates prior to the prorenin activation 
procedure (on the basis of acid activation22) confirmed that this procedure resulted in 
complete prorenin activation. However, small rises in aliskiren-inhibitable AGA were also 
observed in brain homogenates from Ren1c-/- mice after their exposure to acid. Because 
Ren1c-/- mouse brain tissue cannot contain prorenin, this implies that the brain contains a 
nonrenin proenzyme, which is activated by acid exposure, and which is capable of cleaving 
Ang I from angiotensinogen in an aliskiren-inhibitable manner. A possible candidate is 
procathepsin D. Indeed, renin inhibitors, at high micromolar concentrations, do inhibit 
cathepsin D.23 Our difficulty to demonstrate prorenin in the brain is reminiscent of earlier 
studies in organs not synthesizing prorenin themselves, like the heart.22 Obviously, blood 
plasma contains prorenin, and thus some prorenin should be detected in the blood-
containing homogenates derived from such tissues. Yet only under conditions where 
circulating prorenin levels were greatly elevated, like in heart failure in humans, did we 
reliably detect prorenin in cardiac tissue.24 In mice, in contrast to humans, circulating 
prorenin levels are relatively low (versus renin), making it even more difficult to show a 
rise in AGA on top of already low renin-mediated AGA. A further complicating factor is 
that tissue homogenization per se may result in (partial) prorenin activation. In summary, 
given the presence of prorenin in blood plasma, brain homogenates should minimally 
contain the amount of prorenin present in a few microliter of blood. The rises in AGA 
after prorenin activation are consistent with this view, but should still be interpreted with 
caution given the fact that nonrenin enzymes also came into play after acid activation. 
Brain-selective prorenin rises, for example, after DOCA salt, were not observed. This im-
plies that prorenin-(pro)renin receptor interaction is unlikely to occur in the mouse brain, 
particularly after DOCA salt (which lowers brain (pro)renin), although it may obviously 
occur after intracerebroventricular infusion of pharmacological prorenin doses into the 
brain.10
Most, if not all, studies on brain renin relied on the detection of renin mRNA in the 
brain, either under normal conditions or after deleting/overexpressing sREN or icREN. 
Deleting sREN in neurons or glia did not affect blood pressure, heart rate, water intake, 
or metabolic rate,25 while preservation of icREN did not compensate for the consequences 
of whole-body sREN deficiency (hypotension, renal defects, and lethality).26 Surprisingly, 
brain-selective deletion of icREN even caused neurogenic hypertension, possibly because 
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icREN inhibits sREN.8 These data seem to argue against icREN as an Ang I-generating 
enzyme. Yet, overexpressing either human icREN or sREN in astrocytes, if combined with 
human angiotensinogen, resulted in Ang II-dependent hypertension and an increase 
in drinking volume.27 Because icREN under the latter conditions was not detectable in 
cerebrospinal fluid, it was concluded that this phenomenon involved intracellular Ang 
II formation. We attempted to detect renin mRNA, using either specific assays for sREN 
or icREN or a nonspecific assay that detects both sREN and icREN. Under no condition 
were we able to show renin (secreted+intracellular), sREN, or icREN gene expression in 
any of the different regions of the brain: the expression level was below the detection 
threshold of the reverse transcriptase polymerase chain reaction assay, even with the use 
of the highly sensitive Taqman probes. The specificity of our renin primers was validated 
by making use of the kidneys of Ren1c-/- mice. Of course, poor renin expression in the 
brain has been noted before.28-30 Because of the technical limitations inherent in any 
reverse transcriptase polymerase chain reaction assay, we could not load > 100 ng of total 
RNA. Our results, therefore, indicate that if renin is expressed in the brain, its expression 
is >218-fold lower than that in the kidney (no signal after 40 cycles, with renin detection 
in the kidney at Ct=22). The Ingenuity Pathway Analysis expression data sets confirm this 
view. Yet, Kubo et al31 observed a blood pressure drop after intraventricular renin anti-
sense injection in SHR. In their hands only 1 of 3 tested antisense oligonucleotides acted 
hypotensive, and this response was accompanied by a 20% drop in renin mRNA (detected 
after 45 cycles of reverse transcriptase polymerase chain reaction). These authors did not 
measure renin levels in brain or plasma and were unable to rule out antisense leakage to 
the kidney. Therefore, these data cannot be taken as definitive proof for the existence of 
an independent brain RAS.      
The mouse RAS differs from the human RAS, in that the circulating renin levels 
in mice are ≤1000-fold higher (on a nanogram Ang I/mL hour basis) than in humans. 
As a consequence, circulating angiotensinogen levels in mice are far below Km range, as 
confirmed in the present study. Nevertheless, despite these differences, mouse angioten-
sin levels in blood and tissue are comparable to those in humans, rats and pigs.32-35 We 
attempted to measure angiotensinogen in the mouse brain, both at the mRNA and protein 
level. Although we did observe angiotensinogen mRNA expression in different regions of 
the brain, in full agreement with previous work,36, 37 expression was ≤500-fold lower than in 
the liver. Under no condition were we able to detect angiotensinogen protein in the brain. 
Given the detection limit of our assay (1 pmol/g), this implies that brain angiotensinogen, 
if present, occurs at levels (per gram of tissue) that are <3% of the levels in plasma (per 
milliliter of plasma). Such low levels have been reported before in the rat brain, as well 
as in human and rat cerebrospinal fluid,16, 38-40 and thus, our data entirely agree with the 
literature. Clearly, mice, given their low angiotensinogen levels, are not the optimal spe-
cies to study brain angiotensinogen. As astrocytes are assumed to be the source of brain 
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angiotensinogen,41, 42 we additionally studied angiotensinogen synthesis by rat primary 
cortical astrocytes, but again failed to detect any angiotensinogen. Nevertheless, data from 
Schink et al.40 do support the functional presence of angiotensinogen in the rat brain. 
These authors artificially elevated renin in the brain by either intracerebroventricular 
renin infusion (in Sprague-Dawley rats) or by making use of transgenic hypertensive rats 
overexpressing mouse Ren2. The responses to both approaches (drinking and blood pres-
sure reduction, respectively) were greatly diminished after lowering brain angiotensinogen 
by brain-selective expression of an antisense RNA against angiotensinogen mRNA. 
Finally, given our observation that brain renin is confined to the plasma compart-
ment, while brain angiotensinogen is extremely low (if not also confined to the plasma 
compartment), an urging question is what degree local angiotensin generation truly 
occurs in the brain. We, therefore, collected brain stem tissue (ie, the brain region with 
the highest renin level) from SHR under control conditions and during RAS blockade 
with olmesartan or lisinopril. Rats rather than mice were used here, because at identical 
angiotensin levels in both species, the larger rat brain stem would allow a more reliable 
quantification of angiotensins. Without treatment, brain Ang I was undetectable, while 
Ang II occurred at levels that were ≈25% of the levels in plasma (per gram tissue weight). 
This contrasts with other organs where Ang II is usually much higher than in plasma, 
while Ang I is easily detectable.43-46 RAS blockade induced the usual rise in Ang I levels in 
plasma, and now brain Ang I became detectable, however, at only 1% (v/v) of its plasma 
levels. It seems reasonable to assume that also in the untreated animals, brain Ang I levels 
were in the 1% range of plasma Ang I and, therefore, too low to be detected with our 
assays. If so, this implies that under all conditions, brain Ang I at most represented the 
amount of Ang I that is inherently present in brain tissue because it contains a small 
amount (≈1%) of blood.16 Lisinopril decreased brain Ang II to undetectable levels, while 
olmesartan reduced the brain/plasma Ang II ratio by >80%. The latter finding suggests 
that, normally, circulating Ang II accumulates in brain tissue via binding to AT1 receptors. 
Such uptake occurs in multiple organs47 and facilitates the intracellular accumulation of 
Ang II.48 Without receptors (ie, in AT receptor-deficient mice), tissue Ang II levels drop 
dramatically,49 suggesting that tissue Ang II levels do not originate intracellularly. If Ang 
II binding to AT1 receptors is the only source of Ang II in the brain, one would expect 
angiotensin metabolites that do not (or only with low affinity) bind to this receptor to 
be undetectable in the brain. This is indeed what we observed for both Ang-(2-8) and 
Ang-(1-7). An olmesartan-induced reduction in brain Ang II levels was also observed in 
Dahl-sensitive hypertensive rats, albeit in the absence of an effect on blood pressure.50 
Clearly, therefore, the changes observed in brain Ang II are blood pressure independent. 
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PERSPECTIvES
The absence of renin-dependent AGA in the brain outside the blood compartment implies 
that angiotensin generation in the brain, if occurring, does not involve renin. Brain pro-
renin levels, if anything, were even lower than brain renin levels and, therefore, like renin, 
at most represented the amount of prorenin expected in brain tissue based on its blood 
content. Selective brain prorenin upregulation, for example, after DOCA salt, could not 
be observed, arguing against the concept that DOCA salt-induced neurogenic hyperten-
sion involves prorenin-(pro)renin receptor interaction. Finally, the absence of Ang I in 
brain tissue outside the blood compartment (which contrasts sharply with the presence 
of Ang I in every other organ of the body) strongly suggests that there is no local Ang I 
generation in the brain. Apparently, therefore, nonrenin enzymes do not compensate for 
the absence of renin, assuming at least that brain angiotensinogen levels are of sufficient 
magnitude to allow independent Ang I generation at all. Only ex vivo, after prohormone-
activating procedures, did we occasionally obtain evidence for a modest contribution of 
such nonrenin enzymes, but the in vivo relevance of these findings is questionable. Brain 
Ang II, therefore, seems to originate in the blood compartment. Of course, circulating 
Ang II will bind to brain AT receptors that are outside the blood-brain barrier (eg, in the 
circumventricular organ). Yet, it may also gain access to brain areas behind this barrier, for 
example, under conditions where blood-brain barrier permeability is compromised, like 
in (DOCA salt) hypertension.51, 52 In fact, Ang II itself may be responsible for disturbing 
the blood-brain barrier, thus, facilitating its own access to critical brain areas like the 
hypothalamus and brain stem. From this perspective, the brain RAS in reality represents 
circulating Ang II that accumulates in brain nuclei, possibly after it has (partially) broken 
down the blood-brain barrier. This Ang II subsequently activates sympatho-neurohumoral 
outflow, for instance, by upregulating reactive oxygen species.52, 53 This is entirely different 
from other organs like heart, kidney, and vascular wall, where renin and angiotensinogen 
diffuse freely into the interstitial space, allowing local production of Ang I to occur.20, 54, 55 
Blocking AT1 receptors or enhancing Ang II degradation (eg, by angiotensin-converting 
enzyme 2) will prevent the effects of circulating Ang II in the brain, thereby explaining the 
success of intracerebroventricular application of losartan or brain-selective angiotensin-
converting enzyme 2 overexpression in DOCA salt hypertension.56 
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dISCLOSuRES
None.
NOvELTy ANd SIGNIFICANCE
What is new?
•	 Brain renin levels parallel plasma renin levels in a variety of hypertension models and 
in fact are as high as can be expected on the basis of the presence of blood in brain 
tissue.
•	 Because the latter was also true for brain prorenin, this implies that neither renin nor 
prorenin contributes to angiotensin I production in the brain. 
What is relevant?
•	 Brain angiotensin II originates in the circulation, and the brain renin-angiotensin 
system activation that has been claimed to occur under pathological conditions (hy-
pertension, deoxycorticosterone acetate salt) most likely represents a compromised 
blood-brain barrier, allowing circulating angiotensin II access to brain regions behind 
the blood-brain barrier. 
Summary 
Quantifying brain (pro)renin in wild-type mice, renin-deficient mice, deoxycorticosterone 
acetate salt-treated mice, and angiotensin II-infused mice, revealed that changes in brain 
renin paralleled those in plasma renin, that brain renin disappeared after buffer perfusion 
of the brain, and that brain renin and prorenin levels were as high as expected based on 
the presence of (pro)renin in blood in brain tissue. Angiotensin I was undetectable in the 
brain, while angiotensin II type 1 receptor blockade reduced the brain/plasma angiotensin 
II concentration ratio by 80%. In conclusion, (pro)renin-mediated angiotensin I produc-
tion in the brain is unlikely, and brain angiotensin II therefore represents angiotensin II 
sequestered from blood via angiotensin II type 1 receptor binding. 
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SuPPLEMENTAL INFORMATION
METhOdS
All animal experiments were performed under the regulation and permission of the 
Animal Care Committee, conforming to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 8523, 
revised 1985). 
Brain renin, prorenin and angiotensinogen levels in wild-type mice, mice treated with 
DOCA-salt	or	angiotensin	II,	and	renin-deficient	mice
Male and female C57BL/6J mice (wild-type, WT) were obtained by in-house breeding or 
purchased from Charles River (Sulzfeld, Germany). Mice (age 3-4 months) were either 
untreated, treated with deoxycorticosterone acetate (DOCA)-salt (150 mg, 60-day release 
pellet [Innovative Research of America, Sarasota, USA]) for 4 weeks, or infused with Ang 
II (490 ng/kg/min by osmotic minipump [Alzet, model 2004, DURECT, Cupertino, USA]1) 
for 2 weeks. Ren1c homozygous null mice (Ren1c-/-; 3 females and 1 male) were generated 
as described before (C57BL/6J background)2 and sacrificed at the age of 3-6 months. All 
mice were housed under standard laboratory conditions (temperature 23±1°C, 12-hour 
light-dark cycle) and maintained on standard chow (Special Diets Services, Essex, UK) 
with ad libitum access to tap water. DOCA-salt-treated mice had ad libitum access to 0.15 
mol/L (0.9%) NaCl solution. At the end of the treatment period, mice were sacrificed 
with an overdose of isoflurane and blood was collected by cardiac puncture into EDTA-
coated tubes. Blood was centrifuged at 4600 rpm for 10 minutes and plasma was stored at 
-80ºC until analysis. Five untreated mice were perfused transcardially with PBS to wash 
away blood from the brain vasculature. Brains were rapidly removed from all mice and 
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the desired regions (cerebellum, brainstem, cortex, hippocampus, midbrain, striatum and 
thalamus) were dissected, frozen in liquid nitrogen, and stored at -80°C until analysis. 
Brain and plasma angiotensin levels in spontaneously hypertensive rats
Male 10-week old SHR (Janvier Labs, Le Genest St. Isle, France) were treated with either 
vehicle (tap water), the ACE inhibitor lisinopril (15 mg/kg body weight; Sigma-Aldrich, 
Darmstadt, Germany) or the AT1 receptor blocker olmesartan (10 mg/kg body weight, 
Daiichi Sankyo Co., Ltd., Japan) once daily per gavage for four weeks. Animals were housed 
under standard laboratory conditions (temperature 23±1°C, 12-hour light-dark cycle), they 
were fed a standard pellet diet (1.8% NaCl; Velaz, Prague, Czech Republic), and drank tap 
water ad libitum. At the end of treatment period, the animals were sacrificed in terminal 
isoflurane anesthesia (2-3%) by being bled out. Blood was collected in the presence of 
an inhibitor cocktail containing ethylenediaminetetraacetic acid (EDTA), pepstatin A, 
p-hydroxymercuribenzoic acid, phenanthroline and specific inhibitors for renin and ami-
nopeptidases to a final concentration of 5% v/v (Attoquant Diagnostics, Vienna, Austria) 
and immediately cooled on ice.3 Plasma was isolated by centrifugation at 4°C and frozen 
at -80°C until analysis. Brains were sampled via scull trepanation followed by removal 
of the hemispheres and cerebellum. The brainstem was isolated, rapidly frozen in liquid 
nitrogen and preserved at -80°C until analysis. 
Angiotensinogen	synthesis	by	rat	primary	cortical	astrocytes	
Rat primary cortical astrocytes (Invitrogen, Thermo Fisher, Waltham, USA) were grown 
in 6-well plates (Corning Incorporated, Corning, USA) in DMEM medium (85% Dul-
becco’s Modified Eagle Medium containing high glucose 4.5 g/L, 15% FCS (Gibco, Thermo 
Fisher) and L-glutamine (600 mg/L; Flow Lab, UK)) in an incubator at 37°C and 5% CO2 
until confluency. Medium and cells were collected after 24, 48, 72 or 96 hours. For the 
determination of angiotensinogen, the culture medium was removed and stored at -80°C, 
while cells were gently washed with PBS, lysed with RIPA buffer (50 mmol/L Tris-HCl, 150 
mmol/L NaCl, 1% Triton x-100, 0.5% sodium deoxylcholate, 0.1% SDS, 1 mmol/L EDTA), 
and frozen at -80°C until analysis. 
Measurement of renin, prorenin and angiotensinogen 
Mouse plasma renin and prorenin were measured as described before.4 Brain tissue was 
homogenized in 0.01 mol/L phosphate buffer, pH 7.4, containing 0.15 mol/L NaCl, and 
the homogenates were used to measure renin, total renin (i.e., renin plus prorenin), and 
angiotensinogen. AGA was measured by enzyme-kinetic assay in the presence of excess 
sheep angiotensinogen, both without and with the renin inhibitor aliskiren (10 pmol/L-10 
mmol/L).5 Total renin was measured identically after conversion of prorenin to renin by 
acidification.5 Angiotensinogen was measured in mouse plasma, mouse brain homog-
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enate, rat astrocyte cell culture medium and astrocyte cell lysate (after its centrifugation 
at 8000 x g for 10 min) as the maximum quantity of Ang I that was generated during 
incubation with excess recombinant rat renin.6 
LC-MS/MS	based	quantification	of	angiotensin	metabolites	
Plasma was thawed on ice, and samples were spiked with 200 pg of stable isotope-labeled 
internal standards for Ang I, Ang II, Ang-(1-7) and Ang-(2-8). Following C18-based solid-
phase-extraction, samples were subjected to LC-MS/MS analysis using a reversed-phase 
analytical column (Acquity UPLC® C18, Waters, Milford, USA) operating in line with a 
XEVO TQ-S triple quadrupole mass spectrometer (Waters) in MRM mode. Internal 
standards were used to correct for peptide recovery of the sample preparation procedure 
for each angiotensin metabolite in each individual sample. Angiotensin peptide concen-
trations were calculated considering the corresponding response factors determined in 
matrix calibration curves, on condition that integrated signals exceeded a signal-to-noise 
ratio of 10. Brain tissue samples were grinded under liquid nitrogen (pestle and mortar) 
and the resulting frozen tissue powder was rapidly dissolved in ice cold 6 mol/L guanidine 
hydrochloride supplemented with 1 % (v/v) TFA at a concentration of 100 mg tissue/mL.7 
Resulting homogenates were spiked with 200 pg of stable isotope-labelled internal stan-
dard for each angiotensin metabolite analyzed and subjected to solid phase based peptide 
extraction and subsequent LC-MS/MS analysis. The lower limits of quantification for Ang 
I, Ang II, Ang-(1-7) and Ang-(2-8) in plasma were 2.1, 0.9, 1.9 and 1.1 pg/mL, and in brain 
8.1, 6.7, 12.7 and 8.0 pg/g tissue, respectively.
Renin	and	angiotensinogen	expression	
Total RNA was isolated from kidney and liver tissue, using Tri Reagent (Sigma-Aldrich, 
Darmstadt, Germany), and from brain tissue (cerebellum, brainstem, cortex, hippo-
campus, midbrain, striatum and thalamus), using the RNeasy Lipid kit (Qiagen, Venlo, 
The Netherlands). RNA concentration was quantified using micro-spectrophotometry 
(NanoDrop Technologies, Wilmington, USA). Single stranded complementary DNA was 
synthesized using the genomic DNA-free total RNA using the Quantitect Reverse Tran-
scription kit (Qiagen) according to the manufacturer’s protocol. Quantitative real-time 
PCRs were conducted in 10 μL and 100 ng of cDNA, using the CFX384 Touch™ Real-time 
PCR detection system (BioRad, Hercules, USA), followed by measurement using either 
IQ™ SYBR® Green Supermix (BioRad) or Taqman probes (IDT, Coralville, USA). The 
exon-exon junction spanning oligonucleotide primers for qPCR were designed with NCBI 
(Primer-BLAST). Primer sequences and GenBank accession numbers for the sequences 
used to design the primers are listed in Table S1. Regarding mouse renin, primers were de-
signed to selectively detect sREN and icREN, as well as to detect renin independently of its 
signal peptide and prosegment (‘secreted + intracellular renin’; Figure S1A). The following 
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cycling conditions were used [95°C for 3 min, (95°C for 3 sec, 60°C for 25 sec) × 40 cycles] 
for the KAPA SYBR ® FAST qPCR Master Mix, [95°C for 5 min, (95°C for 10 sec, 59-72°C 
for 40 sec) × 40 cycles] for the IQ™ SYBR® Green Supermix, and [95°C for 3 min, (95°C for 
15 sec, 60°C for 1 min) × 45 cycles] for the Taqman assay. Expression levels in kidney, liver 
and brain tissue were normalised to the housekeeping genes B2M and TubG2, respectively. 
The 2−ΔΔCt method was used for relative quantification of gene expression.
Renin expression in brain tissue was also explored by using Ingenuity Pathway Anal-
ysis (IPA). In IPA, tissue expression datasets were created based on expression annotations 
from the GNF Body Atlas (expression calls were made from microarray data from dissec-
tion of healthy, adult, untreated C57/BL6 mouse tissues). Data was also available in Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1133). 
Published8 cases where a gene was marked “Present” in a particular tissue (based upon the 
Affymetrix MAS5 Absence/ Presence call) were used as evidence of mRNA expression, and 
were incorporated into the tissue expression dataset for that particular tissue. The criteria 
used to define a gene as expressed in the body atlas data in IPA correspond to an average 
concentration of 3 transcripts per cell (10 transcripts per million). Additional mRNA ex-
pression calls were derived from findings in the Ingenuity Knowledge Base that describes 
observations of mRNA expression in normal, healthy, adult mammalian tissue (human, 
mouse, rat and mammalian orthologs). Only findings where high quality mRNA detection 
methods were used (e.g. Northern Blots, quantitative RT-PCR, etc.) were included. Ad-
ditional information is provided at the following link: http://ingenuity.force.com/ipa/IPA
Tutorials?id=kA250000000TN5CCAW.
Statistical	analysis
Data are expressed as mean±SEM. To determine the minimum number of animals needed 
for this study, we reasoned that, if renin is synthesized locally in certain brain areas, the 
majority of this renin (>50%) should not be washed away by buffer perfusion. Moreover, 
Grobe et al.9 have suggested that brain sREN expression doubles after DOCA-salt. On the 
basis of these 2-fold changes, at an SD of 40% (as observed in brainstem, see Results), 
with α = 0.05 and β = 80%, the minimum n-number is 3. Univariate linear associations 
between plasma and brain renin levels were assessed by calculation of Pearson’s coefficient 
of correlation. Differences between groups were evaluated by Student’s t-test or ANOVA, 
and corrected for multiple testing by post-hoc Bonferroni analysis when needed. P<0.05 
was considered significant. Statistical analysis was performed with IBM SPSS Statistics 
version 21.0 (IBM, Armonk, New York, USA).
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Table S1. Primer sequences and GenBank accession numbers.
Kidney and brain tissue (Mus musculus)
SYBR green assay
Beta-2 microglobulin (B2M) CTCACACTGAATTCACCCCCA
GTCTCGATCCCAGTAGACGGT
>NM_009735.3
Tubulin gamma-2 chain (TubG2) CAGACCAACCACTGCTACAT
AGGGAATGAAGTTGGCCAGT
>NM_134028.2
Renin (secreted + intracellular) AGCTACATGGAGAACGGGTC
TTCCACCCACAGTCACCGAG
>NM_031192.3
Secreted renin (sRen) GCACCTTCAGTCTCCCAACAC
TCCCGGACAGAAGGCATTTTC
>NM_031192.3
Intracellular renin (icRen) CCGGCTGCTTTGAAGATTTGAT
ATGCCAATCTCGCCGTAGTA
-
Angiotensinogen (Agt) ACCCCCGAGTGGGAGAGGTTC
GCCAGGCTGCTGGACAGACG
>NM_007428.3
Taqman	assay
Beta-2 microglobulin (B2M) Assay ID-Mm.PT.58.10497647 (IDT) 
NM_009735(1)
Tubulin gamma-2 chain (TubG2) Assay ID-Mm.PT.58.41559687 (IDT) 
NM_134028(1)
Renin (secreted + intracellular) FW:    TCAGCAAGACTGACTCCTGGC
Rev:    GCACAGCCTTCTTCACATAGC
Probe: TCACGATGAAGGGGGTGTCTGTGGG
Secreted renin (sRen) FW:    GCACCTTCAGTCTCCCAACAC
Rev:    TCCCGGACAGAAGGCATTTTC
Probe: CCTTTGAACGAATCCC
Intracellular renin (icRen) FW:    CCGGCTGCTTTGAAGATTTGAT
Rev:    CAGGTAGTTGGTGAGGACCAC
Probe: TCACAAAGAGGCCTTCCTTGACCA
Table S2. Percent inhibition of angiotensin I-generating activity by aliskiren in brain nucleus homog-
enates before and after buffer perfusion. Data are mean±SEM of n=5. 
brain nucleus before buffer Perfusion After buffer Perfusion
Renin Total Renin Renin Total renin
Brainstem 96±1 91±3 92±3 87±3
Thalamus 81±6 81±9 18±20 28±19
Cerebellum 86±4 92±2 73±12 54±18
Striatum 71±2 60±18 51±16 34±20
Midbrain 83±10 84±6 37±19 30±19
Hippocampus 49±6 48±22 47±15 13±13
Cortex 50±23 36±17 15±17 0±0
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Table S3. Angiotensin (Ang) metabolites in SHR plasma and brain during treatment with placebo, 
olmesartan or lisinopril. Data are mean±SEM of n=4-6, and if undetectable, were based on the detec-
tion limit.
Ang I
(pg/mL or g) 
Ang II
(pg/mL or g)
Ang-(2-8)
(pg/mL or g)
Ang-(1-7)
(pg/mL or g)
Plasma
Placebo 139±20 39±11 8±2 <2±0
Olmesartan 2579±497 911±171 223±57 9±2
Lisinopril 3142±362 2±1 <1±0 58±14
brain
Placebo <8±1 9±2 <9±0 <13±1
Olmesartan 25±5 50±11 <8±0 <13±1
Lisinopril 53±10 <7±1 <8±0 <13±1
Figure S1A. Proposed pathway for secreted renin and intracellular renin. It is hypothesized that in the 
brain, a diff erent mRNA, renin-b, is transcribed that result in a novel transcript lacking exon 1a. This 
renin isoform lacks the signal peptide and part of the prosegment, and is believed to remain intracel-
lular. Adapted from Grobe et al..10
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Figure S1B. Renin (secreted or intracel-
lular), sRen and icRen mRNA expression 
in kidneys of wild-type (WT, n=6) and 
Ren1c-/- mice (n=4). icRen was undetect-
able under all conditions, while renin 
(secreted + intracellular) and sRen were 
undetectable in kidneys of Ren1c-/- mice. 
Ct values were generated with the SYBR 
Green assay. 
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ABSTRACT
Background: Renin inhibition with aliskiren induced the largest increases in renal plasma 
flow (RPF) in salt-depleted healthy volunteers of all renin-angiotensin system (RAS) 
blockers. However, given its side effects at doses >300 mg, no maximum effect of renin 
inhibition could be established. We hypothesized that VTP-27999, a novel renin inhibitor 
without major side effects at high doses, would allow us to establish this. 
Methods and Results: The effects of escalating VTP-27999 doses (75-600 mg) on 
RPF, glomerular filtration rate (GFR), and plasma RAS components were compared with 
those of 300 mg aliskiren in 22 normal volunteers on a low-sodium diet. VTP-27999 dose-
dependently increased RPF and GFR; its effects on both parameters at 600 mg (increases 
of 18±4% and 20±4%, respectively) were equivalent to those at 300 mg, indicating that a 
maximum had been reached. The effects of 300 mg aliskiren (increases of +13±5% and 
+8±6%, respectively; P<0.01 versus 300 and 600 mg VTP-27999) resembled those of 150 
mg VTP-27999. VTP-27999 dose-dependently increased renin, and lowered plasma renin 
activity and angiotensin II to detection limit levels. The effects of aliskiren on RAS compo-
nents were best comparable to those of 150 mg VTP-27999. 
Conclusion: Maximum renal renin blockade in healthy, salt-depleted volunteers, 
requires aliskiren doses >300 mg, but can be established with 300 mg VTP-27999. To what 
degree such maximal effects (exceeding those of ACE inhibitors and AT1 receptor block-
ers) are required in patients with renal disease, given the potential detrimental effects of 
excessive RAS blockade, remains to be determined. 
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INTROduCTION
The effects of renin-angiotensin system (RAS) blockers in the kidney, i.e., with regard 
to renal hemodynamics, albuminuria and renal function, require higher doses than 
their blood pressure effects.1-3 This most likely reflects the fact that renin, angiotensin-
converting enzyme (ACE) and angiotensin (Ang) II type 1 (AT1) receptors in the kidney 
are less easily accessible to drugs taken orally than in blood or the vascular wall.4-10 In 
addition, their levels at renal tissue sites, in particular those of renin, are much higher 
than in blood9, 11, therefore requiring even higher doses to obtain sufficient blockade. 
A well-known model to test the efficacy of blockade of RAS activity in the kidney is to 
measure the renal vasodilator responses to RAS blockade in subjects in whom the RAS 
has been activated by restriction of sodium intake.12-14 We have wide experience with this 
model, both in healthy volunteers and in (diabetic) patients under carefully standardized 
conditions (e.g., receiving a fixed sodium diet) during a multiple day-stay in our clinical 
research center.
Remarkably, when using this model, we observed that the renal plasma flow (RPF) 
responses to aliskiren exceeded those seen with ACE inhibitors or AT1 receptor blockers.13 
Doses of 300 mg and 600 mg aliskiren were tested, and the effects of 600 mg were ≈20% 
larger than those of 300 mg. Unfortunately, 600 mg of aliskiren leads to diarrhea; there-
fore, aliskiren is clinically used at a maximum dose of 300 mg/day. Consequently, at this 
stage, we do not know to what degree the effects of 600 mg aliskiren, which were twice as 
large as those observed with captopril (25 mg), and 40% larger than those observed with 
AT1 receptor blockers (300 mg irbesartan, 16 mg candesartan, or 600 mg eprosartan)12, 14, 15, 
resembled the maximum effects of RAS blockade in the kidney. 
A new renin inhibitor, VTP-27999, has recently been compared with aliskiren in 
healthy volunteers.16 The drug was safe and well tolerated. Since VTP-27999 is a potent 
renin inhibitor with an oral bioavailability that is about 10-fold higher than that of aliski-
ren17, 18, we hypothesized that, with the help of this new and well-tolerated renin inhibitor, 
we would be able to establish the maximum effect of renin inhibition in the kidney. There-
fore, in the present study, we compared the acute renal effects of escalating VTP-27999 
doses (75-600 mg) with those of 300 mg aliskiren in healthy, salt-depleted volunteers. 
MATERIAL ANd METhOdS
Study protocol
This single-center, prospective randomized, double-blinded, placebo-controlled study 
was performed in healthy volunteers between the age of 18 and 75 years of both sexes. 
Ethical approval was obtained by expedited review through the Brigham and Women’s 
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Hospital/Partner Healthcare Human Research Committee. Female subjects were required 
to be postmenopausal or surgically sterilized to participate.  Subjects were free of hyper-
tension, diabetes, or any significant medical condition. After an outpatient evaluation, 
which included history, physical examination, screening chemistry, and hematology 
laboratory tests, all subjects were studied during a 7-day admission to a metabolic ward, at 
the Brigham and Women’s Hospital General Clinical Research Center (GCRC) (see Table 
S1). Written informed consent was obtained from each subject, and the protocol was ap-
proved by the Human Subjects Committee of the institution. Subjects were placed on a 
controlled low sodium diet (10 mmol sodium daily, the first several days as outpatient) and 
randomly assigned to 2 groups. The diet did not affect blood pressure (126±5/76±4 mm Hg 
versus 120±5/73±3 mm Hg in group 1, and 125±4/75±3 mm Hg versus 116±4/71±2 mm Hg in 
group 2; P=NS for both). The first group received 75 mg VTP-27999, placebo, and 300 mg 
aliskiren, respectively. The second group received VTP-27999 in 3 doses, 150 mg, 300 mg, 
and 600 mg. All drugs were given in single doses on separate study days. 
Twenty four-hour urine samples were collected daily; when urinary sodium matched 
sodium intake (usually on day 5), the first study was initiated. Each subject was tested on 
three separate study days (Monday, Wednesday, and Friday), separated by a rest interval 
of 48 hours; drug/placebo was only administered on study days. Phlebotomy limitations 
prevented subjects from undergoing more than three studies each. Studies began at 6 AM. 
Subjects had been recumbent and fasting overnight and remained recumbent throughout 
the study. RPF was measured by the clearance of paraaminohippurate (PAH; Clinalfa, 
Laufelfingen, Switzerland) and glomerular filtration rate (GFR) by the clearance of inulin 
(Inutest Polyfructosan, Fresenius Pharma, Linz, Austria) by autoanalyzer methods de-
scribed previously.19 
After a 60-minute control period to establish basal RPF, placebo/drug was dosed 
by mouth. Over the next four (treatment day 2) or five (treatment days 1 and 3) hours, 
blood pressure was checked every 15 minutes by an automatic recording device (Dinamap, 
Critikon Inc, Tampa, FL, USA) or as deemed necessary by study staff. Blood samples were 
collected on ice at the start of the PAH infusion, at 60-minute intervals throughout, and at 
the end of each study (after five hours). Due to limited PAH stock, on treatment day 2, the 
PAH clearance measurements stopped at four hours. Samples were spun immediately, and 
plasma was stored at -80°C until the time of assay. 
biochemical measurements
PRA was determined by measuring Ang I generation during incubation of plasma at 37°C 
and pH 7.4 using an in-house assay.16 PRC was measured with an immunoradiometric kit 
(Renin III, Cisbio, Gif-sur-Yvette, France).13 Plasma prorenin was measured with a direct 
prorenin enzyme-linked immunosorbent assay (Molecular Innovations, Novi, MI, USA).20 
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Plasma Ang II was measured by radioimmunoassay after SepPak extraction as described 
before.21 
Statistical analysis
RPF and GFR are presented as percent change from baseline on each respective study 
day. An F-test was applied to the mean percent change of each group to assess overall 
significance of the linear mixed model. In this analysis, we assumed non-independence 
of observations across the protocol assignment and the intervention dosings. All other 
parameters are presented as absolute values or changes (mean±SEM), and have been ana-
lyzed by Student’s t-test or one-way ANOVA, followed by post-hoc evaluation according to 
Bonferroni. P<0.05 was considered statistically significant. All authors had full access to 
and take responsibility for the data.  
RESuLTS
Baseline characteristics of the two groups of healthy volunteers that participated in this 
study were equivalent (Table 1), and thus all subjects were evaluated together. VTP-27999 
dose-dependently increased RPF (Fig. 1A&B), its maximum effect reached at a dose of 300 
Table 1. Baseline characteristics (mean±SEM) of the 2 treatment groups under low-sodium conditions. 
Group 1 received 75 mg VTP-27999, 300 mg aliskiren, and placebo, respectively. Group 2 received VTP-
27999 in 3 doses, 150 mg, 300 mg, and 600 mg. BMI, body mass index; SBP, DBP, systolic, diastolic blood 
pressure; PRA, plasma renin activity; Ang, angiotensin. 
Parameter group 1 (n=10) group 2 (n=12)
Age (years) 48±5 43±5
Male, % 70% 100%
Race (Caucasian/Hispanic), % 90/10% 92/8%
BMI (kg/m2) 25±1 28±1
SBP (mm Hg) 126±5 125±4
DBP (mm Hg) 76±4 75±3
Heart rate 73±5 72±3
Hematocrit (%) 44±0.9 45±1.0
Serum glucose (mg/dL) 79±4 81±4
Blood urea nitrogen (mg/dL) 14±1 16±1
Serum creatinine (mg/dL) 1.0±0.1 1.0±0.0
Serum Sodium (mmol/L) 140±0 140±1
Serum Potassium (mmol/L) 4.3±0.2 4.3±0.1
Plasma renin (ng/L) 26±5 31±3
Plasma prorenin (ng/L) 82±16 85±10
PRA (nmol Ang I/L.hr) 2.36±0.49 3.12±0.30
Plasma Ang II (pmol/L) 7.6±1.1 8.9±0.8
Renal plasma flow (mL/min.1.73 m2) 432±17 436±18
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mg, given the fact that the effects observed at 600 mg were equivalent to those at 300 mg. 
Aliskiren 300 mg effects on RPF were similar to those obtained with 150 mg VTP-27999, 
and significantly lower than those obtained at 300 and 600 mg VTP-27999 (P<0.01). Renin 
inhibitor-induced GFR changes paralleled this pattern (Fig. 1C&D), although significant 
increases in fact only occurred at the highest VTP-27999 dose (P<0.05 versus placebo). 
Both renin inhibitors induced small, non-significant decreases in blood pressure (Table 
2). No serious adverse effects were observed (Table S2). 
Figure 1. Percent change in renal plasma flow (panels A&B) and glomerular filtration rate (panels C&D) 
in healthy, salt-depleted volunteers over a 5-hour period following oral intake of placebo, VTP-27999 
(VTP; 75, 150, 300 or 600 mg) or 300 mg aliskiren (ALI). Data are mean±SEM of n=9-12. See text for 
statistical analysis. 
Table 2. Change in systolic blood pressure (SBP) and mean arterial pressure (MAP) at 5 hours after 
placebo/drug intake. Data are mean±SEM of n=9-12. No significant changes vs. placebo were noted.
Treatment Δ SbP (mm hg) MAP (mm hg)
Placebo 4.1±4.3 112±4
VTP-27999 75 mg -5.9±3.3 110±4
VTP-27999 150 mg 0.0±3.6 114±2
VTP-27999 300 mg -5.2±4.1 108±3
VTP-27999 600 mg -5.0±4.4 112±2
Aliskiren 300 mg -4.8±4.1 100±5
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VTP-27999 dose-dependently increased renin, and lowered PRA and Ang II at 5 
hours after dosing (P<0.01 for all renin inhibitor groups versus placebo), without signifi-
cantly affecting prorenin (Fig. 2A-D). The effects of aliskiren on RAS components again 
were best comparable to those of 150 mg VTP-27999. 
Importantly, when determining RPF, renin, and Ang II at t=0 on each specific treat-
ment day, it became clear that RPF and Ang II, but not renin, at 48 hours after the previous 
treatment day had returned to baseline (pre-treatment) levels. Baseline renin levels in 
group 1, receiving 75 mg VTP-27999, placebo and 300 mg aliskiren on Monday, Wednesday 
and Friday, respectively, were 27±5, 70±14 (P<0.05 versus Monday) and 57±13 pg/mL (P<0.05 
versus Monday), while in group 2, receiving 150, 300 and 600 mg VTP-27999 on Monday, 
Wednesday and Friday, respectively, they were 31±3, 130±15 (P<0.01 versus Monday), and 
238±28 pg/mL (P<0.01 versus Monday). For RPF, these values were 432±17, 442±16 and 
442±26 versus 436±18, 448±19 and 456±23 mL/min.1.73 m2, respectively, and for Ang II 
7.6±1.1, 9.0±1.3 and 9.4±1.5 versus 8.9±0.8, 8.7±0.8 and 7.9±0.9 pmol/L, respectively. These 
data demonstrate that not all drug had been washed away at 48 hours, but that the original 
state of renal hemodynamics and RAS activity had been restored at that time point due to 
Figure 2. Plasma levels of renin (A) and prorenin (B), plasma renin activity (C) and the plasma level 
of angiotensin (Ang) II (D) in healthy, salt-depleted volunteers at 5 hours after oral intake of placebo, 
VTP-27999 (VTP; 75, 150, 300 or 600 mg) or 300 mg aliskiren (ALI). Data are mean±SEM of n=9-12. See 
text for statistical analysis.
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the rise in renin. This observation has been made before13, and is in full agreement with the 
fact that the half life of both aliskiren and VTP-27999 is ≈24 hours.16  
dISCuSSION
This study revealed a maximum effect of oral renin inhibition on RPF and GFR, which 
was reached at VTP-27999 doses of 300 mg and higher, but not at an aliskiren dose of 300 
mg. The maximum effect of VTP-27999 was roughly 30% higher than the effect of 300 mg 
aliskiren. This difference is close to the ≈20% larger effect observed with 600 mg aliskiren 
versus 300 mg aliskiren in our previous study.13 Therefore, retrospectively, the effects of 
600 mg aliskiren most likely did resemble the maximum effects that can be established 
with renin inhibition. Yet, such high aliskiren doses are not clinically recommended, and 
only now, with VTP-27999, could we establish that indeed larger RPF increases cannot be 
accomplished with renin inhibition. 
In the current acute study we did not make a comparison with other RAS blockers. 
Selected comparisons have been made in the past, and, taken together, suggested that the 
maximum effects of renin inhibition with aliskiren are double those of captopril (25 mg), 
and 40% larger than those observed with the AT1 receptor blockers eprosartan (600 mg), 
irbesartan (300 mg) and candesartan (16 mg).12-15, 22 Yet, since none of these studies titrated 
the doses of all three types of RAS blockers up to a maximum effect in a parallel fashion, 
it is still likely that similar maximal renal effects can be achieved with all types of RAS 
blockade. Therefore, our data at most indicate that maximum renal effects of renin inhibi-
tion are reached at doses that are in or slightly above the normal clinical range, whereas 
for the other types of RAS blockers much higher doses are required to induce maximum 
renal effects.1-3 A likely explanation of this observation is that renin inhibitors, and VTP-
27999 in particular, more easily accumulate in the kidney.23-26 Although it seems logical to 
attribute this to the fact that renin is abundantly present and stored in the kidney, studies 
in renin knockout animals showed that this accumulation is in fact unrelated to the pres-
ence of renin.25 However, since accumulation was selective for the kidney, it must involve 
a kidney-specific uptake system, possibly the organic anion-transporting polypeptide 2B1 
(OATP2B1).27 Interestingly, due to its accumulation at renal tissue sites, the renin inhibitor 
can still be demonstrated in renal tissue several weeks after stopping treatment.24, 28 Yet, as 
a consequence, particularly following treatment with very high doses of VTP-27999, renal 
RAS inhibition may exceed RAS inhibition in the circulation after stopping drug intake. 
This will paradoxically cause a rise in circulating Ang II and aldosterone, due to the fact 
that renal RAS inhibition continues to stimulate renin release, while after stopping drug 
intake the VTP-27999 levels in plasma are no longer sufficient to block this renin.16 
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In the present study, volunteers received placebo, aliskiren or VTP-27999 on 3 dif-
ferent treatment days with a 48-hour rest interval in between. Clearly, given the half life of 
aliskiren and VTP-27999 (≈24 hours for both)16, not all drug will have been washed away 
on each subsequent treatment day. Indeed, renin levels were still elevated at 48 hours fol-
lowing a dose of either aliskiren or VTP-27999, like in our previous study.13 Nevertheless, 
Ang II and RPF at that time had returned to pre-drug baseline values, suggesting that the 
renin rise was sufficient to overcome the blocking effects of any remaining renin inhibitor 
still being present. Importantly therefore, baseline hemodynamics and RAS activity were 
identical at each occasion. Moreover, changes in RPF and GFR have been expressed as a 
percentage of the baseline value on each respective study day, to correct for any carry-over 
effect.
RAS inhibitor-induced RPF changes reflect renal vascular function, and may thus 
serve as an indication of the efficacy on renal vasculature of these drugs. Obviously, the 
observed acute physiologic response is only a surrogate of the acute drug effect on the 
kidney that does not by definition indicate meaningful clinical responses in the real world 
in terms of the drug benefit, when the drug is given on a continuous basis. For instance, 
under the latter condition, multiple compensatory mechanisms may come into play, 
which may alter the net effect of renin inhibition. The most important of these is the 
rise in renin release. Nevertheless, given our current and earlier findings, it seems that 
maximum beneficial effects of RAS blockade in the kidney may be achieved more easily 
with a renin inhibitor (i.e., at relatively low doses) than with other types of RAS blockers. 
Importantly, to obtain beneficial effects, renin inhibitors should be dosed optimally rather 
than maximally.29 The combination of a renin inhibitor with other RAS blockers might 
rapidly tip the balance (i.e., induce too much RAS blockade), as has become apparent in 
the ALTITUDE trial.30 Other trials investigating dual or triple RAS blockade31 also yielded 
the typical consequences of RAS annihilation: hypotension, renal dysfunction and hyper-
kalaemia.
Consequently, the optimal dose of VTP-27999 is not necessarily 600 mg, but rather 
150-300 mg/day.16 In the present study, the renal and hormonal effects of VTP-27999 at 
a dose of 150 mg most closely resembled those of 300 mg aliskiren. Neither of the two 
renin inhibitors affected prorenin, due to the fact that changes in prorenin require de novo 
synthesis, because prorenin, unlike renin, is not stored in the kidney. Only VTP-27999, 
at its highest dose, significantly increased GFR. Since changes in GFR, at least in healthy 
volunteers, directly correlate with changes in RPF32, this simply reflects the larger effects 
of VTP-27999 on RPF. The mechanism underlying this phenomenon involves a change in 
intravascular oncotic pressure along the glomerular capillary, resulting in greater surface 
area available for filtration.32 No significant effects on blood pressure were observed. This 
is most likely related to the fact that this is an acute study, evaluating a single dose only in 
a small number of healthy subjects. Similarly, in our previous study, evaluating different 
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aliskiren doses in healthy, salt-depleted volunteers, we also did not detect significant de-
creases in blood pressure.13 Certainly, when dosing repetitively, blood pressure decreases 
are more likely to occur – particularly in patients with an activated RAS, since such acti-
vation will limit their compensatory capacity. Indeed, blood pressure responses to RAS 
blockers are generally the highest in patients with the highest degree of RAS activation.33  
In conclusion, of all RAS blockers, renin inhibitors require relatively the lowest 
doses to inhibit renal RAS activity completely. This may relate to their capacity to selec-
tively accumulate in the kidney. It may also reflect the fact that renin inhibition is the 
most efficient way to block the RAS, hampered the least by counteracting mechanisms 
(PRA rise, ACE upregulation) and/or the appearance of multiple angiotensin metabolites 
acting on non-AT1 receptors.34 On the one hand, this implies that maximal beneficial renal 
effects can be achieved easily with a single RAS blocker, i.e., a renin inhibitor, instead of 
combining 2 or more alternative RAS blockers at varying (and often high!) doses. How-
ever, selective renal accumulation also implies that the degree of renal RAS blockade may 
rapidly become too high. Therefore, studies are warranted to carefully determine the renin 
inhibitor dose required for optimal rather than maximal renal RAS blockade. Ultimately, 
the effects of these doses will need to be tested in large clinical trials specifically in patients 
with diabetes and nephropathy, where there is a large unmet need. 
Unfortunately, an extensive preclinical comparison of the 3 types of RAS blockers is 
virtually impossible because (human) renin inhibitors are highly species-specific and do 
not act in rodents, except at high doses.35 The only model that is available for this purpose 
is the so-called double transgenic rat, a hypertensive rat model expressing both human 
renin and human angiotensinogen.36 Yet, whether this artificial model truly mimics all 
aspects of hypertension is questionable to date.  Furthermore, animal models may also 
help to shed light on the contribution of the (pro)renin receptor, if at all, to the beneficial 
effects of RAS blockers. This receptor binds and activates prorenin at high concentrations 
in vitro.37 However, recent studies questioned the physiological relevance of these find-
ings, since in reality, prorenin concentrations are many orders of magnitude below the 
levels that are required to interact with this receptor, even during treatment with RAS 
blockers.38 Indeed, the (pro)renin receptor has now also been linked to functions beyond 
the RAS.39 To what degree its concentrations vary in relation with salt intake still needs to 
be investigated further.
Finally, an important aspect of future trials might be whether the effects of RAS 
blockade are sex-specific. Currently, there are no sex-specific recommendations for RAS 
blocker therapy, given the lack of strong evidence that men and women may respond dif-
ferentially to RAS blockers.40, 41 Animal studies do, however, support the existence of such 
differences.42 Moreover, men display higher renin levels than women43, and thus there is a 
reason to believe that men and women may respond differently, e.g., with regard to renal 
effects, when exposed to renin inhibitors.
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SuMMARy ANd PERSPECTIvES 
Cardiovascular disease is an umbrella term for any type of disorder that affects the heart 
and/or circulation. Despite improvements in knowledge and treatment options over the 
last decades, it remains one of the leading causes of disability and death. The underlying 
mechanisms vary depending on the disease in question. Most often there is not one cause 
for cardiovascular disease, but instead several risk factors are involved that increase the 
risk of development and progression of disease. Some of these risk factors can be avoided, 
controlled, treated or modified such as high cholesterol, high blood pressure and obesity. 
While others, such as family history and gender, cannot be avoided and their emphasis 
lies on monitoring and treatment. In this thesis, different mouse models were used to 
examine the role of DNA damage, atherosclerosis and the renin angiotensin system (RAS) 
on cardiovascular disease development and progression. Moreover, the present studies 
explored the effect of nutritional and therapeutic interventions. 
This chapter describes the main findings of this thesis and concludes each part with sug-
gestions for future research.
Part I Introduction
Chapter 2 provides an overview of the general structure and cell biology of the vessel wall. 
The vessel wall consists of three different layers termed tunica intima, tunica media and 
tunica adventitia. The main components of these layers include endothelial cells, vascular 
smooth muscle cells, cytoskeleton proteins and extracellular matrix proteins. Interaction 
between the components of these different layers determines the biological and physical 
properties of the blood vessel. Changes and damage to these components and cellular 
constituents contribute to the pathogenesis and progression of several vascular diseases, 
as well as to ageing of the vasculature.
In Chapter 3, the role of the RAS in the pathogenesis of vascular disease is reviewed. 
Activity of the RAS affects factors that contribute to the development and progression of 
vascular disease; i.e. extracellular matrix defects, atherosclerosis and ageing. Oxidative 
stress seems to be related to all of these components, subsequently contributing to the 
onset of vascular disease. Though, the precise mechanisms by which these components 
induce vascular damage is not entirely clear. RAS inhibiting therapies seem to have ben-
eficial effects in treating cardiovascular disease, however, they are not 100 percent effective 
in all patients and occasionally even give rise to adverse side effects, including hypoten-
sion and hyperkalemia. Yet, when an angiotensin receptor blockade is used simultaneous 
with a neprilysin inhibition (‘ARNI’), a much stronger favorable effect was found when 
compared to angiotensin receptor blockade only, without any extra associated negative 
side effects.1, 2 However, insight into the mechanism of action of ARNI is still needed. Thus, 
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future research should explore optimal strategies of (combined) RAS blockade to prevent 
or stop the progression of vascular disease. Moreover, it would be particularly interest-
ing to test the efficacy of combined RAS/reactive oxygen species suppressing therapy in 
animal models of cardiovascular disease, as it might give further beneficial effects on the 
vasculature. 
Part II Aortic aneurysms
In part II, the effect of two risk factors, atherosclerosis and increased RAS signaling, on 
the development and progression of aortic aneurysms was studied. In Chapter 4, the rela-
tion between atherosclerosis and aortic aneurysms formation was investigated. In order 
to get a more representative physiological situation as observed in humans, aneurysmal 
susceptible heterozygous Fibulin-4 deficient mice (Fibulin-4+/R) were combined with the 
atherosclerotic ApoE knockout mouse model. Our study showed that subtle thoracic 
aortic wall defects, such as increased elastic fiber fragmentation, induce increased ath-
erosclerotic plaques formation and changes in plaque composition, including decreased 
elastin content, in ApoE-/-Fibulin-4+/R mice after 10 weeks of high fat diet. Moreover, 
ApoE-/-Fibulin-4+/R mice already showed relatively small thoracic dilatations when exposed 
to 20 weeks of low-fat diet. Interestingly, between 20 and 30 weeks of age, some of these 
ApoE-/-Fibulin-4+/R mice developed symptoms of paralysis and 30% did not survive. These 
results indicate that subtle thoracic aortic wall defects in association with atherosclerosis, 
predisposes for development of aortic dilatations and altered plaque morphology. Whole 
body angiographs might help to further study the cause of paralysis and death observed in 
the ApoE-/-Fibulin-4+/R mice. This will be a challenge since their death is quite sudden and 
unpredictable. Moreover, preliminary mouse RNA sequencing data suggests a difference 
in expression of genes involved in mitochondrial dysfunction and the immune system be-
tween atherosclerosis and aneurysm formation. Human RNA expression analysis similarly 
showed differences in immune pathway regulation between abdominal aneurysms and 
aortic occlusion (AAA vs AOD). Therefore, further analysis of specific immune factors 
in plasma of both mouse and human might shed light on the observed differences. It is 
evident that external factors such as diet have an enormous influence on aortic dilatations, 
especially abdominal. With this ApoE-/-Fibulin-4+/R mouse model, we can now study the 
effect of high- and normal fat diet in a controlled manner, and elucidate the mechanisms 
that play a role in abdominal aneurysm formation and progression next to genetic factors. 
Chapter 5 evaluated whether treating Fibulin-4R/R mice with the angiotensin II type 
1 (AT1) receptor antagonist losartan outperforms the effect of the renin inhibitor aliskiren 
or the effect of the β-blocker propranolol on aneurysm progression. Although both types 
of RAS blockers (losartan and aliskiren) identically lowered hemodynamic stress, only 
losartan increased survival, reduced aneurysm size and improved aortic wall distensibility. 
Moreover, losartan increased ejection fraction, decreased left ventricular diameter and 
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reduced cardiac TGF-β signaling, while the other drugs did not have these effects. None 
of the drugs examined here affected aortic wall morphology. To explain the beneficial 
effect of losartan compared to aliskiren, we reasoned that losartan offers an additional 
advantage, possibly by simulation of angiotensin II (AT2) type receptors and/or activation 
of the angiotensin-(1-7)/Mas receptor axis. It still remains unclear whether RAS inhibition 
is effective in the prevention or reduction of aortic root dilations.3, 4 Most clinical studies 
have a heterogeneous patient population in which they do not make a distinction between 
different underlying mutations, which makes it more difficult to draw firm conclusions. In 
addition, these clinical studies all start at different ages with their treatment, e.g. children, 
adolescent, adults and elderly. The strength of our study is the fact that these mice have 
the same genetic mutation, are treated from the same starting point, and accurate moni-
toring of aneurysm progression is followed within the same animal over time. Moreover, 
in this present study mice were treated postnatally, when aneurysm formation has already 
started, which is more clinically relevant as treatment of aneurysmal patients usually starts 
in the presence of an aneurysm. Timing of treatment as well as the underlying mutation 
are of utmost importance, as they may explain the success, or lack thereof, of different RAS 
blockers in clinical trials.4, 6 Thus, future research should follow the same patient and/or 
animal over time, and should make a distinction between the underlying mutations of 
disease causing genes. 
Part III Cardiovascular aging
In part III, the effect of defective DNA repair and the consequential aging process on the 
development of cardiovascular damage was examined. Previous studies have shown that 
the well-established premature aging Ercc1d/- mouse model shows signs of accelerated age-
dependent vasodilator dysfunction, accompanied by increased blood pressure, vascular 
stiffness and vascular senescence. In Chapter 6, it was examined whether this accelerated 
age-dependent vasodilator dysfunction could be prevented by either treating the mice 
with the chronic AT1 receptor blocker losartan, a well-known antihypertensive drug, 
or exposing them to dietary restriction, known to induce an anti-aging response. This 
study shows that dietary restriction is a very efficient intervention to prevent vasodila-
tor dysfunction caused by genomic instability. Improvement of prostaglandin-mediated 
endothelium-dependent signaling and better vascular smooth muscle cell responses to 
nitric oxide were identified as mechanisms. Conversely, endothelial dysfunction was not 
reversible with chronic losartan treatment. These results suggest that this aging mouse 
model appears to represent the RAS blockade-resistant part of aging-related vascular dis-
ease. Accordingly, future research should use progeroid mouse models to further explore 
the underlying mechanism leading to age-related vascular disease and test the efficacy of 
drugs targeting vascular disease in order to extrapolate the results to the elderly popula-
tion. A possible explanation for the lack of effect of losartan might be that vascular dys-
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function in Ercc1d/- mice is largely ROS-independent, while often part of the detrimental 
effects of Ang II involve ROS formation. Additionally, Ercc1d/- mice show an upregulation 
of anti-oxidant and detoxification defense genes as part of a so-called survival response 
that aims to extend their lifespan.7, 8 Research efforts should therefore also continue to 
fully elucidate the role of ROS in age-related vascular dysfunction.  
In Chapter 7, the effect of aging on the heart was characterized and the use of 
fluorescent molecular markers for the early detection of cardiovascular disease was tested. 
MicroCT imaging showed that premature aging Ercc1d/- mice at 24 weeks of age display 
changes in left ventricular geometry and functioning, e.g. increased ventricular volumes 
and reduced ejection fraction. Results were similar when compared to functional analysis 
by echocardiography. Moreover, specific loss of Ercc1 in cardiomyocytes, comparably 
showed adverse cardiac remodeling and poor cardiac functioning, suggesting the direct 
involvement of Ercc1 in the heart. Furthermore, the combination of microCT and opti-
cal imaging allowed simultaneous analysis of molecular and functional changes in these 
mouse models for accelerated aging. Our study showed that a temporal increase in matrix 
metalloprotease activity and apoptosis precede cardiac functional decline in progeroid 
Ercc1 mice. It would be interesting to investigate whether the increase in matrix metallo-
protease activity is derived from senescent cells. In addition, this study did not investigate 
the direct causal effect of DNA damage on the development of heart failure; therefore, 
future research should be aimed at elucidating this question, for examples by measuring 
DNA damage markers in the hearts of the Ercc1 mice, as well as inducing DNA damage by 
radiation and examining the effect on cardiac function. Furthermore, extensive analysis of 
mutations in DNA damage and repair genes leading to cardiovascular diseases is needed 
to expand our comprehension on how DNA damaging factors increase the susceptibility 
to cardiovascular event.
Part IV The renin-angiotensin system
In part IV, the role of the RAS was investigated. In Chapter 8, the use of the NIRF probe 
ReninSense680™ was tested to study renin activity in vivo and characterize renin activ-
ity in progeroid Ercc1∆/- mice which have premature age-related kidney pathology due 
to a defective nucleotide excision repair gene. Our study confirmed that Ercc1d/- kidneys 
display severe tubular attenuation and degeneration with marked anisokaryosis, which 
was shown previously.9-11 In addition, we demonstrated that non-invasive imaging, using 
the NIRF probe ReninSense680™, enables imaging of altered renin activity in the kidney 
over time. The increased intrarenal activity detected with the ReninSense680™ probe after 
losartan treatment, is in full agreement with the literature, and thus not only validates 
the specificity of this probe, but also supports its use for longitudinal imaging of altered 
RAS signaling in aging. Moreover, our observations in the premature aging Ercc1d/- mouse 
model provides evidence that intrarenal renin activity does not necessarily run in parallel 
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with circulating renin. This observation was also seen in animal models of early diabetic 
nephropathy and patients with diabetes mellitus.12-16 Hence, it would be interesting to 
further explore the association between aging and diabetes mellitus on the development 
of renal injury as well as the implications for future therapies; should we aim at locally 
lowering the intrarenal RAS in these models? Moreover, in several of the diabetic animal 
studies it was suggested that altered renin release from the kidney, and not reduced pro-
duction, is responsible for the low circulating renin levels (reviewed within Price et al.)14. 
Future research should investigate the release and production of renin and other RAS 
components in aging mouse models. 
In Chapter 9, our study re-evaluated the occurrence of (pro)renin in the brain, 
as the concept of a brain RAS has been controversial and this controversy continues to 
this day. It was found that buffer perfusion reduced mouse brain renin by approximately 
60% and although renin-dependent Ang I-generating activity (AGA) could be detected in 
virtually every region, plasma renin was 40-800x higher than brain renin. Furthermore, 
deoxycorticosterone acetate (DOCA) salt, like Ang II, reduced circulating renin, and, 
contrary to our expectations did not increase brain prorenin. In fact, both DOCA-salt 
and Ang II lowered brain renin in parallel with plasma renin. Aliskiren-inhibitable AGA 
was entirely absent in the brain of Ren1c-/- mice, supporting the validity of our brain renin 
measurement. Thus, our data do not support the presence of locally synthesized, kidney-
independent renin in the brain and we conclude that brain renin must represent renin that 
is taken up from blood. Moreover, the absence of Ang I in brain tissue outside the blood 
compartment strongly suggests that there is no local Ang I generation in the brain, and 
it appears that brain Ang II therefore originates from the blood compartment. Thus, it 
would be interesting to explore how this Ang II enters the blood-brain barrier, for instance 
by binding to brain angiotensin type-receptors that are outside the blood-brain barrier or 
rather by entering at sites where the blood-brain barrier permeability is compromised. In 
addition, the ReninSense probe holds considerable promise to localize and detect renin 
activity in tissues, and future studies should address the possibilities of assessing renin 
activity in other tissues than the kidney.
In Chapter 10, the use of VTP-27999, a novel renin inhibitor -without major side-
effects at high doses- was examined in order to establish the maximum effect of renin 
inhibition in the kidney. The effect of VTP-27999 was compared to the clinically used 
renin-inhibitor aliskiren in 22 healthy volunteers on a low-sodium diet. A maximum effect 
of renin inhibition on renal plasma flow (RPF) and glomerular filtration rate (GFR) was 
found at VTP-27999 doses of 300 mg and higher, while a maximum effect was not reached 
with aliskiren at a dose of 300 mg. The maximum effect of VTP-27999 was approximately 
30% higher than the effect of aliskiren at the same dose. The maximum effect of VTP-
27999 can most likely be reached with 600 mg of aliskiren, however such high doses 
of aliskiren are clinically not recommended because of its side effects. With this study, 
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we could establish that maximum RPF increases cannot be established with aliskiren at 
clinically relevant doses. As our study only included healthy patients, future research 
in patients with diabetes, hypertension and/or kidney disease is necessary to confirm 
these results, as the use of RAS blockers increases the risk of adverse events, including 
hyperkalemia, in this population. In addition, it would be interesting to test the effect of 
VTP-27999 in an aging mouse model, as they may have an altered RAS activity resulting in 
a different responsiveness. Moreover, in this study we did not compare males and females, 
thus further research should distinguish between males and females to determine whether 
or not the effect is similar in both genders. 
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Hart- en vaatziekten is een overkoepelende term voor elk type aandoening die het hart en/
of de bloedsomloop beïnvloedt. Ondanks verbeteringen omtrent de kennis en behandel 
opties in de afgelopen decennia, blijft het een van de belangrijkste oorzaken van overlijden 
en invaliditeit. De mechanismen variëren naargelang de desbetreffende ziekte. Meestal is 
er niet één oorzaak voor de ziekte, maar zijn er verschillende risicofactoren betrokken die 
de kans op ontwikkeling en progressie van de ziekte verhogen. Een aantal van deze risi-
cofactoren kunnen worden vermeden, gecontroleerd, behandeld of zelfs verandert zoals 
hoog cholesterol, hoge bloeddruk en obesitas. Terwijl anderen, zoals familiegeschiedenis 
en geslacht, niet vermeden kunnen worden en de nadruk ligt hier dan ook op de controle 
en behandeling. In dit proefschrift, hebben we aan de hand van verschillende muismodel-
len onderzocht wat de rol van DNA schade, aderverkalking (atherosclerose) en het renine-
angiotensine systeem (RAS) is op de ontwikkeling en progressie van hart- en vaatziekten. 
Daarnaast hebben we het effect van voedings- en therapeutische interventies onderzocht. 
Dit hoofdstuk beschrijft de belangrijkste bevindingen van dit proefschrift en concludeert 
elk deel met een aantal suggesties voor toekomstig onderzoek.
Deel I Introductie
Hoofdstuk 2 geeft een overzicht van de algemene structuur en celbiologie van de vaat-
wand. De vaatwand bestaat uit drie verschillende lagen genaamd: tunica intima, tunica 
media en tunica adventitia. De belangrijkste componenten van deze lagen zijn endotheel-
cellen, gladde spiercellen, eiwitten van het cytoskelet en extracellulaire matrix eiwitten. 
Interactie tussen de componenten van deze verschillende lagen bepaalt de biologische 
en fysische eigenschappen van het bloedvat. Veranderingen en beschadiging van deze 
onderdelen en cel bestanddelen draagt bij aan het ontstaan en de progressie van verschil-
lende vaatziekten, evenals aan veroudering van het vaatstelsel.
In hoofdstuk 3, wordt de rol van het RAS in de pathogenese van vasculaire ziekte 
beoordeeld. Activiteit van het RAS beïnvloed factoren die bijdragen aan de ontwikkel-
ing en progressie van vaatziekten; o.a. extracellulaire matrix defecten, atherosclerose en 
veroudering. Oxidatieve stress lijkt gerelateerd te zijn aan al deze onderdelen, en draagt 
daarmee bij aan het ontstaan van vaatziekten. Echter, de precieze mechanismen waarmee 
deze componenten bijdragen aan het induceren van vaatschade is niet geheel duidelijk. 
RAS-remmende therapieën lijken effectief bij het behandelen van hart- en vaatziekten, 
maar ze zijn niet 100 procent effectief bij alle patiënten en hebben soms zelfs nadelige 
neveneffecten zoals hypotensie en hyperkaliëmie (verhoogd kalium gehalte in plasma). 
Echter, wanneer een angiotensine receptor remmer gelijktijdig wordt gebruikt met nepri-
lysine remming (zogenaamde ‘ARNI ‘), heeft dit een veel sterker positief effect in vergeli-
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jking met slechts angiotensine receptor remming, zonder extra bijbehorende negatieve 
effecten. Echter meer inzicht in het werkingsmechanisme van ARNI is nog steeds nodig. 
Daarom is het belangrijk dat toekomstig onderzoek zich richt op het vinden van optimale 
strategieën met betrekking tot (gecombineerde) RAS remming, om zo verdere progressie 
van vaatziekten te voorkomen of zelfs te stoppen. Bovendien is het heel interessant om 
de werkzaamheid van gecombineerde RAS/zuurstofradicalen onderdrukkende therapie 
te testen in diermodellen die leiden aan hart- en vaatziekten, omdat dit misschien ad-
ditionele  gunstige effecten heeft op de vaten. 
Deel II Aorta aneurysmata
In deel II, wordt het effect van twee risicofactoren, zijnde atherosclerose en verhoogde 
RAS signalering, bestudeerd op de ontwikkeling en progressie van aorta aneurysmata. In 
hoofdstuk 4 is de relatie tussen atherosclerose en aorta aneurysma vorming onderzocht. 
Om een representatieve fysiologische toestand te krijgen die wordt waargenomen bij 
mensen, werden aneurysma gevoelige heterozygote Fibuline-4 deficiënte (Fibuline-4+/R) 
muizen gekruist met een muismodel voor atherosclerose; de ApoE knockout muis. 
Onze studie toonde aan dat een subtiele afwijkingen in de thoracale aorta wand, zoals 
verhoogde elastische vezels fragmentatie, een verhoogde vorming van atherosclerotische 
plaques veroorzaakt en veranderingen in plaque samenstelling teweeg brengt, inclusief 
verminderde elastine aanwezigheid, in ApoE-/-Fibuline-4+/R muizen na 10 weken hoog 
vet dieet. Bovendien toonde de ApoE-/-Fibuline-4+/R al relatief kleine thoracale verwi-
jdingen van de aorta bij blootstelling aan een 20 weken vetarm dieet. Een interessante 
observatie is dat sommige van deze ApoE-/-Fibuline-4+/R muizen tussen de 20 en 30 weken 
dieet, verlammingsverschijnselen ontwikkelden en zelfs 30% van de muizen vroegtijdig 
overlijden. Deze resultaten geven aan dat subtiele thoracale aorta wand afwijkingen in 
combinatie met atherosclerose, de mens vatbaar maken voor de ontwikkeling van aorta 
verwijdingen en veranderde plaque morfologie. Angiografie van het hele lichaam, zou 
kunnen helpen om de oorzaak van de verlamming en de waargenomen vroegtijdige dood 
in de ApoE-/-Fibuline-4+/R muizen te achterhalen. Echter, dit zal een uitdaging zijn omdat 
hun dood heel plotseling en onvoorspelbaar is. Verder suggereert preliminaire muis RNA 
sequentie data dat er een verschil is in de expressie van genen betrokken bij mitochon-
driële dysfunctie en het immuunsysteem wanneer atherosclerose en aneurysmavorming 
worden vergeleken. Humane RNA-expressie analyse toonde vergelijkbare verschillen in 
immunologische regulering tussen abdominale aneurysmata en aorta occlusie (AAA vs 
AOD). Verdere analyse van  specifieke immune factoren in plasma van zowel muis als 
mens zou meer kennis kunnen geven over de waargenomen verschillen. Het is duidelijk 
dat externe factoren zoals dieet een enorme invloed heeft op de aorta verwijdingen, in het 
bijzonder in de buik. Dit ApoE-/-Fibuline-4+/R muismodel helpt ons enerzijds om het effect 
van hoog-vet en normaal dieet te bestuderen op een gecontroleerde manier, en anderzijds 
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bij het in beeld brengen van mechanismen, die naast de genetische factoren,  een rol 
spelen in de vorming en progressie van abdominale aorta aneurysmata.
In hoofdstuk 5 evalueerden we of het behandelen van Fibuline-4R/R muizen met 
de angiotensine I (AT1) receptor antagonist losartan beter werkt in het tegengaan van 
aneurysma progressie dan de renine-inhibitor aliskiren of het effect van de β-blokker 
propranolol. Hoewel beide typen RAS blokkers (losartan en aliskiren) identiek de bloed-
druk verlagen, zien we dat alleen losartan zorgde voor een betere overleving, verminderde 
aneurysma groei en een verbeterde aortawand flexibiliteit. Bovendien zorgde losartan 
behandeling voor een toegenomen ejectiefractie, een verkleining in linker ventrikel diam-
eter en een verlaging in TGF-β signalering in het hart, terwijl de andere geneesmiddelen 
geen effect hadden. Geen van deze geneesmiddelen beïnvloed de aortawand morfologie. 
Om het gunstige effect van losartan ten opzichte van aliskiren te verklaren, redeneren 
wij dat losartan een extra voordeel biedt, mogelijk door stimulatie van de angiotensine 
II (AT2) type receptoren en/of activering van de angiotensine-(1-7)/Mas receptor as. Het 
is nog onduidelijk of remming van het RAS effectief is in het voorkomen of verminderen 
van aortawortel verwijdingen. De meeste klinische studies hebben een heterogene patiën-
tenpopulatie waarin zij geen onderscheid maken tussen verschillende onderliggende 
mutaties, waardoor het moeilijker is om harde conclusies te trekken. Bovendien starten 
deze klinische studies vaak op verschillende leeftijden met de behandeling van patiënten, 
zoals kinderen, adolescenten, volwassenen en ouderen. De kracht van onze studie is dat 
deze muizen dezelfde genetische mutatie hebben, worden behandeld vanaf hetzelfde be-
ginpunt en dat aneurysma progressie over tijd nauwkeurig wordt gevolgd in hetzelfde dier. 
Daarnaast hebben wij in onze studie de muizen postnataal behandeld, wanneer de vorming 
van het aneurysma al is ontstaan,  zodat het meer klinisch relevant is omdat behandeling 
van aneurysma patiënten meestal begint als een aneurysma al aanwezig is. Juiste timing 
van de behandeling, evenals de onderliggende mutatie zijn van groot belang, omdat zij het 
succes kunnen verklaren, of het gebrek daaraan, van verschillende RAS-blokkers gebruikt 
in de klinische studies. Toekomstig onderzoek zou daarom dezelfde patiënt en/of dier 
moeten volgen over tijd, daarbij onderscheid makende tussen de onderliggende mutaties 
van genen die betrokken zijn bij ziekte.
Deel III hart- en vaat veroudering
In deel III, onderzochten we het effect van defect DNA herstel en het daaruit voortv-
loeiende verouderingsproces op de ontwikkeling van cardiovasculaire schade. Eerdere 
studies hebben aangetoond dat het bekende muismodel voor vroegtijdige veroudering, 
het Ercc1Δ/- muismodel, tekenen heeft van versnelde, leeftijdsafhankelijke vaatverwij-
dende dysfunctie, wat vergezeld wordt door verhoogde bloeddruk, vasculaire stijfheid en 
vasculaire veroudering. In hoofdstuk 6 onderzochten we of deze versnelde, leeftijdsaf-
hankelijke vaatverwijdende dysfunctie kan worden voorkomen door hetzij behandeling 
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van de muizen met chronische AT1 receptor blokker losartan, (een bekende antihyper-
tensivum) of behandeling met dieet restrictie (DR), bekend voor het induceren van een 
anti-veroudering response. Onze studie toont aan dat DR een zeer efficiënte interventie 
is tegen vaatverwijdende dysfunctie die veroorzaakt wordt door genomische instabiliteit. 
Verbetering van de prostaglandine gemedieerde endotheel-afhankelijke signalering en 
van vaat-gerelateerde spiercel reacties op NO werden geïdentificeerd als mechanismen. 
Endotheel dysfunctie was niet omkeerbaar met chronische losartan behandeling. Deze 
resultaten suggereren dat dit snel verouderende muismodel het RAS blokkade-bestendige 
gedeelte van leeftijdsgerelateerde vaatziekten vertegenwoordigd. Toekomstig onderzoek 
zou daarom zulke snel verouderende muismodellen moeten gebruiken om het onder-
liggende mechanisme dat leidt tot leeftijdgerelateerde vaatziekten verder te onderzoeken, 
evenals gebruiken bij het testen van de werkzaamheid van geneesmiddelen gericht tegen 
vaatziekte, zodat deze geëxtrapoleerd kunnen worden naar de oudere bevolking. Een 
mogelijke verklaring voor het gebrek aan effect van losartan is dat de vaatdysfunctie bij 
Ercc1d/- muizen grotendeels ROS onafhankelijk is, terwijl Ang II vaak ROS vorming als 
nadelige effect heeft. Bovendien vertonen deze  Ercc1d/- muizen een opregulatie van anti-
oxidant en detox verdedigingsgenen als onderdeel van een zogenaamde overlevingsreactie 
met als doel het verlengen van de levensduur. Toekomstig onderzoek zou de rol van ROS 
in leeftijdsgerelateerde vaatziekten moeten ophelderen. 
In hoofdstuk 7, karakteriseerden we het effect van veroudering op het hart en testen we 
het gebruik van fluorescente moleculaire markers voor de vroege detectie van hart- en 
vaatziekte. Met het gebruik van microCT, vonden we dat vroegtijdige verouderende Ercc1d/- 
muizen van 24 weken oud een verandering in linker ventrikel (LV) geometrie en werking 
laten zien, zoals vergrootte ventriculaire volumes en een verminderde ejectiefractie. De 
resultaten waren vergelijkbaar met een functionele analyse door middel van echocardio-
grafie. Daarnaast lieten we zien dat specifiek verlies van Ercc1 in hartspiercellen, vergeli-
jkbare remodellering van het hart vertoonde met een verslechterde hartfunctie, wat de 
directe betrokkenheid van Ercc1 in het hart suggereert. Bovendien toonden we aan dat 
combinatie van microCT en optische beeldvorming gelijktijdige analyse van moleculaire 
en functionele veranderingen mogelijk maakt in muismodellen voor versnelde verouder-
ing. Onze studie laat zien dat een tijdelijke verhoging van matrix metalloproteinase activ-
iteit en apoptose gevolgd wordt door functionele achteruitgang van het hart in deze snel 
verouderende Ercc1d/- muizen. Het is interessant  om te onderzoeken of deze verhoging 
van matrix metalloproteinase activiteit afkomstig is van senescent cellen. Daarnaast heeft 
deze studie niet het direct causale effect van DNA-schade op de ontwikkeling van hartfalen 
onderzocht; daarom zou toekomstig onderzoek gericht moeten zijn op het ophelderen 
van deze vraag, bijvoorbeeld door het meten van DNA-schade markers in het hart van 
de (cardiospecifieke) Ercc1 muizen, evenals het induceren van DNA schade door straling 
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en het onderzoeken van het effect op de hartfunctie. Uitgebreide analyse van mutaties 
in DNA-schade en herstel genen die leiden tot hart- en vaatziekten is bovendien nodig 
om te begrijpen hoe DNA-beschadigende factoren de gevoeligheid op het ontstaan van 
cardiovasculaire gebeurtenissen vergroten. 
Deel IV het renine-angiotensine systeem
In deel IV, onderzochten we de rol van het RAS. In hoofdstuk 8 evalueerden we het 
gebruik van de NIRF probe ReninSense680™ om in vivo renine activiteit te bestuderen 
en daarnaast onderzochten we de renine activiteit in muizen met een vroegtijdige, leefti-
jdsgebonden nier pathologie als gevolg van een defect in het nucleotide excisie herstel 
mechanisme (Ercc1d/- muizen). Als eerste hebben we bevestigd dat de nieren van de 
vroegtijdige verouderende Ercc1d/- muizen ernstige tubulaire degeneratie vertonen met 
uitgesproken anisokaryosis, zoals eerder werd aangetoond. Daarnaast lieten we zien dat 
niet-invasieve beeldvorming met behulp van de NIRF probe ReninSense680™, beeldvorm-
ing van veranderde renine activiteit in de nieren in de tijd mogelijk maakt. De verhoogde 
intrarenale activiteit gedetecteerd met de ReninSense680™ probe na losartan behandeling, 
is in volledige overeenstemming met de literatuur, en valideert niet alleen de specificiteit 
van deze probe maar ondersteunt ook het gebruik ervan voor longitudinale beeldvorming 
van veranderde RAS signalering tijdens veroudering. Bovendien toonden onze observaties 
in het vroegtijdig verouderende Ercc1d/- muismodel dat intrarenale renine activiteit niet 
noodzakelijkerwijs parallel loopt met het circulerende renine. Deze waarneming werd 
ook gedaan in diermodellen van vroege diabetische nefropathie en patiënten met diabetes 
mellitus. Het is dus interessant om het verband tussen veroudering en diabetes mellitus 
verder te onderzoeken met betrekking op de ontwikkeling van nierschade alswel de gevol-
gen voor de toekomstige therapieën; moeten we streven naar het lokaal verlagen van het 
intrarenale RAS in deze modellen? Bovendien werd er in een van de diabetische dierstud-
ies gesuggereerd dat veranderde renine afgifte uit de nier verantwoordelijk is voor de lage 
circulerende renine niveaus, en niet de verminderde productie (besproken in Price et al., 
1999). Toekomstig onderzoek zou dan ook de afgifte en de productie van renine en andere 
RAS componenten in verouderende muismodellen moeten onderzoeken.
Onze studie, in hoofdstuk 9, heronderzocht of (pro) renine zich in de hersenen 
bevindt, omdat het concept van een brein RAS altijd al controversieel is geweest en mo-
menteel nog steeds heerst. Onze studie toonde aan dat buffer perfusie het muizen hersen-
renine met ongeveer 60% verminderde en dat hoewel renine-afhankelijk gegenereerde-Ang 
I activiteit (AGA) in vrijwel alle regio’s kon worden gedetecteerd, plasma renine altijd nog 
40-800 keer hoger was dan hersen-renine. Verder, zagen wij dat deoxycorticosteronacetaat 
(DOCA) zout, zoals Ang II, circulerende renine verminderde, en, in tegenstelling tot onze 
verwachtingen niet leidde tot verhoging van hersen-prorenine. In feite, zowel DOCA-zout 
en Ang II verlaagde hersen-renine parallel aan plasma-renine. Aliskiren-geremde AGA was 
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geheel afwezig in de hersenen van Ren1c-/- muizen, wat de validiteit van onze hersen-renine 
meting ondersteunt. Onze data biedt dus geen ondersteuning aan het concept van lokaal 
gesynthetiseerd, nier-onafhankelijke renine aanwezigheid in de hersenen, en we conclud-
eren dan ook dat hersen-renine, eigenlijk renine vertegenwoordigd dat wordt opgenomen 
uit het bloed. Bovendien suggereert het ontbreken van Ang I in hersenweefsel buiten het 
bloedcompartiment, dat er geen lokale Ang I productie is in de hersenen, en het lijkt er 
dus op dat hersen-Ang II afkomstig is van het bloedcompartiment. Het is interessant om te 
onderzoeken hoe deze Ang II de bloed-hersenbarrière passeert, bijvoorbeeld door binding 
aan de hersen-angiotensine type-receptoren buiten de bloed-hersenbarrière of door het 
binnentreden van de hersenen op plaatsen waar de bloed-hersenbarrière permeabiliteit is 
aangetast. De ReninSense probe biedt daarnaast de mogelijkheid renine activiteit in weef-
sels te lokaliseren en detecteren, en toekomstige studies zouden de mogelijkheid moeten 
onderzoeken of renine-activiteit kan worden beoordeelt in andere weefsels dan de nieren.
In hoofdstuk 10 werd het gebruik van VTP-27999, een nieuwe renine-remmer 
(zonder belangrijke bijwerkingen bij hoge doses) onderzocht bij de vaststelling van het 
maximale effect van renine-remming in de nier. Het effect van VTP-27999 werd vergeleken 
met de veelgebruikte renine-inhibitor aliskiren in 22 gezonde vrijwilligers op een zoutarm 
dieet. Een maximaal effect van renine remming op de renale plasmastroom (RPF) en de 
glomerulaire filtratiesnelheid (GFR) werd gevonden bij VTP-27999 doses van 300 mg en 
hoger, terwijl dit maximale effect niet bereikt werd met aliskiren in een dosis van 300 mg. 
Het maximale effect van VTP-27999 was ongeveer 30% groter dan het effect van aliskiren 
bij dezelfde dosis. Het maximale effect zoals gezien bij VTP-27999 kan waarschijnlijk 
worden bereikt met 600 mg aliskiren, echter zijn zulke hoge doses aliskiren klinisch niet 
aanbevolen vanwege de bijwerkingen. Met deze studie, konden we vaststellen dat de maxi-
male RPF verhogingen niet kan worden vastgesteld met klinisch relevante doseringen van 
aliskiren. Aangezien onze studie alleen uit gezonde patiënten bestaat, is  het noodzakelijk 
dat deze resultaten worden bevestigd in patiënten met diabetes, hoge bloeddruk en/of 
nierfalen omdat het gebruik van RAS blokkers de kans op bijwerkingen in deze populatie 
verhoogt, waaronder hyperkaliëmie. Bovendien zou het interessant zijn om het effect van 
VTP-27999 te testen in een snel verouderend muismodel, aangezien deze muizen mogelijk 
een veranderde RAS activiteit hebben die resulteert in een andere respons. Ook hebben 
we in deze studie geen onderscheid gemaakt tussen mannen en vrouwen, en zou verder 
onderzoek dit onderscheid wel moeten maken om te bepalen of het effect vergelijkbaar is 
in beide geslachten.
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•	 Travel award, NAVBO meeting 2015
•	 Poster prize, Gordon research conference  2016
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2.	 Teaching	activities
Teaching (0.5 ECTS) Year
Bsc Nanobiology - PCR practicum  2013
MSc Molecular Medicine -   2014
Keuze onderwijs: ‘Ever thought of doing research?’
Supervision students (0.5 ECTS) Year
Partial supervision of master student 2013
Partial supervision of bachelor student  2013-2014
Total 2012-2017 (46.5 ECTS)
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Cardiovascular diseases are a major cause of mortality worldwide, and includes all diseases of the heart and circulation. Despite improvements in knowledge and 
treatment options over the last decades, it remains one of the 
leading causes of disability and death. The underlying mecha-
nisms vary depending on the disease in question. Some of 
these risk factors can be avoided, controlled, treated or modi-
 ed such as high cholesterol, high blood pressure and obesity. 
While others, such as family history and gender, cannot be 
avoided and their emphasis lies on monitoring and treatment. 
In this thesis, the role of DNA damage, atherosclerosis and the 
renin angiotensin system, factors that modulate cardiovascu-
lar damage and disease, are investigated and discussed. Addi-
tionally, the e­ ect of nutritional and therapeutic interventions 
is explored. 
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